WO2022230964A1 - 化合物またはその塩、脂質粒子および医薬組成物 - Google Patents
化合物またはその塩、脂質粒子および医薬組成物 Download PDFInfo
- Publication number
- WO2022230964A1 WO2022230964A1 PCT/JP2022/019220 JP2022019220W WO2022230964A1 WO 2022230964 A1 WO2022230964 A1 WO 2022230964A1 JP 2022019220 W JP2022019220 W JP 2022019220W WO 2022230964 A1 WO2022230964 A1 WO 2022230964A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- hydrocarbon group
- independently represent
- group
- bis
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 160
- 150000001875 compounds Chemical class 0.000 title claims abstract description 158
- 239000002245 particle Substances 0.000 title claims abstract description 123
- 150000003839 salts Chemical class 0.000 title claims abstract description 53
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 74
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 74
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 72
- 125000004432 carbon atom Chemical group C* 0.000 claims description 396
- 150000002430 hydrocarbons Chemical class 0.000 claims description 281
- -1 R 54 Chemical compound 0.000 claims description 155
- 125000003118 aryl group Chemical group 0.000 claims description 61
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 40
- 229930195733 hydrocarbon Natural products 0.000 claims description 25
- 239000004215 Carbon black (E152) Substances 0.000 claims description 22
- 230000007935 neutral effect Effects 0.000 claims description 14
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 12
- 229930182558 Sterol Natural products 0.000 claims description 9
- 150000003432 sterols Chemical class 0.000 claims description 9
- 235000003702 sterols Nutrition 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical group CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 3
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 3
- IFAWYXIHOVRGHQ-UHFFFAOYSA-N Nonadecandioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCCC(O)=O IFAWYXIHOVRGHQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 123
- 238000005538 encapsulation Methods 0.000 abstract description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 82
- 239000000203 mixture Substances 0.000 description 77
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- 239000002904 solvent Substances 0.000 description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- 238000006243 chemical reaction Methods 0.000 description 51
- 108020004999 messenger RNA Proteins 0.000 description 51
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 51
- 239000012230 colorless oil Substances 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 38
- 239000002585 base Substances 0.000 description 37
- 239000011541 reaction mixture Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 33
- 239000012044 organic layer Substances 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 239000008346 aqueous phase Substances 0.000 description 29
- 238000001816 cooling Methods 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 239000003921 oil Substances 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 238000010898 silica gel chromatography Methods 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 239000006185 dispersion Substances 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 19
- 239000012071 phase Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 229920001223 polyethylene glycol Polymers 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 239000007864 aqueous solution Substances 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- IJNYXAHWDLCGOI-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl-(2-hydroxyethyl)amino]ethanol Chemical compound CCN(CC)CCN(CCO)CCO IJNYXAHWDLCGOI-UHFFFAOYSA-N 0.000 description 13
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 13
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 13
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 13
- 150000002170 ethers Chemical class 0.000 description 13
- XMVBHZBLHNOQON-UHFFFAOYSA-N 2-butyl-1-octanol Chemical compound CCCCCCC(CO)CCCC XMVBHZBLHNOQON-UHFFFAOYSA-N 0.000 description 12
- 239000007984 Tris EDTA buffer Substances 0.000 description 12
- 150000002825 nitriles Chemical class 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 150000007530 organic bases Chemical class 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 102000003951 Erythropoietin Human genes 0.000 description 10
- 108090000394 Erythropoietin Proteins 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 10
- 150000008282 halocarbons Chemical class 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000007529 inorganic bases Chemical class 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000011002 quantification Methods 0.000 description 9
- 150000003462 sulfoxides Chemical class 0.000 description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 9
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 8
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 8
- 229940105423 erythropoietin Drugs 0.000 description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 8
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 7
- XULHFMYCBKQGEE-MRXNPFEDSA-N 2-Hexyl-1-decanol Natural products CCCCCCCC[C@H](CO)CCCCCC XULHFMYCBKQGEE-MRXNPFEDSA-N 0.000 description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- NYVWQUGCZOIWAC-UHFFFAOYSA-N 2-pentylheptan-1-ol Chemical compound CCCCCC(CO)CCCCC NYVWQUGCZOIWAC-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000003149 assay kit Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 5
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 229940106189 ceramide Drugs 0.000 description 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 4
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 4
- VBFPQNKLKQDSCH-UHFFFAOYSA-N 10-oxohexadecanoic acid Chemical compound CCCCCCC(=O)CCCCCCCCC(O)=O VBFPQNKLKQDSCH-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- PFRIMEOUDPHCHE-UHFFFAOYSA-N CCCCCCC(CCCC(=O)OCC(CCCCC)CCCCC)O Chemical compound CCCCCCC(CCCC(=O)OCC(CCCCC)CCCCC)O PFRIMEOUDPHCHE-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- AZLPEJUVWWGLHA-UHFFFAOYSA-N ethyl acetate;hexane;methanol Chemical compound OC.CCCCCC.CCOC(C)=O AZLPEJUVWWGLHA-UHFFFAOYSA-N 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
- 229920000570 polyether Polymers 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 3
- HLMHCDKXKXBKQK-UHFFFAOYSA-N 2-bromoethyl(diethyl)azanium;bromide Chemical compound Br.CCN(CC)CCBr HLMHCDKXKXBKQK-UHFFFAOYSA-N 0.000 description 3
- YXJJHZJYPMYYTR-UHFFFAOYSA-N 2-hexyldecyl 10-(4-nitrophenoxy)carbonyloxyhexadecanoate Chemical compound [N+](=O)([O-])C1=CC=C(OC(=O)OC(CCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCC)CCCCCC)C=C1 YXJJHZJYPMYYTR-UHFFFAOYSA-N 0.000 description 3
- ZMGLDPZVDZFNLE-UHFFFAOYSA-N 2-hexylsulfanylethanol Chemical compound CCCCCCSCCO ZMGLDPZVDZFNLE-UHFFFAOYSA-N 0.000 description 3
- LXPXOCHGDNNXCA-UHFFFAOYSA-N 4-heptanoyl butyric acid Chemical compound CCCCCCC(=O)CCCC(O)=O LXPXOCHGDNNXCA-UHFFFAOYSA-N 0.000 description 3
- GTCHZEFRDKAINX-UHFFFAOYSA-N 5-oxononanedioic acid Chemical compound OC(=O)CCCC(=O)CCCC(O)=O GTCHZEFRDKAINX-UHFFFAOYSA-N 0.000 description 3
- AGDCIOVLTTWMHF-UHFFFAOYSA-N 8-methylsulfanyloctan-1-ol Chemical compound CSCCCCCCCCO AGDCIOVLTTWMHF-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- VIRDERRLFQCCJT-UHFFFAOYSA-N CCCCCCCOC(CCCC(CCCC(OCCCCCCC)=O)OC(N1C=NC=C1)=O)=O Chemical compound CCCCCCCOC(CCCC(CCCC(OCCCCCCC)=O)OC(N1C=NC=C1)=O)=O VIRDERRLFQCCJT-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 description 3
- 229910001386 lithium phosphate Inorganic materials 0.000 description 3
- ZUUUAAZQEMFVSN-UHFFFAOYSA-N methyl 10-chloro-10-oxodecanoate Chemical compound COC(=O)CCCCCCCCC(Cl)=O ZUUUAAZQEMFVSN-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 3
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- TWQULNDIKKJZPH-UHFFFAOYSA-K trilithium;phosphate Chemical compound [Li+].[Li+].[Li+].[O-]P([O-])([O-])=O TWQULNDIKKJZPH-UHFFFAOYSA-K 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- FHQVHHIBKUMWTI-ZCXUNETKSA-N 1-palmitoyl-2-oleoyl phosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC FHQVHHIBKUMWTI-ZCXUNETKSA-N 0.000 description 2
- KXPXKNBDCUOENF-UHFFFAOYSA-N 2-(Octylthio)ethanol Chemical compound CCCCCCCCSCCO KXPXKNBDCUOENF-UHFFFAOYSA-N 0.000 description 2
- JJTRBLDHULFFNG-UHFFFAOYSA-N 2-[3-(diethylamino)propyl-(2-hydroxyethyl)amino]ethanol Chemical compound CCN(CC)CCCN(CCO)CCO JJTRBLDHULFFNG-UHFFFAOYSA-N 0.000 description 2
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 2
- UNWRBFUTPKHUOL-UHFFFAOYSA-N 2-butyloctyl 5-hydroxyundecanoate Chemical compound OC(CCCC(=O)OCC(CCCCCC)CCCC)CCCCCC UNWRBFUTPKHUOL-UHFFFAOYSA-N 0.000 description 2
- KBWRWCSRYCKEOR-UHFFFAOYSA-N 3-capryl propionic acid Chemical compound CCCCCCCC(=O)CCC(O)=O KBWRWCSRYCKEOR-UHFFFAOYSA-N 0.000 description 2
- WVUULNDRFBHTFG-UHFFFAOYSA-N 3-chloro-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCCl WVUULNDRFBHTFG-UHFFFAOYSA-N 0.000 description 2
- SPUWOYCLMKSXKU-UHFFFAOYSA-N 4-oxo capric acid Chemical compound CCCCCCC(=O)CCC(O)=O SPUWOYCLMKSXKU-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- XJTWZETUWHTBTG-UHFFFAOYSA-N 8-sulfanyloctan-1-ol Chemical compound OCCCCCCCCS XJTWZETUWHTBTG-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- BUPRYSPCAREDDP-UHFFFAOYSA-N CCCCCCOC(CCCC(CCCC(OCCCCCC)=O)OC(OCCN(CCN(CC)CC)CCO)=O)=O Chemical compound CCCCCCOC(CCCC(CCCC(OCCCCCC)=O)OC(OCCN(CCN(CC)CC)CCO)=O)=O BUPRYSPCAREDDP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- ZQSCEMYEJFSARK-UHFFFAOYSA-M O1CCCC1.[Br-].C(CCCC)[Mg+] Chemical compound O1CCCC1.[Br-].C(CCCC)[Mg+] ZQSCEMYEJFSARK-UHFFFAOYSA-M 0.000 description 2
- HQLAFAODIASKTD-UHFFFAOYSA-M O1CCCC1.[Br-].C(CCCCC)[Mg+] Chemical compound O1CCCC1.[Br-].C(CCCCC)[Mg+] HQLAFAODIASKTD-UHFFFAOYSA-M 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- SSCDRSKJTAQNNB-WVZYQCMWSA-N [3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC SSCDRSKJTAQNNB-WVZYQCMWSA-N 0.000 description 2
- QZRLFVIKBLTCEQ-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(OC(=O)OC(CCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCC)CCCCC)C=C1 Chemical compound [N+](=O)([O-])C1=CC=C(OC(=O)OC(CCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCC)CCCCC)C=C1 QZRLFVIKBLTCEQ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000012615 aggregate Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 125000001821 azanediyl group Chemical group [H]N(*)* 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- NMSBXSKECXMJCJ-UHFFFAOYSA-N ethyl 3-(2,6-dioxocyclohexyl)propanoate Chemical compound CCOC(=O)CCC1C(=O)CCCC1=O NMSBXSKECXMJCJ-UHFFFAOYSA-N 0.000 description 2
- ZQZBPLVTKYAPOF-UHFFFAOYSA-N ethyl 3-oxononanoate Chemical compound CCCCCCC(=O)CC(=O)OCC ZQZBPLVTKYAPOF-UHFFFAOYSA-N 0.000 description 2
- MNGJUPPXQPRNJP-UHFFFAOYSA-N ethyl 4-oxodecanoate Chemical compound CCCCCCC(=O)CCC(=O)OCC MNGJUPPXQPRNJP-UHFFFAOYSA-N 0.000 description 2
- UBTQVPMVWAEGAC-UHFFFAOYSA-N ethyl 8-bromooctanoate Chemical compound CCOC(=O)CCCCCCCBr UBTQVPMVWAEGAC-UHFFFAOYSA-N 0.000 description 2
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 150000002759 monoacylglycerols Chemical class 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 238000000235 small-angle X-ray scattering Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
- UXDBPOWEWOXJCE-DIPNUNPCSA-N 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine Chemical compound CCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCCN)OCCCCCCCCCCCCCCCC UXDBPOWEWOXJCE-DIPNUNPCSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonic acid Chemical compound CC1=CC(C)=C(S(O)(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- ZBIDZPHRNBZTLT-UHFFFAOYSA-N 2-(1-adamantyl)ethanol Chemical compound C1C(C2)CC3CC2CC1(CCO)C3 ZBIDZPHRNBZTLT-UHFFFAOYSA-N 0.000 description 1
- QNMCWJOEQBZQHB-UHFFFAOYSA-N 2-Hexyl-1-octanol Chemical compound CCCCCCC(CO)CCCCCC QNMCWJOEQBZQHB-UHFFFAOYSA-N 0.000 description 1
- LBNNZKQHIBEBBR-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl-ethylamino]ethanol Chemical compound CCN(CC)CCN(CC)CCO LBNNZKQHIBEBBR-UHFFFAOYSA-N 0.000 description 1
- BSHBGKYGJSPXEC-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl-propan-2-ylamino]ethanol Chemical compound CCN(CC)CCN(C(C)C)CCO BSHBGKYGJSPXEC-UHFFFAOYSA-N 0.000 description 1
- KOTHTSHIGYKYDO-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl-(2-hydroxyethyl)amino]ethanol Chemical compound CN(C)CCN(CCO)CCO KOTHTSHIGYKYDO-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- WRYDGMWSKBGVHS-UHFFFAOYSA-N 2-bromo-n,n-diethylethanamine Chemical compound CCN(CC)CCBr WRYDGMWSKBGVHS-UHFFFAOYSA-N 0.000 description 1
- YMDNODNLFSHHCV-UHFFFAOYSA-N 2-chloro-n,n-diethylethanamine Chemical compound CCN(CC)CCCl YMDNODNLFSHHCV-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- CXMYWOCYTPKBPP-UHFFFAOYSA-N 3-(3-hydroxypropylamino)propan-1-ol Chemical compound OCCCNCCCO CXMYWOCYTPKBPP-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- JOKMBONIEGNKBM-UHFFFAOYSA-N 3-[2-(diethylamino)ethyl-(3-hydroxypropyl)amino]propan-1-ol Chemical compound CCN(CC)CCN(CCCO)CCCO JOKMBONIEGNKBM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRIVEULBLVCCSL-UHFFFAOYSA-N 3-pentyloctan-1-ol Chemical compound CCCCCC(CCO)CCCCC ZRIVEULBLVCCSL-UHFFFAOYSA-N 0.000 description 1
- FTGIHCSSXPBYMX-UHFFFAOYSA-N 4-(4-hydroxybutylamino)butan-1-ol Chemical compound OCCCCNCCCCO FTGIHCSSXPBYMX-UHFFFAOYSA-N 0.000 description 1
- HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 1
- UDDSEESQRGPVIL-UHFFFAOYSA-N 4-oxoheptanedioic acid Chemical compound OC(=O)CCC(=O)CCC(O)=O UDDSEESQRGPVIL-UHFFFAOYSA-N 0.000 description 1
- PESKGJQREUXSRR-UXIWKSIVSA-N 5alpha-cholestan-3-one Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 PESKGJQREUXSRR-UXIWKSIVSA-N 0.000 description 1
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 description 1
- PESKGJQREUXSRR-UHFFFAOYSA-N 5beta-cholestanone Natural products C1CC2CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 PESKGJQREUXSRR-UHFFFAOYSA-N 0.000 description 1
- GMXIEASXPUEOTG-UHFFFAOYSA-N 8-bromooctan-1-ol Chemical compound OCCCCCCCCBr GMXIEASXPUEOTG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- KLBZFFUGCUCORR-UHFFFAOYSA-N CCCCCCCCOC(CCCC(CCCC(OCCCCCCCC)=O)OC(N1C=NC=C1)=O)=O Chemical compound CCCCCCCCOC(CCCC(CCCC(OCCCCCCCC)=O)OC(N1C=NC=C1)=O)=O KLBZFFUGCUCORR-UHFFFAOYSA-N 0.000 description 1
- JFHOZAYZOLEFTA-UHFFFAOYSA-N CCN(CC)CCN(CCCCO)CCCCO Chemical compound CCN(CC)CCN(CCCCO)CCCCO JFHOZAYZOLEFTA-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100036284 Hepcidin Human genes 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101001021253 Homo sapiens Hepcidin Proteins 0.000 description 1
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical class NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- PQBDJYQJGFKKQH-UHFFFAOYSA-N O=C(CCCC(=O)OCC(CCCCCC)CCCC)CCCCCC Chemical compound O=C(CCCC(=O)OCC(CCCCCC)CCCC)CCCCCC PQBDJYQJGFKKQH-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001662443 Phemeranthus parviflorus Species 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
- 108091029810 SaRNA Proteins 0.000 description 1
- OSYQOBUUFRGFNG-UHFFFAOYSA-N Sebacic acid monomethyl ester Chemical compound COC(=O)CCCCCCCCC(O)=O OSYQOBUUFRGFNG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- RQQIRMLGKSPXSE-WIPMOJCBSA-N [1-acetyloxy-2-[[(2s,3r,5s,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxyethyl] acetate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-WIPMOJCBSA-N 0.000 description 1
- FTRXVOHYOXLMHK-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(OC(=O)OC(CCCC(=O)OCC(CCCCCC)CCCC)CCCCCC)C=C1 Chemical compound [N+](=O)([O-])C1=CC=C(OC(=O)OC(CCCC(=O)OCC(CCCCCC)CCCC)CCCCCC)C=C1 FTRXVOHYOXLMHK-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-L azelaate(2-) Chemical compound [O-]C(=O)CCCCCCCC([O-])=O BDJRBEYXGGNYIS-UHFFFAOYSA-L 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 description 1
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HJSLFCCWAKVHIW-UHFFFAOYSA-N cyclohexane-1,3-dione Chemical compound O=C1CCCC(=O)C1 HJSLFCCWAKVHIW-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000001985 dialkylglycerols Chemical class 0.000 description 1
- ZGBUXZJMZBBISR-UHFFFAOYSA-N diethyl 4-oxoheptanedioate Chemical compound CCOC(=O)CCC(=O)CCC(=O)OCC ZGBUXZJMZBBISR-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
- GMVIQOCPXTZUFJ-UHFFFAOYSA-L dipotassium;2-ethylpropanedioate Chemical compound [K+].[K+].CCC(C([O-])=O)C([O-])=O GMVIQOCPXTZUFJ-UHFFFAOYSA-L 0.000 description 1
- 125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- IXZFDJXHLQQSGQ-UHFFFAOYSA-N ethyl 4-chloro-4-oxobutanoate Chemical compound CCOC(=O)CCC(Cl)=O IXZFDJXHLQQSGQ-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000003916 ethylene diamine group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- UCVODTZQZHMTPN-UHFFFAOYSA-N heptanoyl chloride Chemical compound CCCCCCC(Cl)=O UCVODTZQZHMTPN-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- LZFCBBSYZJPPIV-UHFFFAOYSA-M magnesium;hexane;bromide Chemical compound [Mg+2].[Br-].CCCCC[CH2-] LZFCBBSYZJPPIV-UHFFFAOYSA-M 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YUKZJEQIDOFUPV-UHFFFAOYSA-N n',n'-diethyl-n,n-dimethylethane-1,2-diamine Chemical compound CCN(CC)CCN(C)C YUKZJEQIDOFUPV-UHFFFAOYSA-N 0.000 description 1
- JILXUIANNUALRZ-UHFFFAOYSA-N n',n'-diethylbutane-1,4-diamine Chemical compound CCN(CC)CCCCN JILXUIANNUALRZ-UHFFFAOYSA-N 0.000 description 1
- TZOQABCMUFLDOI-UHFFFAOYSA-N n-(2-bromoethyl)-n-propylpropan-1-amine;hydrobromide Chemical compound Br.CCCN(CCC)CCBr TZOQABCMUFLDOI-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000005064 octadecenyl group Chemical group C(=CCCCCCCCCCCCCCCCC)* 0.000 description 1
- KZCOBXFFBQJQHH-UHFFFAOYSA-N octane-1-thiol Chemical compound CCCCCCCCS KZCOBXFFBQJQHH-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-M pentadecanoate Chemical compound CCCCCCCCCCCCCCC([O-])=O WQEPLUUGTLDZJY-UHFFFAOYSA-M 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- UMBKGTQQGYPQBE-OGFXRTJISA-M potassium 2-[(4S)-4-carboxy-4,5-dihydro-1,3-thiazol-2-yl]-1,3-benzothiazol-6-olate Chemical compound [K+].OC(=O)[C@H]1CSC(=N1)c1nc2ccc([O-])cc2s1 UMBKGTQQGYPQBE-OGFXRTJISA-M 0.000 description 1
- WVUCPRGADMCTBN-UHFFFAOYSA-M potassium;3-ethoxy-3-oxopropanoate Chemical compound [K+].CCOC(=O)CC([O-])=O WVUCPRGADMCTBN-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YLQLIQIAXYRMDL-UHFFFAOYSA-N propylheptyl alcohol Chemical compound CCCCCC(CO)CCC YLQLIQIAXYRMDL-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940078677 sarna Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- GYBMSOFSBPZKCX-UHFFFAOYSA-N sodium;ethanol;ethanolate Chemical compound [Na+].CCO.CC[O-] GYBMSOFSBPZKCX-UHFFFAOYSA-N 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- GHIZCSMTYWOBQA-BZSCQJQFSA-N spinasterol Natural products CC[C@H](C=C[C@@H](C)[C@@H]1CC[C@@]2(C)C3=CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C GHIZCSMTYWOBQA-BZSCQJQFSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005063 tetradecenyl group Chemical group C(=CCCCCCCCCCCCC)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000005040 tridecenyl group Chemical group C(=CCCCCCCCCCCC)* 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PNQBEPDZQUOCNY-UHFFFAOYSA-N trifluoroacetyl chloride Chemical compound FC(F)(F)C(Cl)=O PNQBEPDZQUOCNY-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 125000005065 undecenyl group Chemical group C(=CCCCCCCCCC)* 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/16—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Definitions
- the present invention relates to compounds or salts thereof, and lipid particles and pharmaceutical compositions using the same.
- Nucleic acid drugs have a clear mechanism of action against diseases, have few side effects, and are expected to be next-generation drugs.
- nucleic acid medicines using siRNA small interfering RNA
- siRNA small interfering RNA
- diseases and conditions caused by aberrant expression of a particular gene or gene group can be alleviated or treated.
- a viral vector such as a retrovirus or adenovirus.
- the method using a viral vector has a high gene transfer efficiency, there are concerns about the size of the gene to be transferred, immunogenicity, and safety.
- gene transfer using lipid particles is being actively developed because there are no restrictions on the transgenes and the above problems can be resolved.
- Patent Document 1 discloses a compound having an ester group, an acetal group, or the like as a linking group that connects an aliphatic group and an amino group.
- Patent Document 2 describes a compound having an alkylenediamine structure such as an ethylenediamine structure, and describes that lipid particles containing this compound exhibit a high nucleic acid encapsulation rate and excellent nucleic acid delivery.
- Lipid particles that can function as vectors and compounds that compose them are being further explored, and the development of compounds that can achieve excellent nucleic acid delivery is desired.
- the present invention provides a compound or a salt thereof that constitutes a lipid particle capable of realizing a high nucleic acid encapsulation rate and excellent nucleic acid delivery, and a lipid capable of realizing a high nucleic acid encapsulation rate and excellent nucleic acid delivery using the same.
- the problem to be solved was to provide particles and pharmaceutical compositions.
- the present inventors have made intensive studies to solve the above problems, and found that lipid particles prepared using a compound represented by the following formula (1) or a salt thereof exhibit a high nucleic acid encapsulation rate and excellent nucleic acid delivery. After confirming this, the present invention was completed. According to the present invention, the following inventions are provided.
- R 1 and R 2 each independently represents a hydrocarbon group having 1 to 18 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 8 carbon atoms
- the hydrocarbon represented by R 1 , R 2 and R 3 The groups are from —OH, COOH, —NR 51 R 52 , —OC(O)OR 53 , —C(O)OR 54 , —OC(O)—R 55 , and —OR 56 optionally substituted with one or more selected substituents
- R 4 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 5 and R 6 each independently represent a hydrocarbon group having 1 to 8 carbon atoms, or -R 8 -L 1 -R 9 , provided that both R 5 and R 6 are hydrocarbon groups having 1 to 8 carbon atoms except if it is a base
- R 7 represents -R 10 -L 2 -R 11 -L 3 -R 12
- R 51 represents -R 10 -L 2 -R 11 -L 3
- R 61 and R 62 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 63 , R 64 , R 65 and R 66 each independently represent a hydrocarbon group having 1 to 24 carbon atoms
- the hydrocarbon groups represented by R 63 , R 64 , R 65 and R 66 may be substituted with an aryl group having 6 to 20 carbon atoms or —S—R 68
- the above aryl groups having 6 to 20 carbon atoms are —OH, COOH, —NR 61 R 62 , —OC(O)OR 63 , —C(O)OR 64 , —OC(O)—R optionally substituted with 65 , —OR 66 , or —(hydrocarbon group having 1 to 12 carbon atoms) —R 67
- R 68 represents a hydrocarbon group having 1 to 12 carbon atoms
- L 1 , L 2 and L 3 each independently represent -OC(O)O-, -C(O)O
- R 8 represents a hydrocarbon group having 1 to 12 carbon atoms
- R 9 represents a hydrocarbon group having 1 to 24 carbon atoms
- R 10 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 11 represents a hydrocarbon group having 1 to 24 carbon atoms
- R 12 represents a hydrocarbon group having 1 to 24 carbon atoms
- the hydrocarbon group represented by R 9 and R 12 is an aryl group, —OC(O)OR 53 , —C(O)OR 54 , —OC(O)—R 55 , or —SR optionally substituted with 58 , the definitions of R 53 , R 54 , R 55 and R 58 being as above;
- the hydrocarbon group represented by R 11 may be substituted with —OC(O)OR 53 , —C(O)OR 54 , or —OC(O)—R 55 , and R 53 , R 54 , and R 55 are defined as above.
- R 1 and R 2 each independently represent a hydrocarbon group having 1 to 3 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 4 carbon atoms
- R 1 , R 2 and R 3 are The indicated hydrocarbon group may be substituted with —OH
- R 4 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 5 and R 6 each independently represent a hydrocarbon group having 1 to 8 carbon atoms, or -R 8 -L 1 -R 9 , provided that both R 5 and R 6 are hydrocarbon groups having 1 to 8 carbon atoms except if it is a base
- R 7 represents -R 10 -L 2 -R 11 -L 3 -R 12
- L 1 and L 3 each independently represent -C(O)O- or -OC(O)-.
- L2 represents -OC ( O)O-, -C(O)O-, or -OC(O)-.
- R 8 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 9 represents a hydrocarbon group having 1 to 16 carbon atoms
- R 10 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 11 represents a hydrocarbon group having 1 to 9 carbon atoms
- R 12 represents a hydrocarbon group having 1 to 16 carbon atoms
- the hydrocarbon group represented by R 9 and R 12 may be substituted with an aryl group or —S—R 58
- R 58 represents a hydrocarbon group having 1 to 8 carbon atoms
- the hydrocarbon group represented by R 11 may be substituted with —C(O)OR 55 or —OC(O)—R 56
- R 55 and R 56 each independently represent a hydrocarbon group having 1 to 16 carbon atoms
- the hydrocarbon group represented by R 55 and R 56 may be substituted with an aryl group having 6 to 20 carbon
- ⁇ 3> The compound or its salt according to ⁇ 1>, which is a compound represented by the following formula (1-1) or a salt thereof.
- R 1 and R 2 each independently represents a hydrocarbon group having 1 to 18 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 8 carbon atoms
- the hydrocarbon represented by R 1 , R 2 and R 3 The group is —OH, COOH, —NR 51 R 52 , —OC(O)OR 53 , —C(O)OR 54 , —OC(O)—R 55 , or —OR 56 may be substituted
- R 4 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 5 and R 6 each independently represent a hydrocarbon group having 1 to 8 carbon atoms, or -R 8 -L 1 -R 9 , provided that both R 5 and R 6 are hydrocarbon groups having 1 to 8 carbon atoms except if it is a base
- L 1 represents
- R 13 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 14 represents -R 15 -L 5 -R 16
- R 15 represents a hydrocarbon group having 1 to 24 carbon atoms
- L 5 represents -OC(O)O-, -C(O)O-, -OC(O)- or -O-
- R 16 represents a hydrocarbon group having 1 to 24 carbon atoms
- the hydrocarbon group having 1 to 24 carbon atoms represented by R 15 may be substituted with —OC(O)OR 53 , —C(O)OR 54 , or —OC(O)—R 55 .
- R 53 , R 54 and R 55 are as above,
- the hydrocarbon group having 1 to 24 carbon atoms represented by R 16 is an aryl group having 6 to 20 carbon atoms, —OC(O)OR 53 , —C(O)OR 54 , —OC(O)— It may be substituted with R 55 , or —SR 58 , where R 53 , R 54 , R 55 and R 58 are defined as above.
- R 1 and R 2 each independently represent a hydrocarbon group having 1 to 3 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 4 carbon atoms
- the hydrocarbon represented by R 1 , R 2 and R 3 the group is optionally substituted with -OH
- R 4 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 5 and R 6 each independently represent a hydrocarbon group having 1 to 8 carbon atoms, or -R 8 -L 1 -R 9 , provided that both R 5 and R 6 are hydrocarbon groups having 1 to 8 carbon atoms except if it is a base
- L 1 represents -C(O)O- or -OC(O)-
- R 8 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 9 represents a hydrocarbon group having 1 to 18 carbon atoms
- the hydrocarbon group represented by R 9 may be substituted with an aryl group having 6 to 20 carbon atoms or —S—R 58
- R 58 represents a
- R 1 and R 2 each independently represents a hydrocarbon group having 1 to 18 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 8 carbon atoms
- the hydrocarbon represented by R 1 , R 2 and R 3 The group is —OH, COOH, —NR 51 R 52 , —OC(O)OR 53 , —C(O)OR 54 , —OC(O)—R 55 , or —OR 56
- R 4 and R 8 each independently represent a hydrocarbon having 1 to 8 carbon atoms
- R 21 and R 22 each independently represent a hydrocarbon group having 1 to 18 carbon atoms
- R 23 and R 24 each independently represent a hydrocarbon group having 1 to 12 carbon atoms
- R 25 and R 26 each independently represent a hydrocarbon group having 1 to 24 carbon atoms
- R 58 represents a hydrocarbon group having 1 to 12 carbon atoms.
- R 1 and R 2 each independently represent a hydrocarbon group having 1 to 3 carbon atoms, and the hydrocarbon group represented by R 1 and R 2 may be substituted with —OH
- R 3 represents a hydrocarbon group having 2 to 4 carbon atoms
- R 4 and R 8 each independently represent a hydrocarbon having 1 to 8 carbon atoms
- R 21 and R 22 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 23 and R 24 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 25 and R 26 each independently represent a hydrocarbon group having 1 to 16 carbon atoms
- L 21 and L 22 each independently represent -C(O)O- or -OC(O)-;
- R 1 and R 2 each independently represent a hydrocarbon group having 1 to 3 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 4 carbon atoms
- R 4 and R 8 each independently represent a hydrocarbon having 1 to 8 carbon atoms
- R 21 and R 22 each independently represent a hydrocarbon group having 1 to 6 carbon atoms
- R 23 and R 24 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 25 and R 26 each independently represent a hydrocarbon group having 1 to 12 carbon atoms
- L 21 and L 22 each independently represent -C(O)O- or -OC(O)-;
- R 1 and R 2 each independently represents a hydrocarbon group having 1 to 18 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 8 carbon atoms
- the hydrocarbon represented by R 1 , R 2 and R 3 The group is —OH, COOH, —NR 51 R 52 , —OC(O)OR 53 , —C(O)OR 54 , —OC(O)—R 55 , or —OR 56 may be substituted
- R 4 and R 8 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 31 , R 32 , R 33 and R 34 each independently represent a hydrocarbon group having 1 to 12 carbon atoms
- R 35 , R 36 , R 37 and R 38 each independently represent a hydrocarbon group having 1 to 24 carbon atoms
- L 31 , L 32 , L 33 and L 34 each independently represent -OC(
- R 58 represents a hydrocarbon group having 1 to 12 carbon atoms.
- R 1 and R 2 each independently represent a hydrocarbon group having 1 to 3 carbon atoms, and the hydrocarbon group represented by R 1 and R 2 may be substituted with —OH
- R 3 represents a hydrocarbon group having 2 to 4 carbon atoms
- R 4 and R 8 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 31 , R 32 , R 33 and R 34 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 35 , R 36 , R 37 and R 38 each independently represent a hydrocarbon group having 1 to 16 carbon atoms
- L 31 , L 32 , L 33 and L 34 each independently represent -C(O)O- or -OC(O)-
- the hydrocarbon group represented by R 35 , R 36 , R 37 and R 38 may be substituted with an aryl group having 6 to 20 carbon atoms or S—R 58 , R 58 represents a hydrocarbon
- R 1 and R 2 each independently represent a hydrocarbon group having 1 to 3 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 4 carbon atoms
- R 4 and R 8 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 31 , R 32 , R 33 and R 34 each independently represent a hydrocarbon group having 1 to 3 carbon atoms
- R 35 , R 36 , R 37 and R 38 each independently represent a hydrocarbon group having 1 to 12 carbon atoms
- L 31 , L 32 , L 33 and L 34 each independently represent -C(O)O- or -OC(O)-
- the hydrocarbon groups represented by R 35 , R 36 , R 37 and R 38 may be substituted with —S—R 58
- R 58 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 1 and R 2 each independently represent a hydrocarbon group having 1 to 3 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 4 carbon atoms
- R 4 and R 8 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 31 , R 32 , R 33 and R 34 each independently represent a hydrocarbon group having 1 to 3 carbon atoms
- R 35 , R 36 , R 37 and R 38 each independently represents a hydrocarbon group having 1 to 12 carbon atoms substituted with —S—R 58
- R 58 is a hydrocarbon group having 1 to 8 carbon atoms indicate the group
- L 31 , L 32 , L 33 and L 34 each independently represent -C(O)O- or -OC(O)-;
- R 1 and R 2 each independently represent a hydrocarbon group having 1 to 3 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 4 carbon atoms
- R 4 and R 8 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 31 , R 32 , R 33 and R 34 each independently represent a hydrocarbon group having 1 to 3 carbon atoms
- R 35 , R 36 , R 37 and R 38 each independently represent a hydrocarbon group having 1 to 12 carbon atoms
- L 31 , L 32 , L 33 and L 34 each independently represent -C(O)O- or -OC(O)-;
- lipid particle according to ⁇ 14> wherein the lipid is at least one lipid selected from the group consisting of lipids having a sterol and a nonionic hydrophilic polymer chain.
- lipid particle according to ⁇ 14> or ⁇ 15> further comprising a neutral lipid.
- lipid particle according to any one of ⁇ 14> to ⁇ 16> further comprising a nucleic acid.
- nucleic acid contains a nucleic acid having 50 or more bases.
- a pharmaceutical composition comprising the lipid particles according to any one of ⁇ 14> to ⁇ 18> as an active ingredient.
- lipid particles and pharmaceutical compositions capable of realizing a high nucleic acid encapsulation rate and excellent nucleic acid delivery.
- the lipid particles and pharmaceutical composition of the present invention can achieve a high nucleic acid encapsulation rate and excellent nucleic acid delivery.
- R 1 and R 2 each independently represent a hydrocarbon group having 1 to 18 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 8 carbon atoms
- the hydrocarbon represented by R 1 , R 2 and R 3 The groups are from —OH, COOH, —NR 51 R 52 , —OC(O)OR 53 , —C(O)OR 54 , —OC(O)—R 55 , and —OR 56 optionally substituted with one or more selected substituents
- R 4 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 5 and R 6 each independently represent a hydrocarbon group having 1 to 8 carbon atoms, or -R 8 -L 1 -R 9 , provided that both R 5 and R 6 are hydrocarbon groups having 1 to 8 carbon atoms except if it is a base
- R 7 represents -R 10 -L 2 -R 11 -L 3 -R 12
- R 51 and R 52 each independently represent a hydrocarbon group having 1 to 8 carbon atom
- R 61 and R 62 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 63 , R 64 , R 65 and R 66 each independently represent a hydrocarbon group having 1 to 24 carbon atoms
- the hydrocarbon groups represented by R 63 , R 64 , R 65 and R 66 may be substituted with an aryl group having 6 to 20 carbon atoms or —S—R 68
- the above aryl groups having 6 to 20 carbon atoms are —OH, COOH, —NR 61 R 62 , —OC(O)OR 63 , —C(O)OR 64 , —OC(O)—R optionally substituted with 65 , —OR 66 , or —(hydrocarbon group having 1 to 12 carbon atoms) —R 67
- R 68 represents a hydrocarbon group having 1 to 12 carbon atoms
- L 1 , L 2 and L 3 each independently represent -OC(O)O-, -C(O)O
- R 8 represents a hydrocarbon group having 1 to 12 carbon atoms
- R 9 represents a hydrocarbon group having 1 to 24 carbon atoms
- R 10 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 11 represents a hydrocarbon group having 1 to 24 carbon atoms
- R 12 represents a hydrocarbon group having 1 to 24 carbon atoms
- the hydrocarbon group represented by R 9 and R 12 is an aryl group, —OC(O)OR 53 , —C(O)OR 54 , —OC(O)—R 55 , or —SR optionally substituted with 58 , the definitions of R 53 , R 54 , R 55 and R 58 being as above;
- the hydrocarbon group represented by R 11 may be substituted with —OC(O)OR 53 , —C(O)OR 54 , or —OC(O)—R 55 , and R 53 , R 54 , and R 55 are defined as above.
- a hydrocarbon group having 1 to 24 carbon atoms a hydrocarbon group having 1 to 18 carbon atoms, a hydrocarbon group having 1 to 12 carbon atoms, a hydrocarbon group having 2 to 8 carbon atoms, and a hydrocarbon group having 1 to 8 carbon atoms are preferably alkyl groups, alkenyl groups or alkynyl groups, respectively.
- the alkyl group may be linear or branched, and may be chain or cyclic. Specific examples of the alkyl group include methyl group, ethyl group, propyl group, isopropyl group, cyclopropyl group, butyl group, isobutyl group, tert-butyl group, cyclobutyl group, pentyl group, cyclopentyl group, hexyl group, and cyclohexyl.
- the alkenyl group may be linear or branched, and may be chain or cyclic. Specifically, allyl group, prenyl group, pentenyl group, hexenyl group, heptenyl group, octenyl group, nonenyl group (preferably (Z)-2-nonenyl group or (E)-2-nonenyl group), decenyl group, undecenyl group, dodecenyl group, dodecadienyl group, tridecenyl group (preferably (Z)-trideca-8-enyl group), tetradecenyl group (preferably tetradeca-9-enyl group), pentadecenyl group (preferably, ( Z)-pentadeca-8-enyl group), hexadecenyl group (preferably (Z)-hexadec-9-enyl group), hexadecadienyl group, heptadecenyl group (
- the alkynyl group may be linear or branched, and may be chain or cyclic. Specifically, propargyl group, butynyl group, pentynyl group, hexynyl group, heptynyl group, octynyl group, nonynyl group, decynyl group, undecynyl group, dodecynyl group, tetradecynyl group, pentadecynyl group, hexadecynyl group, heptadecynyl group, octadecynyl group, etc. are mentioned.
- All of the above alkenyl groups preferably have one or two double bonds, and all alkynyl groups preferably have one or two triple bonds.
- the hydrocarbon group having 1 to 12 carbon atoms in —R 67 is preferably an alkylene group having 1 to 12 carbon atoms or an alkenylene group having 2 to 12 carbon atoms.
- the alkylene group having 1 to 12 carbon atoms and the alkenylene group having 2 to 12 carbon atoms may be linear or branched, and may be chain or cyclic. Specific examples include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene, decamethylene, and undecamethylene groups.
- the aryl group preferably has 6 to 20 carbon atoms, more preferably 6 to 18 carbon atoms, and even more preferably 6 to 10 carbon atoms. Specific examples include phenyl group, naphthyl group, anthracenyl group, phenanthrenyl group and the like.
- R 1 and R 2 each independently represent preferably a hydrocarbon group having 1 to 12 carbon atoms, more preferably a hydrocarbon group having 1 to 6 carbon atoms, still more preferably a hydrocarbon group having 1 to 3 carbon atoms. Indicates a hydrogen group.
- R 3 preferably represents a hydrocarbon group having 2 to 6 carbon atoms, more preferably a hydrocarbon group having 2 to 4 carbon atoms.
- the hydrocarbon groups represented by R 1 , R 2 and R 3 may preferably be substituted with —OH.
- L 1 and L 3 each independently preferably represent -C(O)O- or -OC(O)-.
- L 2 preferably denotes -OC(O)O-, -C(O)O- or -OC(O)-.
- R 8 preferably represents a hydrocarbon group having 1 to 10 carbon atoms, more preferably a hydrocarbon group having 1 to 8 carbon atoms.
- R 9 preferably represents a hydrocarbon group having 1 to 20 carbon atoms, more preferably a hydrocarbon group having 1 to 16 carbon atoms.
- R 11 preferably represents a hydrocarbon group having 1 to 16 carbon atoms, more preferably a hydrocarbon group having 1 to 9 carbon atoms.
- R 12 preferably represents a hydrocarbon group having 1 to 20 carbon atoms, more preferably a hydrocarbon group having 1 to 16 carbon atoms.
- the hydrocarbon groups represented by R 9 and R 12 may preferably be substituted with an aryl group or —S—R 58 .
- R 58 here preferably represents a hydrocarbon group having 1 to 8 carbon atoms.
- the hydrocarbon group represented by R 11 is preferably optionally substituted with —C(O)OR 55 , or —OC(O)—R 56 , wherein R 55 and R 56 are each independently represents a hydrocarbon group having 1 to 16 carbon atoms,
- the hydrocarbon group represented by R 55 and R 56 may preferably be substituted with an aryl group having 6 to 20 carbon atoms or —S—R 58 , and the definition of R 58 is as described above.
- the compound represented by Formula (1) is preferably a compound represented by Formula (1-1) below.
- R 1 and R 2 each independently represents a hydrocarbon group having 1 to 18 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 8 carbon atoms
- the hydrocarbon represented by R 1 , R 2 and R 3 The group is —OH, COOH, —NR 51 R 52 , —OC(O)OR 53 , —C(O)OR 54 , —OC(O)—R 55 , or —OR 56 may be substituted
- R 4 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 5 and R 6 each independently represent a hydrocarbon group having 1 to 8 carbon atoms, or -R 8 -L 1 -R 9 , provided that both R 5 and R 6 are hydrocarbon groups having 1 to 8 carbon atoms except if it is a base
- L 1 represents -OC(O)O-, -C(O)O-, -OC(O)-
- R 13 represents a hydrocarbon group having 1 to 8 carbon atoms
- R 14 represents -R 15 -L 5 -R 16
- R 15 represents a hydrocarbon group having 1 to 24 carbon atoms
- L 5 represents -OC(O)O-, -C(O)O-, -OC(O)- or -O-
- R 16 represents a hydrocarbon group having 1 to 24 carbon atoms
- the hydrocarbon group having 1 to 24 carbon atoms represented by R 15 may be substituted with —OC(O)OR 53 , —C(O)OR 54 , or —OC(O)—R 55 .
- R 53 , R 54 and R 55 are as above,
- the hydrocarbon group having 1 to 24 carbon atoms represented by R 16 is an aryl group having 6 to 20 carbon atoms, —OC(O)OR 53 , —C(O)OR 54 , —OC(O)— It may be substituted with R 55 , or —SR 58 , where R 53 , R 54 , R 55 and R 58 are defined as above.
- R 1 and R 2 each independently represent preferably a hydrocarbon group having 1 to 12 carbon atoms, more preferably a hydrocarbon group having 1 to 6 carbon atoms, and still more preferably , represents a hydrocarbon group having 1 to 3 carbon atoms.
- R 3 preferably represents a hydrocarbon group having 2 to 6 carbon atoms, more preferably a hydrocarbon group having 2 to 4 carbon atoms.
- the hydrocarbon groups represented by R 1 , R 2 and R 3 may preferably be substituted with —OH.
- L 1 preferably represents -C(O)O- or -OC(O)-.
- R 8 preferably represents a hydrocarbon group having 1 to 10 carbon atoms, more preferably a hydrocarbon group having 1 to 8 carbon atoms.
- R 9 preferably represents a hydrocarbon group having 1 to 18 carbon atoms, and the hydrocarbon group represented by R 9 may be substituted with an aryl group having 6 to 20 carbon atoms or —SR 58 .
- R 14 preferably represents -R 15 -L 5 -R 16 , R 15 represents a hydrocarbon group having 1 to 18 carbon atoms, L 5 represents -OC(O)O-, and R 16 is , represents a hydrocarbon group having 1 to 18 carbon atoms.
- the hydrocarbon group having 1 to 18 carbon atoms represented by R 15 may preferably be substituted with —C(O)OR 55 or —OC(O)—R 56 .
- R 55 and R 56 each independently represent a hydrocarbon group having 1 to 16 carbon atoms, and the hydrocarbon group represented by R 55 and R 56 is an aryl group having 6 to 20 carbon atoms or —S—R 58 and the definition of R 58 is as above.
- the hydrocarbon group having 1 to 18 carbon atoms represented by R 16 may preferably be substituted with an aryl group or —S—R 58 , and the definition of R 58 is as described above.
- the compound represented by the formula (1) is preferably a compound represented by the following formula (1-2).
- R 1 and R 2 each independently represents a hydrocarbon group having 1 to 18 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 8 carbon atoms
- the hydrocarbon represented by R 1 , R 2 and R 3 The group is —OH, COOH, —NR 51 R 52 , —OC(O)OR 53 , —C(O)OR 54 , —OC(O)—R 55 , or —OR 56 may be substituted
- R 4 and R 8 each independently represent a hydrocarbon having 1 to 8 carbon atoms
- R 21 and R 22 each independently represent a hydrocarbon group having 1 to 18 carbon atoms
- R 23 and R 24 each independently represent a hydrocarbon group having 1 to 12 carbon atoms
- R 25 and R 26 each independently represent a hydrocarbon group having 1 to 24 carbon atoms
- L 21 and L 22 each independently represent -OC(O)O-, -C(O)
- R 1 and R 2 each independently represent preferably a hydrocarbon group having 1 to 12 carbon atoms, more preferably a hydrocarbon group having 1 to 6 carbon atoms, and still more preferably , represents a hydrocarbon group having 1 to 3 carbon atoms.
- the hydrocarbon groups represented by R 1 and R 2 are preferably optionally substituted with --OH, but are more preferably unsubstituted hydrocarbon groups.
- R 3 preferably represents a hydrocarbon group having 2 to 6 carbon atoms, more preferably a hydrocarbon group having 2 to 4 carbon atoms.
- R 21 and R 22 each independently represent preferably a hydrocarbon group having 1 to 12 carbon atoms, more preferably a hydrocarbon group having 1 to 8 carbon atoms, still more preferably a hydrocarbon group having 1 to 6 carbon atoms indicates a group.
- R 23 and R 24 each independently represent preferably a hydrocarbon group having 1 to 10 carbon atoms, more preferably a hydrocarbon group having 1 to 8 carbon atoms.
- R 25 and R 26 each independently represent preferably a hydrocarbon group having 1 to 20 carbon atoms, more preferably a hydrocarbon group having 1 to 16 carbon atoms, still more preferably a hydrocarbon group having 1 to 12 carbon atoms indicates a group.
- L 21 and L 22 each independently preferably represent -C(O)O- or -OC(O)-.
- the compound represented by the formula (1) is preferably a compound represented by the following formula (1-3).
- R 1 and R 2 each independently represents a hydrocarbon group having 1 to 18 carbon atoms
- R 3 represents a hydrocarbon group having 2 to 8 carbon atoms
- the hydrocarbon represented by R 1 , R 2 and R 3 The group is —OH, COOH, —NR 51 R 52 , —OC(O)OR 53 , —C(O)OR 54 , —OC(O)—R 55 , or —OR 56 may be substituted
- R 4 and R 8 each independently represent a hydrocarbon group having 1 to 8 carbon atoms
- R 31 , R 32 , R 33 and R 34 each independently represent a hydrocarbon group having 1 to 12 carbon atoms
- R 35 , R 36 , R 37 and R 38 each independently represent a hydrocarbon group having 1 to 24 carbon atoms
- L 31 , L 32 , L 33 and L 34 each independently represent -OC(O)O-, -C
- R 1 and R 2 each independently represent preferably a hydrocarbon group having 1 to 12 carbon atoms, more preferably a hydrocarbon group having 1 to 6 carbon atoms, still more preferably , represents a hydrocarbon group having 1 to 3 carbon atoms.
- the hydrocarbon groups represented by R 1 and R 2 are preferably optionally substituted with --OH, but are more preferably unsubstituted hydrocarbon groups.
- R 3 preferably represents a hydrocarbon group having 2 to 6 carbon atoms, more preferably a hydrocarbon group having 2 to 4 carbon atoms.
- R 31 , R 32 , R 33 and R 34 each independently represent preferably a hydrocarbon group having 1 to 10 carbon atoms, more preferably a hydrocarbon group having 1 to 8 carbon atoms, still more preferably a carbon It represents a hydrocarbon group of numbers 1-3.
- R 35 , R 36 , R 37 and R 38 each independently represent preferably a hydrocarbon group having 1 to 20 carbon atoms, more preferably a hydrocarbon group having 1 to 16 carbon atoms, still more preferably a carbon It represents a hydrocarbon group of numbers 1-12.
- the hydrocarbon group represented by R 35 , R 36 , R 37 and R 38 is preferably an aryl group having 6 to 20 carbon atoms or may be substituted with SR 58 . More preferably, it may be substituted with -SR58 .
- R 35 , R 36 , R 37 and R 38 each independently represent a hydrocarbon group having 1 to 12 carbon atoms substituted with —S—R 58 or a Indicates a hydrocarbon group.
- L 31 , L 32 , L 33 and L 34 each independently represent preferably -C(O)O- or -OC(O)-.
- R 58 preferably represents a hydrocarbon group having 1 to 10 carbon atoms, more preferably a hydrocarbon group having 1 to 8 carbon atoms.
- the compounds of the invention may form salts.
- Salts in basic groups include, for example, salts with mineral acids such as hydrochloric, hydrobromic, nitric and sulfuric acids; formic, acetic, citric, oxalic, fumaric, maleic, succinic, malic, salts with organic carboxylic acids such as tartaric acid, aspartic acid, trichloroacetic acid and trifluoroacetic acid; and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid. mentioned.
- Salts in acidic groups include, for example, salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; and trimethylamine, triethylamine, tributylamine, pyridine, N,N- Nitrogen-containing organic bases such as dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl- ⁇ -phenethylamine, 1-ephenamine and N,N'-dibenzylethylenediamine and salt with.
- preferred salts include pharmacologically acceptable salts.
- Examples 1 to 44 Preferable specific examples of the compounds of the present invention include the compounds described in Examples 1 to 44 below, but the present invention should not be construed as being limited thereto.
- the compounds described in Examples 1-44 are referred to as Compounds 1-44, respectively.
- compound 3 compound 8, compound 10, compound 11, compound 13, compound 14, compound 15, compound 16, compound 17, compound 19, compound 20, compound 21, compound 22, compound 23, compound 24, compound 27, compound 28, compound 29, compound 32, compound 33, compound 34, compound 37, compound 38, compound 39, compound 42, compound 43, and compound 44 are preferred.
- a method for producing the compound of the present invention will be described.
- the compounds of the present invention can be produced by combining known methods, and can be produced, for example, according to the production methods shown below.
- R a and R b represent leaving groups; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 have the same meanings as above. ” Leaving groups such as chloro, fluoro, bromo, trichloromethoxy, 4-nitro-phenoxy, 2,4-dinitrophenoxy, 2,4,6-trichlorophenoxy, pentafluorophenoxy, 2,3,5,6-tetrafluorophenoxy group, imidazolyl group, triazolyl group, 3,5-dioxo-4-methyl-1,2,4-oxadiazolidyl group, N-hydroxysuccinimidyl group, etc. mentioned.
- Known compounds of the formula [3] include, for example, 1,1′-carbonyldiimidazole, 4-nitrophenyl chloroformate, triphosgene and phosgene.
- the compound of formula [4] can be produced by reacting the compound of formula [2] with the compound of formula [3] in the presence or absence of a base.
- the solvent used in this reaction is not particularly limited as long as it does not affect the reaction. Examples include halogenated hydrocarbons, ethers, esters, amides, nitriles, sulfoxides and aromatic Hydrocarbons are mentioned, and these solvents may be mixed and used.
- Preferred solvents include ethers, more preferably tetrahydrofuran.
- the amount of the solvent to be used is not particularly limited, but may be 1 to 500 times (v/w) the amount of the compound of formula [2].
- Bases used in this reaction include inorganic bases and organic bases.
- the base is preferably an organic base, specifically triethylamine, N,N-diisopropylethylamine, 4-methylmorpholine, pyridine, 1,8-diazabicyclo[5.4.0]-7-undecene, or N,N- dimethylaminopyridine and the like.
- the amount of the base to be used may be 1 to 50-fold mol, preferably 1 to 10-fold mol, relative to the compound of formula [2].
- the amount of the compound of formula [3] used is not particularly limited, but may be 0.3 to 10 times (v/w) the amount of the compound of formula [2].
- the reaction may be carried out at -30 to 150°C, preferably 0 to 100°C, for 5 minutes to 48 hours.
- Compounds of formula [5] include, for example, 2,2′-((2-diethylamino)ethyl)azanediyl)bis(ethan-1-ol), 2,2′-((2-dimethylamino)ethyl)azanediyl) Bis(ethan-1-ol) and 2,2′-((3-(diethylamino)propyl)azanediyl)bis(ethan-1-ol) are known.
- a compound of formula [1] can be produced by reacting a compound of formula [4] with a compound of formula [5] in the presence of a base.
- the solvent used in this reaction is not particularly limited as long as it does not affect the reaction.
- Examples include halogenated hydrocarbons, ethers, esters, amides, nitriles, sulfoxides and aromatic Examples include hydrocarbons, and these solvents may be used in combination.
- Preferred solvents include nitriles, with acetonitrile being more preferred.
- the amount of solvent to be used is not particularly limited, but may be 1 to 500 times (v/w) the amount of the compound of formula [4].
- Bases used in this reaction include inorganic bases and organic bases.
- the amount of the base to be used is 1 to 50-fold mol, preferably 1 to 10-fold mol, relative to the compound of formula [4].
- the amount of the compound of formula [5] used is not particularly limited, but may be 0.1 to 10 times (v/w) the amount of the compound of formula [4].
- the reaction may be carried out at -30 to 150°C, preferably 0 to 100°C for 5 minutes to 48 hours.
- Examples of compounds of formula [5] include 2-((2-(diethylamino)ethyl)(ethyl)amino)ethan-1-ol and 2-((2-(diethylamino)ethyl)(isopropyl)amino)ethane- 1-ol and the like are known.
- a compound of formula [1] can be produced by reacting a compound of formula [4] with a compound of formula [6] in the presence of a base. This reaction may be carried out according to the production method (1-2).
- R c and R e are leaving groups; R d and R g are hydrocarbon groups having 1 to 12 carbon atoms or hydrogen; and R f is hydrocarbon groups having 1 to 18 carbon atoms.
- R h is a hydrocarbon group having 1 to 12 carbon atoms; M is an alkali metal, alkaline earth metal or hydrogen; R i is —MgCl, —MgBr, —MgI or —Li ; R 23 and R 25 have the same meanings as above.”
- Leaving groups such as chloro, fluoro, bromo, trichloromethoxy, 4-nitro-phenoxy, 2,4-dinitrophenoxy, 2,4,6-trichlorophenoxy, pentafluorophenoxy, 2,3,5,6-tetrafluorophenoxy group, imidazolyl group, triazolyl group, 3,5-dioxo-4-methyl-1,2,4-oxadiazolidyl group, N-hydroxy
- the compound of formula [9] can be produced by reacting the compound of formula [7] with the compound of formula [8] in the presence or absence of a base and in the presence or absence of anhydrous magnesium chloride. .
- the solvent used in this reaction is not particularly limited as long as it does not affect the reaction. Examples include halogenated hydrocarbons, ethers, esters, amides, nitriles, sulfoxides and aromatic Hydrocarbons are mentioned, and these solvents may be mixed and used. Preferred solvents include nitriles, with acetonitrile being more preferred.
- the amount of the solvent used is not particularly limited, but may be 1 to 500 times (v/w) the amount of the compound of formula [7].
- Bases used in this reaction include inorganic bases and organic bases.
- Organic bases are preferred, specifically triethylamine, N,N-diisopropylethylamine, 4-methylmorpholine, pyridine, 1,8-diazabicyclo[5.4.0]-7-undecene, or N,N-dimethylamino and pyridine.
- the amount of the base to be used is 1 to 50-fold mol, preferably 1 to 10-fold mol, relative to the compound of formula [7].
- the amount of the compound of formula [8] to be used is not particularly limited, but may be 0.1 to 10 times (v/w) the amount of the compound of formula [7].
- the reaction may be carried out at -30 to 150°C, preferably 0 to 100°C, for 5 minutes to 48 hours.
- a compound of formula [11A] can be produced by reacting a compound of formula [9] with a compound of formula [10] in the presence or absence of a base.
- the solvent used in this reaction is not particularly limited as long as it does not affect the reaction. Examples include halogenated hydrocarbons, ethers, esters, amides, nitriles, sulfoxides and aromatic Examples include hydrocarbons, and these solvents may be used in combination.
- Preferred solvents include alcohols, with ethanol and methanol being more preferred.
- the amount of the solvent to be used is not particularly limited, but may be 1 to 500 times (v/w) the amount of the compound of formula [9].
- Bases used in this reaction include inorganic bases and organic bases. Specifically, potassium hydroxide, sodium hydroxide, lithium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, potassium phosphate, sodium phosphate, lithium phosphate, triethylamine, N,N-diisopropylethylamine, 4-methyl morpholine, pyridine, 1,8-diazabicyclo[5.4.0]-7-undecene, N,N-dimethylaminopyridine and the like.
- the amount of the base to be used is 0.1 to 50-fold mol, preferably 1 to 10-fold mol, relative to the compound of formula [9].
- the amount of the compound of formula [8] to be used is not particularly limited, but may be 0.1 to 10 times (v/w) the amount of the compound of formula [9].
- the reaction may be carried out at -30 to 150°C, preferably 0 to 100°C, for 5 minutes to 48 hours.
- the compound of formula [11B] can be produced by hydrolysis reaction of the compound of formula [11A] in the presence of a base or acid.
- the solvent used in this reaction is not particularly limited as long as it does not affect the reaction. Examples include halogenated hydrocarbons, ethers, esters, amides, nitriles, sulfoxides, aromatic Examples include hydrocarbons and water, and these solvents may be used in combination.
- the amount of the solvent to be used is not particularly limited, but may be 1 to 500 times (v/w) the amount of the compound of formula [11A].
- Bases used in this reaction include inorganic bases and organic bases.
- Inorganic bases are preferred, and specific examples include potassium hydroxide, sodium hydroxide, lithium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, potassium phosphate, sodium phosphate and lithium phosphate.
- Acids used in this reaction include inorganic acids and organic acids. Inorganic acids are preferred, and specific examples include hydrochloric acid, hydrobromic acid, iodic acid, sulfuric acid and phosphoric acid.
- the amount of the base to be used is 0.1 to 50-fold mol, preferably 1 to 10-fold mol, relative to the compound of formula [11A].
- the acid is used in an amount of 0.01 to 50 mol, preferably 1 to 10 mol per mol of the compound of formula [11A].
- the reaction may be carried out at -30 to 150°C, preferably 0 to 100°C, for 5 minutes to 48 hours.
- a compound of formula [13] for example, hexylmagnesium bromide and the like are known.
- a compound of formula [11B] can be produced by reacting a compound of formula [12] with a compound of formula [13].
- the solvent used in this reaction is not particularly limited as long as it does not affect the reaction, and examples thereof include halogenated hydrocarbons, ethers, amides and aromatic hydrocarbons. A mixture of solvents may be used. Preferred solvents include ethers, more preferably tetrahydrofuran.
- the amount of the solvent to be used is not particularly limited, but may be 1 to 500 times (v/w) the amount of the compound of formula [12].
- the amount of the compound of formula [13] to be used is not particularly limited, but may be 0.8 to 10 times (v/w) the amount of the compound of formula [12].
- the reaction may be carried out at -30 to 150°C, preferably 0 to 100°C for 5 minutes to 48 hours.
- Preferred solvents include aromatic hydrocarbons and ethers, with toluene and tetrahydrofuran being more preferred.
- the amount of the solvent to be used is not particularly limited, and may be 1 to 500 times (v/w) the amount of the compound of formula [11B].
- Acids used in this reaction include inorganic acids and organic acids.
- the acid is preferably a sulfonic acid, and specific examples include sulfuric acid, 4-toluenesulfonic acid, methanesulfonic acid and the like.
- carbodiimides such as N,N'-dicyclohexylcarbodiimide and 1-ethyl-3-(3-dimethyla
- Acid halides used in this reaction include, for example, carboxylic acid halides such as acetyl chloride and trifluoroacetyl chloride; sulfonic acid halides such as methanesulfonyl chloride and tosyl chloride; ethyl chloroformate and isobutyl chloroformate. and chloroformic acid esters such as Bases used in this reaction include inorganic bases and organic bases.
- the base is preferably an organic base, specifically triethylamine, N,N-diisopropylethylamine, 4-methylmorpholine, pyridine, 1,8-diazabicyclo[5.4.0]-7-undecene, or N,N- dimethylaminopyridine and the like.
- the amount of the base to be used is 1 to 50-fold mol, preferably 1 to 10-fold mol, relative to the compound of formula [11B].
- the amount of the compound of formula [14] to be used is not particularly limited, but may be 0.8 to 10 times (v/w) the amount of the compound of formula [11B].
- the reaction may be carried out at -30 to 150°C, preferably 0 to 100°C, for 5 minutes to 48 hours.
- the compound of formula [2A] can be produced by reducing the compound of formula [11C] in the presence of a reducing agent.
- the solvent used in this reaction is not particularly limited as long as it does not affect the reaction. Examples include halogenated hydrocarbons, ethers, esters, amides, nitriles, alcohols, sulfoxides. , aromatic hydrocarbons and water, and these solvents may be used in combination.
- the amount of the solvent to be used is not particularly limited, but may be 1 to 500 times (v/w) the amount of the compound of formula [11A].
- Examples of reducing agents used in this reaction include boron compounds such as sodium borohydride.
- the reducing agent is used in an amount of 0.1 to 50-fold mol, preferably 1 to 10-fold mol, relative to the compound of formula [11A].
- the reaction may be carried out at -30 to 150°C, preferably 0 to 100°C for 5 minutes to 48 hours.
- the compound of formula [2B] can be produced by reducing the compound of formula [17] in the presence of a reducing agent. This reaction may be carried out according to the production method (2-6).
- R j and R k represent leaving groups; R 1 , R 2 , R 3 , R 4 and R 8 have the same meanings as above.” Leaving groups such as chloro, fluoro, bromo, trichloromethoxy, 4-nitro-phenoxy, 2,4-dinitrophenoxy, 2,4,6-trichlorophenoxy, pentafluorophenoxy, 2,3,5,6-tetrafluorophenoxy group, imidazolyl group, triazolyl group, 3,5-dioxo-4-methyl-1,2,4-oxadiazolidyl group, N-hydroxysuccinimidyl group, etc. mentioned.
- Compounds of formula [19] include, for example, 2-chloro-N,N-diethylethan-1-amine, 3-chloro-N,N-diethylpropan-1-amine and 2-bromo-N,N-diethylethane -1-amine and the like are known.
- a compound of formula [5] can be produced by reacting a compound of formula [18] with a compound of formula [19] in the presence or absence of a base.
- the solvent used in this reaction is not particularly limited as long as it does not affect the reaction. Examples include alcohols, halogenated hydrocarbons, ethers, esters, amides, nitriles, sulfoxides.
- the amount of the solvent to be used is not particularly limited, but may be 1 to 500 times (v/w) the amount of the compound of formula [18].
- Bases used in this reaction include inorganic bases and organic bases.
- the amount of the base to be used is 1 to 10,000-fold mol, preferably 1 to 5,000-fold mol, relative to the compound of formula [18].
- the amount of the compound of formula [19] to be used is not particularly limited, but may be 1 to 10 times the amount (v/w) of the compound of formula [18].
- the reaction may be carried out at -30 to 150°C, preferably 0 to 100°C for 5 minutes to 48 hours.
- a compound of formula [5] can be produced by reacting a compound of formula [20] with a compound of formula [21] in the presence or absence of a base.
- the solvent used in this reaction is not particularly limited as long as it does not affect the reaction. Examples include alcohols, halogenated hydrocarbons, ethers, esters, amides, nitriles, sulfoxides. , aromatic hydrocarbons and water, and these solvents may be used in combination.
- the amount of the solvent to be used is not particularly limited, but may be 1 to 500 times (v/w) the amount of the compound of formula [20].
- Bases used in this reaction include inorganic bases and organic bases.
- the amount of the base to be used is 1 to 10,000-fold mol, preferably 1 to 5,000-fold mol, per mol of the compound of formula [20].
- the amount of the compound of formula [21] to be used is not particularly limited, but may be 1 to 10 times the amount (v/w) of the compound of formula [20].
- the reaction may be carried out at -30 to 150°C, preferably 0 to 100°C, for 5 minutes to 48 hours.
- lipid particles containing the compounds of the present invention or salts thereof can be prepared.
- at least one lipid selected from the group consisting of sterols and lipids having nonionic hydrophilic polymer chains can be used in addition to the compounds of the present invention.
- Lipid particles can further comprise neutral lipids.
- Lipid particles can further comprise nucleic acids.
- the amount of the compound of the present invention is preferably 20 mol% to 80 mol%, more preferably 35 mol% to 70 mol%, and 40 mol% to 65 mol% with respect to the total lipid amount. is more preferable.
- Lipid particles in the present invention preferably contain sterols.
- sterols include, but are not limited to, cholesterol, phytosterol (sitosterol), stigmasterol, fucosterol, spinasterol, brassicasterol, etc.), ergosterol, cholestanone, cholesterolenone, coprostanol, cholesteryl-2′-hydroxyethyl ether. , cholesteryl-4′-hydroxybutyl ether, and the like.
- cholesterol is preferred.
- the amount of sterols is preferably 10 mol% to 60 mol%, more preferably 20 mol% to 55 mol%, and 25 mol% to 50 mol% with respect to the total lipid amount. is more preferred.
- Lipid particles in the present invention may contain neutral lipids.
- Neutral lipids include, but are not particularly limited to, phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramide, and the like, with phosphatidylcholine being preferred.
- the neutral lipid may be used alone or in combination with a plurality of different neutral lipids.
- phosphatidylcholine examples include, but are not limited to, soybean lecithin (SPC), hydrogenated soybean lecithin (HSPC), egg yolk lecithin (EPC), hydrogenated egg yolk lecithin (HEPC), dimyristoylphosphatidylcholine (DMPC), and dipalmitoylphosphatidylcholine (DPPC).
- SPC soybean lecithin
- HSPC hydrogenated soybean lecithin
- EPC egg yolk lecithin
- HEPC hydrogenated egg yolk lecithin
- DMPC dimyristoylphosphatidylcholine
- DPPC dipalmitoylphosphatidylcholine
- DSPC distearoylphosphatidylcholine
- POPC 1-palmitoyl-2-oleoylphosphatidylcholine
- DOPC dioleoylphosphatidylcholine
- the phosphatidylethanolamine is not particularly limited, but dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), distearoylphosphatidylethanolamine (DSPE), dioleoylphosphatidylethanolamine (DOPE), dilinoleoyl phosphatidylethanolamine (DLoPE), diphytanoylphosphatidylethanolamine (D(Phy)PE), 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE), ditetradecylphosphatidylethanolamine, dihexadecylphosphatidylethanolamine, dioctadecylphosphatidylethanolamine, diphytanylphosphatidylethanolamine and the like.
- DMPE dimyristoylphosphatidylethanolamine
- DPPE dipalmitoylphosphatidylethanolamine
- DSPE distea
- Examples of sphingomyelin include, but are not limited to, egg yolk-derived sphingomyelin, milk-derived sphingomyelin, and the like.
- Examples of ceramide include, but are not limited to, egg yolk-derived ceramide, milk-derived ceramide, and the like.
- the neutral lipid content is preferably 0 mol% or more and 55 mol% or less with respect to the total amount of constituent lipid components.
- Lipid particles in the present invention may contain lipids having nonionic hydrophilic polymer chains in the oil phase.
- lipids having nonionic hydrophilic polymer chains in the oil phase by including a lipid having a nonionic hydrophilic polymer chain in the oil phase, an effect of stabilizing the dispersion of lipid particles can be obtained.
- nonionic hydrophilic polymers include, but are not limited to, nonionic vinyl polymers, nonionic polyamino acids, nonionic polyesters, nonionic polyethers, nonionic natural polymers, Nonionic modified natural polymers, and block polymers or graft copolymers having two or more of these polymers as structural units may be mentioned.
- nonionic hydrophilic polymers nonionic polyethers, nonionic polyesters, nonionic polyamino acids or nonionic synthetic polypeptides are preferred, and nonionic polyethers or nonionic synthetic polypeptides are more preferred.
- Ionic polyesters even more preferably nonionic polyethers or nonionic monoalkoxypolyethers, particularly preferably polyethylene glycol (polyethylene glycol is also referred to as PEG below).
- Lipids having a nonionic hydrophilic polymer chain include, but are not limited to, PEG-modified phosphoethanolamine, diacylglycerol PEG derivatives, monoacylglycerol PEG derivatives, dialkylglycerol PEG derivatives, cholesterol PEG derivatives, ceramide PEG derivatives, and the like. mentioned. Among these, monoacylglycerol PEG or diacylglycerol PEG is preferred.
- the weight average molecular weight of the PEG chain of the nonionic hydrophilic polymer derivative is preferably 500-5000, more preferably 750-3000.
- the nonionic hydrophilic polymer chain may be branched and may have a substituent such as a hydroxymethyl group.
- the amount of the lipid having a nonionic hydrophilic polymer chain is preferably 0.25 mol% to 12 mol%, preferably 0.5 mol% to 6 mol%, relative to the total lipid amount. more preferably 1 mol % to 3 mol %.
- the lipid particles of the invention may contain nucleic acids.
- Nucleic acids include plasmids, single-stranded DNA, double-stranded DNA, siRNA (small interfering RNA), miRNA (micro RNA), mRNA, antisense oligonucleotides (also called ASO), ribozymes, aptamers, saRNA, sgRNA, and the like. and may include any. It may also contain modified nucleic acids.
- RNA is particularly preferable as the nucleic acid, and RNA having 5 to 20000 bases is preferable.
- the mass ratio of lipid to nucleic acid is preferably 2 to 1000, more preferably 3 to 500, even more preferably 5 to 200, even more preferably 5 to 100. Especially preferred.
- the method for producing lipid particles is not limited, but all or part of the constituent components of lipid particles are dissolved in an organic solvent or the like to form an oil phase, the water-soluble components are dissolved in water to form an aqueous phase, and the oil phase and water are used. It can be produced by mixing phases.
- a micromixer may be used for mixing, and emulsification may be performed by an emulsifier such as a homogenizer, an ultrasonic emulsifier, a high-pressure injection emulsifier, or the like.
- a lipid-containing solution is dried under reduced pressure using an evaporator or the like, or spray-dried using a spray dryer to prepare a dry mixture containing the lipid. It can also be manufactured by
- step (a) the constituent components of the lipid particles containing the compound of the present invention are dissolved in an organic solvent (alcohol such as ethanol, ester, etc.).
- the total lipid concentration is not particularly limited, but is generally 1 mmol/L to 100 mmol/L, preferably 5 mmol/L to 50 mmol/L, more preferably 10 mmol/L to 30 mmol/L.
- the aqueous phase can be obtained by dissolving a nucleic acid (eg, siRNA, mRNA, antisense nucleic acid, etc.) in water or a buffer.
- a nucleic acid eg, siRNA, mRNA, antisense nucleic acid, etc.
- Components such as antioxidants can be added as needed.
- the mixing ratio (volume ratio) of the water phase and the oil phase is preferably 5:1 to 1:1, more preferably 4:1 to 2:1.
- the mixture can be diluted with water or a buffer solution (eg, phosphate-buffered saline (PBS), etc.).
- a buffer solution eg, phosphate-buffered saline (PBS), etc.
- step (d) the method for removing the organic solvent from the dispersion of nucleic acid-lipid particles is not particularly limited, and general techniques can be used.
- the organic solvent can be removed by dialysis using a solution such as Tris buffer.
- Lipid particles can be sized if desired.
- the sizing method is not particularly limited, but an extruder or the like can be used to reduce the particle size.
- the dispersion liquid containing the lipid particles of the present invention can be subjected to freezing or freeze-drying by a general method.
- lipid particles mean particles composed of lipids, and include compositions having any structure selected from lipid aggregates in which lipids aggregate, micelles, and liposomes.
- the structure of the lipid particles is not limited to these as long as the composition contains.
- Liposomes include monolayer liposomes and multilamellar liposomes having a lipid bilayer structure, an aqueous phase inside, and multiple layers of bilayers. Either liposome may be included in the present invention.
- the morphology of lipid particles can be confirmed by electron microscopic observation or structural analysis using X-rays. For example, by a method using cryo transmission electron microscopy (CryoTEM method), it is possible to determine whether the lipid particles have a lipid bilayer structure (lamellar structure) and an inner water layer like liposomes, or whether the electron density inside the particles is It can be confirmed whether the core has a high core and whether it has a structure packed with constituent components such as lipids. The presence or absence of a lipid bilayer structure (lamellar structure) in lipid particles can also be confirmed by small angle X-ray scattering (SAXS) measurement.
- SAXS small angle X-ray scattering
- the particle size of the lipid particles of the present invention is not particularly limited, it is preferably 10 to 1000 nm, more preferably 30 to 500 nm, and still more preferably 50 to 250 nm.
- the particle size of lipid particles can be measured by common methods (eg, dynamic light scattering method, laser diffraction method, etc.).
- nucleic acids such as RNA
- the lipid particles in the present invention contain a nucleic acid having medical uses
- the lipid particles can be administered to a living body as a nucleic acid drug.
- the lipid particles of the present invention can be used alone or mixed with a pharmaceutically acceptable administration medium (e.g., physiological saline or phosphate buffer), can be administered to
- a pharmaceutically acceptable administration medium e.g., physiological saline or phosphate buffer
- concentration of the lipid particles in the mixture with the pharmaceutically acceptable carrier is not particularly limited, and can generally range from 0.05% by mass to 90% by mass.
- the nucleic acid medicine containing the lipid particles of the present invention may be added with other pharmaceutically acceptable additives such as pH adjusting buffers and osmotic pressure adjusting agents.
- the administration route for administration of the nucleic acid medicine containing the lipid particles of the present invention is not particularly limited, and can be administered by any method.
- Administration methods include oral administration, parenteral administration (intraarticular administration, intravenous administration, intraarterial administration, subcutaneous administration, intradermal administration, intravitreal administration, intraperitoneal administration, intramuscular administration, intravaginal administration, intravesical administration, , intrathecal administration, pulmonary administration, rectal administration, colonic administration, buccal administration, nasal administration, intracisternal administration, inhalation, etc.).
- Parenteral administration is preferred, and the administration method is preferably intravenous injection, subcutaneous injection, intradermal injection or intramuscular injection.
- the nucleic acid medicine containing the lipid particles of the present invention can also be administered by direct injection into the disease site.
- the dosage form of the lipid particles of the present invention is not particularly limited. It can be used in forms such as suspensions and syrups.
- Formulations suitable for parenteral administration also include antioxidants, buffers, bacteriostats, and isotonic sterile injections, suspending agents, solubilizers, thickeners, stabilizers or preservatives. Additives such as can be included as appropriate.
- the lipid particles of the present invention are very useful as nucleic acid delivery carriers because they can retain nucleic acids at a high encapsulation rate.
- the obtained lipid particles can be mixed with nucleic acid or the like and transfected in vitro or in vivo to introduce the nucleic acid or the like into cells.
- the nucleic acid delivery carrier using the present invention is also useful as a nucleic acid delivery carrier in nucleic acid medicine. That is, the lipid particles of the present invention are useful as compositions for nucleic acid delivery in vitro or in vivo (preferably in vivo).
- purification by column chromatography was performed using an automatic purifier ISOLERA (Biotage), a medium-pressure preparative purification apparatus Purif-al-2 (Shoko Science Co., Ltd.), or a medium-pressure liquid chromatograph YFLC W-prep 2XY. (Yamazen Co., Ltd.) was used.
- Chromatorex Q-Pack SI 50 Fluji Silysia Chemical Co., Ltd.
- high flash column W001, W002, W003, W004 or W005 were used as carriers in silica gel column chromatography.
- Example 1 Triethylamine (75.0 mL) and anhydrous magnesium chloride (40.0 g) were added to a mixture of potassium monoethyl malonate (60.1 g) and acetonitrile (400 mL) under ice-cooling, and the mixture was stirred at room temperature for 2 hours. Heptanoyl chloride (25.0 g) was added dropwise to the reaction mixture under ice-cooling, and the mixture was stirred at room temperature for 2 hours. The solvent of the reaction mixture was evaporated under reduced pressure, toluene (200 mL) was added, and after evaporation under reduced pressure, toluene (100 mL) was added.
- the reaction mixture was cooled to room temperature, water and ethyl acetate were added, the organic layer was separated, washed with saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- the resulting residue was purified by silica gel column chromatography (methanol-ethyl acetate) and silica gel column chromatography (ethyl acetate-hexane, NH silica gel) to give bis(2-hexyldecyl)16-(2-) as a colorless oil.
- Example 2 Bis(2-butyloctyl) 16 as a colorless oil was prepared in the same manner as in Example 1, except that 2-butyl-1-octanol was used instead of 2-hexyl-1-decanol. -(2-(Diethylamino)ethyl)-10,22-dihexyl-12,20-dioxo-11,13,19,21-tetraoxa-16-azahentriacontanedioate was obtained.
- Example 3 (1) Potassium carbonate (4.3 g) was added to a mixture of 2,2'-azanediylbis(ethan-1-ol) (2.5 g), 3-chloro-N,N-diethylpropan-1-amine (4.6 g) and ethanol (25 mL). ) was added, and the mixture was stirred under reflux with heating for 6 hours. After the reaction mixture was cooled to room temperature, unnecessary substances were filtered off, and the solvent was distilled off under reduced pressure.
- Example 2 In Example 1, 2-hexyl-1-decanol was replaced with 2-butyl-1-octanol and 2,2′-((2-(diethylamino)ethyl)azanediyl)bis(ethan-1-ol) in the same manner as in Example 1 except that 2,2′-((3-(diethylamino)propyl)azanediyl)bis(ethan-1-ol) was used instead of using bis(2 -butyloctyl)16-(3-(diethylamino)propyl)-10,22-dihexyl-12,20-dioxo-11,13,19,21-tetraoxa-16-azahentriacontanedioate.
- Example 4 Bis(3-pentyloctyl) as a colorless oil was prepared in the same manner as in Example 1, except that 3-pentyloctan-1-ol was used instead of 2-hexyl-1-decanol. 16-(2-(diethylamino)ethyl)-10,22-dihexyl-12,20-dioxo-11,13,19,21-tetraoxa-16-azahentriacontanedioate was obtained.
- Example 5 Bis(2-pentylheptyl) as a colorless oil was prepared in the same manner as in Example 1, except that 2-pentylheptan-1-ol was used instead of 2-hexyl-1-decanol. 16-(2-(diethylamino)ethyl)-10,22-dihexyl-12,20-dioxo-11,13,19,21-tetraoxa-16-azahentriacontanedioate was obtained.
- Example 6 Bis(2-hexyloctyl) as a colorless oil was prepared in the same manner as in Example 1 except that 2-hexyloctan-1-ol was used instead of 2-hexyl-1-decanol. 16-(2-(diethylamino)ethyl)-10,22-dihexyl-12,20-dioxo-11,13,19,21-tetraoxa-16-azahentriacontanedioate was obtained.
- Example 7 A mixture of 10-methoxy-10-oxodecanoic acid (47.6 g), thionyl chloride (47.6 mL) and N,N-dimethylformamide (0.1 mL) was stirred under reflux for 1 hour. The solvent was distilled off under reduced pressure to obtain methyl 10-chloro-10-oxodecanoate (59.7 g) as a brown oil.
- Tetraisopropyl orthotitanate (0.55 g) was added to a mixture of methyl 10-oxopentadecanoate (5.3 g) and 2-hexyldecan-1-ol (7.1 g), and the mixture was stirred at 110°C for 2 hours. After cooling the reaction mixture to room temperature, water (0.5 mL) was added, and the mixture was stirred at room temperature for 15 minutes and purified by silica gel column chromatography (ethyl acetate-hexane) to give 2-hexyldecyl-10-oxo as a colorless oil. Pentadecanoate (9.2 g) was obtained.
- the reaction mixture was cooled to room temperature, water and ethyl acetate were added, the organic layer was separated, washed with saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- the resulting residue was purified by silica gel column chromatography (methanol-ethyl acetate) and silica gel column chromatography (ethyl acetate-hexane, NH silica gel) to give bis(2-hexyldecyl)16-(2-) as a colorless oil.
- Example 8 (1) To a solution of glutaric anhydride (27.3 g) in tetrahydrofuran (273 mL) was added dropwise a 1.0 mol/L hexylmagnesium bromide-tetrahydrofuran solution (200 mL) under ice cooling, and the mixture was stirred at the same temperature for 1 hour. After adding 2 mol/L hydrochloric acid aqueous solution (240 mL) to the reaction mixture under ice-cooling, ethyl acetate (270 mL) was added, the organic layer was separated, washed with water and saturated aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate.
- Example 1 2-hexyldecyl 10-(((4-nitrophenoxy)carbonyl)oxy)hexadecanoate was used instead of 2-butyloctyl 5-(((4-nitrophenoxy)carbonyl)oxy).
- Bis(2-butyloctyl)11-(2-(diethylamino)ethyl)-5,17-dihexyl-7,15-dioxo-6 as a colorless oil was prepared in the same manner as in Example 1, except that undecanoate was used. ,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 9 bis(2-hexyldecyl)11 as a colorless oil was prepared in the same manner as in Example 1 except that 2-hexyl-1-decanol was used instead of 2-butyl-1-octanol. -(2-(Diethylamino)ethyl)-5,17-dihexyl-7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 10 (1) Example 8(1) and Example 8(2) except that 2-pentyl-1-heptanol was used instead of 2-butyl-1-octanol in Example 8(1) and Example 8(2).
- 2-pentylheptyl-5-hydroxyundecanoate was obtained as a colorless oil in the same manner as in 2).
- Example 11 (1) In Example 1(6), 2,2′-((2-(dimethylamino)ethyl)azanediyl)bis was used instead of 2-bromo-N,N-diethylethane-1-amine hydrobromide. 2,2′-((2-(dimethylamino)ethyl)azanediyl)bis(ethane) as a colorless oil was obtained in the same manner as in Example 1 (6) except that (ethan-1-ol) hydrochloride was used. -1-ol).
- Example 12 (1) N-(2-bromoethyl)-N-propylpropan-1-amine bromide instead of 2-bromo-N,N-diethylethane-1-amine hydrobromide in Example 1(6) 2,2′-((2-(dimethylamino)ethyl)azanediyl)bis(ethan-1-ol) as a colorless oil was obtained in the same manner as in Example 1 (6) except for using a hydride. Obtained.
- Example 13 In Example 10, 2,2′-((3-(diethylamino)propyl)azanediyl) was used instead of 2,2′-((2-(diethylamino)ethyl)azanediyl)bis(ethan-1-ol).
- Bis(2-pentylheptyl)11-(3-(diethylamino)propyl)-5,17-dihexyl- was obtained as a colorless oil in a similar manner to Example 10, except using bis(ethan-1-ol). 7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 14 Potassium carbonate (1.5 g) was added to a mixture of N1,N1-diethylbutane-1,4-diamine (0.51 g), 2-bromoethan-1-ol (1.1 g) and acetonitrile (5 mL), and the mixture was heated under reflux. Stirred for 2 hours. After the reaction mixture was cooled to room temperature, unnecessary substances were filtered off, and the solvent was distilled off under reduced pressure.
- Example 15 (1) Example 1 (6) except that 3,3′-azanediylbis(propan-1-ol) was used instead of 2,2′-azanediylbis(ethan-1-ol) in Example 1(6).
- 3,3′-((2-(diethylamino)ethyl)azanediyl)bis(propan-1-ol) was obtained as a pale yellow oil.
- Example 10 3,3′-((2-(diethylamino)ethyl)azanediyl) was used instead of 2,2′-((2-(diethylamino)ethyl)azanediyl)bis(ethan-1-ol).
- Bis(2-pentylheptyl)12-(2-(diethylamino)ethyl)-5,19-dihexyl- was obtained as a colorless oil in the same manner as in Example 10, except that bis(propan-1-ol) was used. 7,17-dioxo-6,8,16,18-tetraoxa-12-azatricosandioate was obtained.
- Example 16 (1) Example 1 (6) except that 4,4'-azanediylbis(butan-1-ol) was used instead of 2,2'-azanediylbis(ethan-1-ol) in Example 1(6). 4,4′-((2-(diethylamino)ethyl)azanediyl)bis(butan-1-ol) as a pale yellow oil was obtained in the same manner as in .
- 1 H-NMR(CDCl 3 ) ⁇ : 3.62-3.58 (4H, m), 2.59-2.46 (12H, m), 1.66-1.59 (8H, m), 1.03 (6H, t, J 7.2Hz). MS m/z(M+H): 261.
- Example 10 2,2'-((2-(diethylamino)ethyl)azanediyl)bis(ethan-1-ol) was used instead of 4,4'-((2-(diethylamino)ethyl)azanediyl) Bis(2-pentylheptyl)13-(2-(diethylamino)ethyl)-5,21-dihexyl- was obtained as a colorless oil in the same manner as in Example 10, except that bis(butan-1-ol) was used. 7,19-dioxo-6,8,18,20-tetraoxa-13-azapentacosandioate was obtained.
- Example 17 (1) In Example 7 (2), instead of using 1.0 mol/L pentylmagnesium bromide-tetrahydrofuran solution, 1.0 mol/L hexylmagnesium bromide-tetrahydrofuran solution was used instead of using methyl 10-chloro-10-oxodecanoate. Ethyl 4-oxodecanoate was obtained as a colorless oil in the same manner as in Example 7(2), except that ethyl 4-chloro-4-oxobutanoate was used in .
- Example 10(2) except that 2-pentylheptyl 4-hydroxydecanoate was used instead of 2-pentylheptyl 5-hydroxyundecanoate in Example 10(2) and Example 10(2).
- Example 18 In Example 17, the colorless oily bis(2 -pentylheptyl)12-(2-(diethylamino)ethyl)-6,18-dihexyl-8,16-dioxo-7,9,15,17-tetraoxa-12-azatricosandioate was obtained.
- Example 10(2) except that 2-pentylheptyl 5-hydroxyhexanoate was used instead of 2-pentylheptyl 5-hydroxyundecanoate in Example 10(2) and Example 10(3).
- Example 10(3) bis(2-pentylheptyl)11-(2-(diethylamino)ethyl)-5,17-dimethyl-7,15-dioxo-6, as a colorless oil, in the same manner as in Example 10(3). 8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 20 the colorless oily bis( 2-Pentylheptyl)11-(2-(diethylamino)ethyl)-5,17-diethyl-7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 21 In Example 10, the colorless oily bis( 2-pentylheptyl)11-(2-(diethylamino)ethyl)-7,15-dioxo-5,17-dipropyl-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 22 In Example 10, the colorless oily bis( 2-pentylheptyl)5,17-dibutyl-11-(2-(diethylamino)ethyl)-7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 23 In Example 10, the colorless oily bis( 2-pentylheptyl)11-(2-(diethylamino)ethyl)-7,15-dioxo-5,17-dipentyl-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 24 the colorless oily bis( 2-pentylheptyl)11-(2-(diethylamino)ethyl)-5,17-diheptyl-7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 25 In Example 10, a colorless oily bis (2-Pentylheptyl)11-(2-(diethylamino)ethyl)-5,17-dioctyl-7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained .
- Example 26 In the same manner as in Example 22, except that 2-pentylheptan-1-ol was used instead of 2-pentylheptan-1-ol, bis(2-hexyloctyl) as a colorless oil was obtained. ) 5,17-dibutyl-11-(2-(diethylamino)ethyl)-7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosandioate.
- Example 27 In the same manner as in Example 10, except that 2-(1-adamantyl)ethanol was used instead of 2-pentylheptan-1-ol, bis(2-(( 3r,5r,7r)-adamantan-1-yl)ethyl)11-(2-(diethylamino)ethyl)-5,17-dihexyl-7,15-dioxo-6,8,14,16-tetraoxa-11- Azahenicosandioate was obtained.
- Example 28 2,2′-((3-(diethylamino)propyl)azanediyl) was used in place of 2,2′-((2-(diethylamino)ethyl)azanediyl)bis(ethan-1-ol) in Example 21.
- Bis(2-pentylheptyl)11-(3-(diethylamino)propyl)-7,15-dioxo- was obtained as a colorless oil in a similar manner to Example 21, except using bis(ethan-1-ol). 5,17-dipropyl-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 29 (1) Ethyl acrylate (24.0 mL) was added to a mixture of cyclohexane-1,3-dione (16.5 g), potassium carbonate (20.3 g), benzyltriethylammonium chloride (33.5 g) and dimethylsulfoxide (165 mL), and the mixture was heated at 60°C. Stirred for 4 hours. After cooling the reaction mixture to room temperature, N-acetyl-L-cysteine (14.4 g) was added and stirred at room temperature for 1 hour. Ethyl acetate (165 mL) and 20% aqueous potassium hydrogensulfate solution (330 mL) were added to the reaction mixture, and the organic layer was separated.
- aqueous hydrochloric acid 200 mL was added to ethyl 3-(2,6-dioxocyclohexyl)propanoate (20.2 g), and the mixture was stirred at 100° C. for 4 hours. After cooling the reaction mixture to room temperature, ethyl acetate (200 mL) was added and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (50 mL) three times, the organic layer and the extract were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- 1,1′-Carbonyldiimidazole (0.398 g) was added to a solution of diheptyl 5-hydroxynonanedioate (0.656 g) in tetrahydrofuran (4.0 mL), and the mixture was stirred at room temperature for 3 hours. Water (4 mL) and hexane (4 mL) were added to the reaction mixture, the organic layer was separated, washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give a pale yellow oil. Diheptyl 5-((1H-imidazole-1-carbonyl)oxy)nonanedioate (0.82 g) of the product was obtained.
- Example 30 bis(2-hexyloctyl)11- (2-(diethylamino)ethyl)-5,17-bis(4-((2-hexyloctyl)oxy)-4-oxobutyl)-7,15-dioxo-6,8,14,16-tetraoxa-11- Azahenicosandioate was obtained.
- Example 31 Dipentyl 11-(2-(diethylamino)ethyl)- was obtained as a colorless oil in the same manner as in Example 29, except that pentan-1-ol was used instead of heptane-1-ol. 7,15-dioxo-5,17-bis(4-oxo-4-(pentyloxy)butyl)-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 33 Dioctyl 11-(2-(diethylamino)ethyl)- was obtained as a colorless oil in the same manner as in Example 29, except that octan-1-ol was used instead of heptane-1-ol. 5,17-bis(4-(octyloxy)-4-oxobutyl)-7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 34 In Example 29, dinonyl 11-(2-(diethylamino)ethyl)- 5,17-bis(4-(nonyloxy)-4-oxobutyl)-7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 35 In Example 29, in the same manner as in Example 29, except that decan-1-ol was used instead of heptane-1-ol, didecyl 5,17-bis(4-(decyloxy) was obtained as a colorless oil. -4-oxobutyl)-11-(2-(diethylamino)ethyl)-7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosandioate was obtained.
- Example 36 (1) Dihexyl 5-((1H-imidazole-1-carbonyl)oxy)nonanedioate (0.691 g), 2,2'-((2-(diethylamino)ethyl)azanediyl)bis(ethan-1-ol) (0.234 g) and Potassium carbonate (0.339 g) was added to a mixture of acetonitrile (3.0 mL) and stirred at 80° C. for 1 hour and 30 minutes.
- acetonitrile 3.0 mL
- Example 37 Example 36 except that dipentyl 5-((1H-imidazole-1-carbonyl)oxy)nonanedioate was used in Example 36, and diheptyl 5-((1H-imidazole-1-carbonyl)oxy)nonanedioate was used.
- Example 38 In Example 29, 2,2′-((3-(diethylamino)propyl)azanediyl) was used instead of 2,2′-((2-(diethylamino)ethyl)azanediyl)bis(ethan-1-ol).
- Diheptyl 11-(3-(diethylamino)propyl)-5,17-bis(4-(heptyloxy) as a colorless oil was prepared in a similar manner to Example 29 except using bis(ethan-1-ol).
- Example 39 (1) A 20% aqueous potassium hydroxide solution (14 g) was added to a mixture of diethyl 4-oxoheptanedioate (5.0 g), tetrahydrofuran (10 mL) and ethanol (10 mL), and the mixture was stirred at room temperature for 30 minutes. A 30% aqueous hydrochloric acid solution (10 mL) and ethyl acetate (10 mL) were added to the reaction mixture, the organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give a pale yellow solid of 4-oxoheptane. Acid (4.3 g) was obtained. 1 H-NMR(CDCl 3 ) ⁇ : 2.82-2.74 (4H, m), 2.68-2.58 (4H, m). MS m/z (MH): 173.
- Example 29(2) and Example 29(3) except that 4-oxoheptanedioic acid was used instead of 5-oxononanedioic acid in Example 29(2) and Example 29(3).
- diheptyl 10-(2-(diethylamino)ethyl)-4,16-bis(3-(heptyloxy)-3-oxopropyl)-6,14-dioxo-5,7, as a colorless oil was obtained. 13,15-tetraoxa-10-azanonadecanedioate was obtained.
- Example 40 Potassium carbonate (9.4 g) was added to a mixture of octane-1-thiol (5.0 g), 2-bromoethan-1-ol (4.7 g) and acetonitrile (25 mL), and the mixture was stirred at 60°C for 4 hours. After cooling the reaction mixture to room temperature, water (25 mL) and hexane (25 mL) were added, and the organic layer was separated and washed with a saturated sodium chloride aqueous solution. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure.
- Example 41 In Example 29, a colorless oil, bis(cyclohexylmethyl)5,17-bis(4-(cyclohexylmethyl)5,17-bis(4-(cyclohexylmethyl) Methoxy)-4-oxobutyl)-11-(2-(diethylamino)ethyl)-7,15-dioxo-6,8,14,16-tetraoxa-11-azahenicosanedioate was obtained.
- Example 42 Except using dioctyl 5-((1H-imidazole-1-carbonyl)oxy)nonanedioate instead of dipentyl 5-((1H-imidazole-1-carbonyl)oxy)nonanedioate in Example 36(2) 1-Hexyl-21-octyl-11-(2-(diethylamino)ethyl)-5-(4-(hexyloxy)-4-oxobutyl)-17- as a colorless oil was obtained in the same manner as in Example 36(2).
- Example 43 (1) 1-Bromohexane (5.2 g) was added to a mixture of 2-mercaptoethanol (3.0 g), potassium hydroxide (2.6 g) and ethanol (100 mL), and the mixture was stirred at room temperature for 2 hours, and then the solvent was evaporated under reduced pressure. . Ethyl acetate (150 mL) and water (200 mL) were added to the obtained residue, and the organic layer was separated and washed with water (100 mL) and saturated aqueous sodium chloride solution. After drying with anhydrous sodium sulfate, the solvent was distilled off under reduced pressure to obtain 2-(hexylthio)ethan-1-ol (6.2 g).
- Example 44 (1) To a solution of 8-bromooctan-1-ol (5.0 g) in N-methylpyrrolidone (25 mL) was added 70% aqueous sodium hydrogen sulfide solution (13.4 g) under ice cooling, and the mixture was stirred at room temperature for 1 hour. Water (100 mL), ethyl acetate (50 mL) and hexane (50 mL) were added to the reaction mixture, and the organic layer was separated and washed with water (100 mL) and saturated aqueous sodium chloride solution.
- Methyl p-toluenesulfonate (2.2 g) was added to a mixture of 8-mercaptooctan-1-ol (1.9 g), potassium hydroxide (0.72 g) and ethanol (60 mL), and the mixture was stirred at room temperature for 1 hour, The solvent was removed under reduced pressure. Ethyl acetate (150 mL) and water (100 mL) were added to the obtained residue, and the organic layer was separated and washed with water (100 mL) and saturated aqueous sodium chloride solution. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure to obtain 8-(methylthio)octan-1-ol (1.3 g).
- Test Example 1 Preparation of mRNA-encapsulated lipid particles and measurement of reporter protein expression rate in mice ⁇ Preparation of EPO mRNA-encapsulated lipid particles> Compounds listed in Table 1, neutral lipids, cholesterol (product name: Cholesterol HP; Nippon Fine Chemical Co., Ltd.), 1,2-dimyristoyl-rac-glycero-3-(methylpolyoxyethylene 2000) (hereinafter, DMG -PEG2000) (product name: SUNBRIGHT (R) GM-020; NOF corporation) was dissolved in ethanol at the molar ratio shown in Table 1 so that the total lipid concentration was 20 mmol/L to obtain an oil phase.
- DMG -PEG2000 product name: SUNBRIGHT (R) GM-020; NOF corporation
- the neutral lipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (product name: COATSOME (R) MC-8080; NOF corporation) (hereinafter referred to as DSPC), or L- ⁇ -dioleoyl phosphatidylethanolamine (hereinafter, DOPE) (product name: COATSOME (R) ME-8181; NOF corporation), or 1,2-dioleoyl-sn-glycero-3-phosphocholine (hereinafter, DOPC) (product name: COATSOME (R) MC- 8181; NOF corporation) was used.
- DOPE 1,2-distearoyl-sn-glycero-3-phosphocholine
- DOPC 1,2-distearoyl-sn-glycero-3-phosphocholine
- EPO mRNA product name: CleanCap EPO mRNA (5moU); TriLink
- pH 4 50mmol/L citrate buffer so that the weight ratio of total lipid concentration to mRNA concentration was about 16:1 to 64:1.
- a NanoAssemblr Precision Nano Systems
- PBS phosphate-buffered saline
- Ethanol was removed by dialysis of this dispersion against a 10% sucrose aqueous solution using a dialysis cassette (Slide-A-Lyzer G2, MWCO: 10 kD, Thermo Fisher Scientific) to obtain EPO mRNA-encapsulating lipid particles.
- the particle size of the mRNA-encapsulating lipid particles was measured by diluting the lipid particle dispersion 10-fold with phosphate-buffered saline (PBS) using a zeta potential/particle size measurement system ELS-Z2 (Otsuka Electronics). . Table 1 shows the results.
- ⁇ Evaluation of encapsulation rate of mRNA> (Quantification of total mRNA concentration) To 30-60 ⁇ L of lipid particles holding mRNA, 15-30 ⁇ L of 3 mol/L sodium acetate aqueous solution and 4.5-9 ⁇ L of glycogen were added, followed by adding 0.75-1.5 mL of ethanol to dissolve the lipid. , only mRNA was precipitated. After that, centrifugation was performed and the supernatant was removed. After air-drying for 15 min or more, water was added to redissolve, and the total mRNA concentration was quantified by measuring the concentration using Nanodrop NF1000 (Thermo Fisher Scientific).
- Quant-iT RiboGreen RNA Assay Kit (Thermo Fisher Scientific) was used and quantified according to the protocol. First, 20 ⁇ TE buffer contained in the above kit was diluted with water to obtain 1 ⁇ TE buffer. TE indicates Tris/EDTA (ethylenediaminetetraacetic acid). In order to quantify only the mRNA in the external aqueous phase, the mRNA-retaining lipid particle dispersion was diluted 10,000-fold with 1 ⁇ TE buffer.
- mRNA encapsulation rate (%) (total mRNA concentration - mRNA concentration in external aqueous phase) / total mRNA concentration x 100
- ⁇ EPO enzyme activity measurement> The dispersion of mRNA lipid particles prepared in ⁇ Preparation of EPO mRNA-encapsulating lipid particles> was intravenously administered to C57BL/6J mice at an mRNA dose of 0.1 mg/kg. Blood was collected from the posterior vena cava 20 to 24 hours after administration to obtain plasma. Human EPO enzymatic activity was quantified using the obtained plasma using ab119522 Erythropoietin (EPO) Human Elisa Kit (Abcam). Quantitative values were described as relative amounts of EPO protein when Comparative Example 1 was set to 1. Table 1 shows the results.
- the nucleic acid-lipid composition of the present invention was shown to have a higher EPO protein expression rate.
- Test Example 2 Preparation of mRNA-encapsulated lipid particles and measurement of reporter protein expression rate in mice ⁇ Preparation of FLuc mRNA-encapsulated lipid particles> Compounds listed in Table 2, neutral lipids, cholesterol (product name: Cholesterol HP; Nippon Fine Chemical Co., Ltd.), 1,2-dimyristoyl-rac-glycero-3-(methylpolyoxyethylene 2000) (hereinafter, DMG -PEG2000) (at the molar ratio shown in Table 2 and dissolved in ethanol so that the total lipid concentration was 20 mmol/L to obtain an oil phase.
- cholesterol product name: Cholesterol HP; Nippon Fine Chemical Co., Ltd.
- DMG -PEG2000 1,2-dimyristoyl-rac-glycero-3-(methylpolyoxyethylene 2000
- the neutral lipid was 1,2-distearoyl-sn-glycero-3-phosphocholine (product name: COATSOME (R) MC-8080; NOF corporation).
- L- ⁇ -dioleoyl phosphatidylethanolamine product name: COATSOME (R) MC-8181; NOF corporation was used.
- Dilute FLuc mRNA product name: CleanCap FLuc mRNA (5moU); TriLink
- pH 4 50mmol/L citrate buffer so that the weight ratio of total lipid concentration to mRNA concentration is about 19:1 to 64:1.
- a NanoAssemblr Precision Nano Systems
- PBS phosphate-buffered saline
- This dispersion was dialyzed against a 10% sucrose aqueous solution using a dialysis cassette (Slide-A-Lyzer G2, MWCO: 10 kD, Thermo Fisher Scientific) to remove ethanol and obtain FLuc mRNA-encapsulating lipid particles.
- a dialysis cassette Slide-A-Lyzer G2, MWCO: 10 kD, Thermo Fisher Scientific
- the particle size of the mRNA-encapsulating lipid particles was measured by diluting the lipid particle dispersion 10-fold with phosphate-buffered saline (PBS) using a zeta potential/particle size measurement system ELS-Z2 (Otsuka Electronics). . Table 2 shows the results.
- ⁇ Evaluation of encapsulation rate of mRNA> (Quantification of total mRNA concentration) To 30-60 ⁇ L of lipid particles holding mRNA, 15-30 ⁇ L of 3 mol/L sodium acetate aqueous solution and 4.5-9 ⁇ L of glycogen were added, followed by adding 0.75-1.5 mL of ethanol to dissolve the lipid. , only mRNA was precipitated. After that, centrifugation was performed and the supernatant was removed. After air-drying for 15 min or more, water was added to redissolve, and the total mRNA concentration was quantified by measuring the concentration using Nanodrop NF1000 (Thermo Fisher Scientific).
- Quant-iT RiboGreen RNA Assay Kit (Thermo Fisher Scientific) was used and quantified according to the protocol. First, 20 ⁇ TE buffer contained in the above kit was diluted with water to obtain 1 ⁇ TE buffer. TE indicates Tris/EDTA (ethylenediaminetetraacetic acid). In order to quantify only the mRNA in the external aqueous phase, the mRNA-retaining lipid particle dispersion was diluted 10,000-fold with 1 ⁇ TE buffer.
- mRNA encapsulation rate (%) (total mRNA concentration - mRNA concentration in external aqueous phase) / total mRNA concentration x 100
- ⁇ Luciferase luminescence measurement> To ICR mice, the dispersion of mRNA lipid particles prepared in ⁇ Preparation of FLuc mRNA-encapsulating lipid particles> was administered once into the rectus femoris muscle from the dorsal side so that the mRNA dose was 1 ⁇ g. Five hours after administration, 150 mg/kg of D-luciferin potassium (Fujifilm Wako Pure Chemical Industries, Ltd.) was intraperitoneally administered, and 6 hours after administration under isoflurane gas anesthesia, luminescence was observed using the IVIS Imaging System (PerkinElmer) in the prone position. It was measured.
- D-luciferin potassium Flujifilm Wako Pure Chemical Industries, Ltd.
- a ROI was set so that the lower extremities on the side of administration were all included, and the amount of light emitted (Photone/Sec) was quantified using Living Image Software (PerkinElmer). Luciferase [P/S] in Table 2 indicates Photons/sec (light intensity).
- the nucleic acid-lipid composition of the present invention was shown to have a high reporter protein expression rate.
- PTEN Phosphatase and Tensin Homolog Deleted from Chromosome 10.
- PTEN ASO An antisense oligonucleotide nucleic acid (PTEN ASO) against PTEN protein was purchased from Hokkaido System Science Co., Ltd.
- PTEN ASO A 20-base oligonucleotide phosphodiester bond, the sequence of which is given below.
- DSPC (1,2-Distearoyl-sn-glycero-3-phosphocholine, product name: COATSOME MC-8080; NOF Corporation) is used as the neutral lipid.
- Cholesterol product name: Cholesterol HP; Nippon Fine Chemical Co., Ltd.
- Monostearyl PEG product name: Polyethylene Glycol Monostearate (4E.O.), Fujifilm Wako Pure Chemical Industries, Ltd. was used as the PEG lipid.
- Monostearyl PEG also referred to as monoPEG
- PTEN ASO 5 mg was dissolved in 1 mL of sterilized water and diluted with 10 mmol/L acetate buffer of pH 4 so that the nucleic acid concentration was 54.6 ⁇ mol/L to obtain an aqueous phase.
- the volume ratio of the aqueous phase and the oil phase was mixed with a micromixer (see Japanese Patent No. 5288254) using a syringe pump so that the volume ratio of the aqueous phase and the oil phase was 3:1, and the mixture was mixed with a phosphate buffer.
- a dispersion of nucleic acid lipid particles was obtained by two-fold dilution with physiological saline (PBS).
- Table 3 also shows the molar ratio of the first lipid, phospholipid, sterol, and PEG lipid in the lipid composition, and the mass ratio of nucleic acid to total lipid when mixed.
- the particle size and polydispersity index of the lipid particles were obtained by diluting the lipid particle dispersion 10 times with phosphate buffered saline (PBS) using a zeta potential/particle size measurement system ELS-Z2 (Otsuka Electronics). It was measured. Table 3 shows the measurement results.
- Quant-iT RiboGreen RNA Assay Kit (Thermo Fisher Scientific) was used and quantified according to the protocol. First, 20 ⁇ TE buffer contained in the above kit was diluted with water to obtain 1 ⁇ TE buffer. TE indicates Tris/EDTA (ethylenediaminetetraacetic acid). In order to quantify only the nucleic acid in the external aqueous phase, the nucleic acid-retaining lipid particle dispersion was diluted 10,000-fold with 1 ⁇ TE buffer.
- nucleic acid encapsulation rate (total nucleic acid concentration - nucleic acid concentration in external aqueous phase) / total nucleic acid concentration x 100 Table 3 shows the calculation results.
- PTEN protein mRNA was measured according to the protocol of TaqMan® Fast Advanced Cells-to-CT TM Kit (Thermo fisher scientific).
- A431 cells or SH-SY5Y cells a dispersion of nucleic acid-lipid particles, Naked ASO or PBS, prepared to a final concentration of 500 nmol/L as ASO, was added. After exposure for 24 hours at 37°C under 5% CO 2 control, the culture supernatant was removed and washed once with PBS at 4°C. After removing the PBS, Lysis solution was added at 50 ⁇ L/well and allowed to stand at room temperature for 5 minutes to obtain a cell lysate.
- TaqMan® Fast Advanced Cells-to-CT TM Kit (Thermo fisher scientific) for cell lysate, Hs02621230_s1, FAM/MGB (Thermo fisher scientific), and Human GAPDH Endogenous (registered trademark) as PCR reaction reagents /MGB (Thermo fisher scientific) was used to perform reverse transcription and PCR reactions.
- the PTEN mRNA value of each sample was calculated by the ⁇ Ct method. Specifically, the ⁇ Ct value of each sample is calculated by subtracting the Ct value of GAPDH from the Ct value of PTEN. The ddCt value was calculated by subtracting the average ⁇ Ct value of the PBS-treated group from the calculated ⁇ Ct value. For each ⁇ Ct value, the relative value for Naked ASO, which is a comparison target, was taken and used as the PTEN mRNA relative value. Table 4 shows the calculation results.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、及び-O-R56から選択される1以上の置換基で置換されていてもよく、
R4は、炭素数1~8の炭化水素基を示し、
R5およびR6がそれぞれ独立に、炭素数1~8の炭化水素基、又は-R8-L1-R9を示し、但し、R5およびR6がともに炭素数1~8の炭化水素基である場合は除かれ、
R7は、-R10-L2-R11-L3-R12を示し、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53,R54,R55,およびR56はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
R53,R54,R55,およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、
上記の炭素数6~20のアリール基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57で置換されていてもよく、
R58は、炭素数1~12の炭化水素基を示し、
R57は、-OH、COOH、-NR61R62、-OC(O)O-R63、-C(O)O-R64、-OC(O)-R65、-O-R66を示す。
R61およびR62はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R63,R64,R65,およびR66はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
R63,R64,R65,およびR66が示す炭化水素基は、炭素数6~20のアリール基または-S-R68で置換されていてもよく、
上記の炭素数6~20のアリール基は、-OH、COOH、-NR61R62、-OC(O)O-R63、-C(O)O-R64、-OC(O)-R65、-O-R66、または-(炭素数1~12の炭化水素基)-R67で置換されていてもよく、
R68は、炭素数1~12の炭化水素基を示し、
L1、L2、及びL3はそれぞれ独立に、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示す。
R8は、炭素数1~12の炭化水素基を示し、
R9は、炭素数1~24の炭化水素基を示し、
R10は、炭素数1~8の炭化水素基を示し、
R11は、炭素数1~24の炭化水素基を示し、
R12は、炭素数1~24の炭化水素基を示し、
R9、およびR12が示す炭化水素基は、アリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-S-R58で置換されていてもよく、R53、R54、R55、およびR58の定義は上記の通りであり、
R11が示す炭化水素基は、-OC(O)O-R53、-C(O)O-R54、または-OC(O)-R55で置換されていてもよく、R53、R54、およびR55の定義は上記の通りである。
<2> R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、R3は、炭素数2~4の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OHで置換されていてもよく、
R4は、炭素数1~8の炭化水素基を示し、
R5およびR6がそれぞれ独立に、炭素数1~8の炭化水素基、又は-R8-L1-R9を示し、但し、R5およびR6がともに炭素数1~8の炭化水素基である場合は除かれ、
R7が、-R10-L2-R11-L3-R12を示し、
L1、およびL3はそれぞれ独立に、-C(O)O-、または-OC(O)-を示す。
L2は、-OC(O)O-、-C(O)O-、または-OC(O)-を示す。
R8は、炭素数1~8の炭化水素基を示し、
R9は、炭素数1~16の炭化水素基を示し、
R10は、炭素数1~8の炭化水素基を示し、
R11は、炭素数1~9の炭化水素基を示し、
R12は、炭素数1~16の炭化水素基を示し、
R9、およびR12が示す炭化水素基は、アリール基、又は-S-R58で置換されていてもよく、
R58は、炭素数1~8の炭化水素基を示し、
R11が示す炭化水素基は、-C(O)O-R55, 又は-OC(O)-R56で置換されていてもよく、
R55,およびR56はそれぞれ独立に、炭素数1~16の炭化水素基を示し、
R55,およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、R58の定義は上記の通りである、
<1>に記載の化合物またはその塩。
<3> 下記式(1-1)で示される化合物またはその塩である、<1>に記載の化合物またはその塩。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-O-R56で置換されていてもよく、
R4は、炭素数1~8の炭化水素基を示し、
R5およびR6がそれぞれ独立に、炭素数1~8の炭化水素基、又は-R8-L1-R9を示し、但し、R5およびR6がともに炭素数1~8の炭化水素基である場合は除かれ、
L1は、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、
R8は、炭素数1~12の炭化水素基を示し、
R9は、炭素数1~24の炭化水素基を示し、R9が示す炭化水素基は、アリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-S-R58で置換されていてもよく、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53,R54,R55,およびR56はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
R53,R54,R55,およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、
上記の炭素数6~20のアリール基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57で置換されていてもよく、
R58は、炭素数1~12の炭化水素基を示し、
R57は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56を示す。
R13は、炭素数1~8の炭化水素基を示し、
R14は、-R15-L5-R16を示し、R15は炭素数1~24の炭化水素基を示し、L5は-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、R16は、炭素数1~24の炭化水素基を示し、
R15が示す炭素数1~24の炭化水素基は、-OC(O)O-R53、-C(O)O-R54、又は-OC(O)-R55で置換されていてもよく、R53、R54、およびR55の定義は上記の通りであり、
R16が示す炭素数1~24の炭化水素基は、炭素数6~20のアリール基、 -OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-S-R58で置換されていてもよく、R53、R54、R55、およびR58の定義は上記の通りである。
<4> 式(1-1)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、R3は、炭素数2~4の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OHで置換されていてもよく、
R4は、炭素数1~8の炭化水素基を示し、
R5およびR6がそれぞれ独立に、炭素数1~8の炭化水素基、又は-R8-L1-R9を示し、但し、R5およびR6がともに炭素数1~8の炭化水素基である場合は除かれ、
L1は、-C(O)O-、または-OC(O)-を示し、
R8は、炭素数1~8の炭化水素基を示し、
R9は、炭素数1~18の炭化水素基を示し、R9が示す炭化水素基は、炭素数6~20のアリール基、又は-S-R58で置換されていてもよく、
R58は、炭素数1~8の炭化水素基を示し、
R13は、炭素数1~8の炭化水素基を示し、
R14は、-R15-L5-R16を示し、R15は炭素数1~18の炭化水素基を示し、L5は-OC(O)O-を示し、R16は、炭素数1~18の炭化水素基を示し、
R15が示す炭素数1~18の炭化水素基は、-C(O)O-R55、又は-OC(O)-R56で置換されていてもよく、
R55,およびR56はそれぞれ独立に、炭素数1~16の炭化水素基を示し、R55、およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、R58の定義は上記の通りであり、
R16が示す炭素数1~18の炭化水素基は、アリール基、又は-S-R58で置換されていてもよく、R58の定義は上記の通りである、
<3>に記載の化合物またはその塩。
<5> 下記式(1-2)で示される化合物またはその塩である、<1>に記載の化合物またはその塩。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-O-R56で置換されていてもよく、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素を示し、
R21およびR22はそれぞれ独立に、炭素数1~18の炭化水素基を示し、
R23およびR24はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
R25およびR26はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
L21およびL22はそれぞれ独立に、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、
R25およびR26が示す炭化水素基は、炭素数6~20のアリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、または-S-R58で置換されていてもよく、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53、R54、R55およびR56はそれぞれ独立に、炭素数1~18の炭化水素基を示し、
上記の炭素数6~20のアリール基は、OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57により置換されていてもよく、
R57は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56を示す。
R58は、炭素数1~12の炭化水素基を示す。
<6> 式(1-2)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、R1およびR2が示す炭化水素基は、-OHで置換されていてもよく、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素を示し、
R21およびR22はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R23およびR24はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R25およびR26はそれぞれ独立に、炭素数1~16の炭化水素基を示し、
L21およびL22はそれぞれ独立に、-C(O)O-、または-OC(O)-を示す、
<5>に記載の化合物またはその塩。
<7> 式(1-2)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素を示し、
R21およびR22はそれぞれ独立に、炭素数1~6の炭化水素基を示し、
R23およびR24はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R25およびR26はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
L21およびL22はそれぞれ独立に、-C(O)O-、または-OC(O)-を示す、
<5>に記載の化合物またはその塩。
<8> 下記式(1-3)で示される化合物またはその塩である、<1>に記載の化合物またはその塩。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-O-R56で置換されていてもよく、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、
R35、R36、R37、およびR38が示す炭化水素基は、炭素数6~20のアリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、またはS-R58で置換されていてもよく、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53、R54、R55、およびR56はそれぞれ独立に、炭素数1~18の炭化水素基を示し、
上記の炭素数6~20のアリール基は、OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57により置換されていてもよく、
R57は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56を示す。
R58は、炭素数1~12の炭化水素基を示す。
<9> 式(1-3)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、R1およびR2が示す炭化水素基は、-OHで置換されていてもよく、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、炭素数1~16の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-C(O)O-、または-OC(O)-を示し、
R35、R36、R37、およびR38が示す炭化水素基は、炭素数6~20のアリール基、またはS-R58で置換されていてもよく、
R58は、炭素数1~8の炭化水素基を示す、
<8>に記載の化合物またはその塩。
<10> 式(1-3)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-C(O)O-、または-OC(O)-を示し、
R35、R36、R37、およびR38が示す炭化水素基は、-S-R58で置換されていてもよく、
R58は、炭素数1~8の炭化水素基を示す、
<8>に記載の化合物またはその塩。
<11> 式(1-3)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、-S-R58で置換された炭素数1~12の炭化水素基を示し、R58は、炭素数1~8の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-C(O)O-、または-OC(O)-を示す、
<8>に記載の化合物またはその塩。
<12> 式(1-3)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-C(O)O-、または-OC(O)-を示す、
<8>に記載の化合物またはその塩。
<13> 以下に記載の化合物またはその塩;
ビス(2-ブチルオクチル)16-(3-(ジエチルアミノ)プロピル)-10,22-ジヘキシル-12,20-ジオキソ-11,13,19,21-テトラオキサ-16-アザヘントリアコンタンジオエート;
<15> 脂質が、ステロールおよび非イオン性親水性高分子鎖を有する脂質からなる群から選択される少なくとも一種の脂質である、<14>に記載の脂質粒子。
<16> さらに中性脂質を含む、<14>または<15>に記載の脂質粒子。
<17> さらに核酸を含む、<14>から<16>の何れか一に記載の脂質粒子。
<18> 核酸が、塩基数が50以上の核酸を含む、<17>に記載の脂質粒子。
<19> <14>から<18>の何れか一に記載の脂質粒子を有効成分として含有する、医薬組成物。
本明細書において「~」は、その前後に記載される数値をそれぞれ最小値および最大値として含む範囲を示す。
本発明の化合物は、下記式(1)で示される。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、及び-O-R56から選択される1以上の置換基で置換されていてもよく、
R4は、炭素数1~8の炭化水素基を示し、
R5およびR6がそれぞれ独立に、炭素数1~8の炭化水素基、又は-R8-L1-R9を示し、但し、R5およびR6がともに炭素数1~8の炭化水素基である場合は除かれ、
R7は、-R10-L2-R11-L3-R12を示し、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53,R54,R55,およびR56はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
R53,R54,R55,およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、
上記の炭素数6~20のアリール基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57で置換されていてもよく、
R58は、炭素数1~12の炭化水素基を示し、
R57は、-OH、COOH、-NR61R62、-OC(O)O-R63、-C(O)O-R64、-OC(O)-R65、-O-R66を示す。
R61およびR62はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R63,R64,R65,およびR66はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
R63,R64,R65,およびR66が示す炭化水素基は、炭素数6~20のアリール基または-S-R68で置換されていてもよく、
上記の炭素数6~20のアリール基は、-OH、COOH、-NR61R62、-OC(O)O-R63、-C(O)O-R64、-OC(O)-R65、-O-R66、または-(炭素数1~12の炭化水素基)-R67で置換されていてもよく、
R68は、炭素数1~12の炭化水素基を示し、
L1、L2、及びL3はそれぞれ独立に、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示す。
R8は、炭素数1~12の炭化水素基を示し、
R9は、炭素数1~24の炭化水素基を示し、
R10は、炭素数1~8の炭化水素基を示し、
R11は、炭素数1~24の炭化水素基を示し、
R12は、炭素数1~24の炭化水素基を示し、
R9、およびR12が示す炭化水素基は、アリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-S-R58で置換されていてもよく、R53、R54、R55、およびR58の定義は上記の通りであり、
R11が示す炭化水素基は、-OC(O)O-R53、-C(O)O-R54、または-OC(O)-R55で置換されていてもよく、R53、R54、およびR55の定義は上記の通りである。
具体的には、メチレン基、エチレン基、トリメチレン基、テトラメチレン基、ペンタメチレン基、ヘキサメチレン基、ヘプタメチレン基、オクタメチレン基、ノナメチレン基、デカメチレン基、ウンデカメチレン基などが挙げられる。
R3は、好ましくは炭素数2~6の炭化水素基を示し、より好ましくは炭素数2~4の炭化水素基を示す。
R1、R2およびR3が示す炭化水素基は、好ましくは、-OHで置換されていてもよい。
L2は、好ましくは、-OC(O)O-、-C(O)O-、または-OC(O)-を示す。
R9は、好ましくは炭素数1~20の炭化水素基を示し、より好ましくは炭素数1~16の炭化水素基を示す。
R11は、好ましくは炭素数1~16の炭化水素基を示し、より好ましくは炭素数1~9の炭化水素基を示す。
R12は、好ましくは炭素数1~20の炭化水素基を示し、より好ましくは炭素数1~16の炭化水素基を示す。
R9、およびR12が示す炭化水素基は、好ましくは、アリール基、又は-S-R58で置換されてもよい。ここでR58は、好ましくは炭素数1~8の炭化水素基を示す。
R11が示す炭化水素基は、好ましくは、-C(O)O-R55, 又は-OC(O)-R56で置換されていてもよく、ここで、R55,およびR56はそれぞれ独立に、炭素数1~16の炭化水素基を示す、
R55,およびR56が示す炭化水素基は、好ましくは、炭素数6~20のアリール基または-S-R58で置換されていてもよく、R58の定義は上記の通りである。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-O-R56で置換されていてもよく、
R4は、炭素数1~8の炭化水素基を示し、
R5およびR6がそれぞれ独立に、炭素数1~8の炭化水素基、又は-R8-L1-R9を示し、但し、R5およびR6がともに炭素数1~8の炭化水素基である場合は除かれ、
L1は、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、
R8は、炭素数1~12の炭化水素基を示し、
R9は、炭素数1~24の炭化水素基を示し、R9が示す炭化水素基は、アリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-S-R58で置換されていてもよく、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53,R54,R55,およびR56はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
R53,R54,R55,およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、
上記の炭素数6~20のアリール基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57で置換されていてもよく、
R58は、炭素数1~12の炭化水素基を示し、
R57は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56を示す。
R13は、炭素数1~8の炭化水素基を示し、
R14は、-R15-L5-R16を示し、R15は炭素数1~24の炭化水素基を示し、L5は-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、R16は、炭素数1~24の炭化水素基を示し、
R15が示す炭素数1~24の炭化水素基は、-OC(O)O-R53、-C(O)O-R54、又は-OC(O)-R55で置換されていてもよく、R53、R54、およびR55の定義は上記の通りであり、
R16が示す炭素数1~24の炭化水素基は、炭素数6~20のアリール基、 -OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-S-R58で置換されていてもよく、R53、R54、R55、およびR58の定義は上記の通りである。
R3は、好ましくは炭素数2~6の炭化水素基を示し、より好ましくは炭素数2~4の炭化水素基を示す。
R1、R2およびR3が示す炭化水素基は、好ましくは、-OHで置換されていてもよい。
R8は、好ましくは炭素数1~10の炭化水素基を示し、より好ましくは炭素数1~8の炭化水素基を示す。
R9は、好ましくは、炭素数1~18の炭化水素基を示し、R9が示す炭化水素基は、炭素数6~20のアリール基、又は-S-R58で置換されてもよい。
R14は、好ましくは、-R15-L5-R16を示し、R15は炭素数1~18の炭化水素基を示し、L5は-OC(O)O-を示し、R16は、炭素数1~18の炭化水素基を示す。
R15が示す炭素数1~18の炭化水素基は、好ましくは、-C(O)O-R55、又は-OC(O)-R56で置換されてもよい。R55,およびR56はそれぞれ独立に、炭素数1~16の炭化水素基を示し、R55、およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、R58の定義は上記の通りである。
R16が示す炭素数1~18の炭化水素基は、好ましくは、アリール基、又は-S-R58で置換されていてもよく、R58の定義は上記の通りである。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-O-R56で置換されていてもよく、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素を示し、
R21およびR22はそれぞれ独立に、炭素数1~18の炭化水素基を示し、
R23およびR24はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
R25およびR26はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
L21およびL22はそれぞれ独立に、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、
R25およびR26が示す炭化水素基は、炭素数6~20のアリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、または-S-R58で置換されていてもよく、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53、R54、R55およびR56はそれぞれ独立に、炭素数1~18の炭化水素基を示し、
上記の炭素数6~20のアリール基は、OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57により置換されていてもよく、
R57は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56を示す。
R58は、炭素数1~12の炭化水素基を示す。
R23およびR24はそれぞれ独立に、好ましくは炭素数1~10の炭化水素基を示し、より好ましくは炭素数1~8の炭化水素基を示す。
R25およびR26はそれぞれ独立に、好ましくは炭素数1~20の炭化水素基を示し、より好ましくは炭素数1~16の炭化水素基を示し、さらに好ましくは炭素数1~12の炭化水素基を示す。
L21およびL22はそれぞれ独立に、好ましくは-C(O)O-、または-OC(O)-を示す。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-O-R56で置換されていてもよく、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、
R35、R36、R37、およびR38が示す炭化水素基は、炭素数6~20のアリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、またはS-R58で置換されていてもよく、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53、R54、R55、およびR56はそれぞれ独立に、炭素数1~18の炭化水素基を示し、
上記の炭素数6~20のアリール基は、OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57により置換されていてもよく、
R57は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56を示す。
R58は、炭素数1~12の炭化水素基を示す。
R35、R36、R37、およびR38はそれぞれ独立に、特に好ましくは、-S-R58で置換された炭素数1~12の炭化水素基を示すか、または炭素数1~12の炭化水素基を示す。
塩基性基における塩としては、例えば、塩酸、臭化水素酸、硝酸および硫酸などの鉱酸との塩;ギ酸、酢酸、クエン酸、シュウ酸、フマル酸、マレイン酸、コハク酸、リンゴ酸、酒石酸、アスパラギン酸、トリクロロ酢酸およびトリフルオロ酢酸などの有機カルボン酸との塩;並びにメタンスルホン酸、ベンゼンスルホン酸、p-トルエンスルホン酸、メシチレンスルホン酸およびナフタレンスルホン酸などのスルホン酸との塩が挙げられる。
酸性基における塩としては、例えば、ナトリウムおよびカリウムなどのアルカリ金属との塩;カルシウムおよびマグネシウムなどのアルカリ土類金属との塩;アンモニウム塩;並びにトリメチルアミン、トリエチルアミン、トリブチルアミン、ピリジン、N,N-ジメチルアニリン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、ジシクロヘキシルアミン、プロカイン、ジベンジルアミン、N-ベンジル-β-フェネチルアミン、1-エフェナミンおよびN,N’-ジベンジルエチレンジアミンなどの含窒素有機塩基との塩などが挙げられる。
上記した塩の中で、好ましい塩としては、薬理学的に許容される塩が挙げられる。
実施例1~実施例44に記載の化合物は、それぞれ化合物1~化合物44と称する。
本発明の化合物の製造法について説明する。
本発明の化合物は、公知の方法を組み合わせることにより製造することができるが、例えば、以下に示す製造法に従い、製造することができる。
脱離基として、例えば、クロロ基、フルオロ基、ブロモ基、トリクロロメトキシ基、4-ニトロ-フェノキシ基、2,4-ジニトロフェノキシ基、2,4,6-トリクロロフェノキシ基、ペンタフルオロフェノキシ基、2,3,5,6-テトラフルオロフェノキシ基、イミダゾリル基、トリアゾリル基、3,5-ジオキソ-4-メチル-1,2,4-オキサジアゾリジル基、N-ヒドロキシスクシンイミジル基などが挙げられる。
式[3]の化合物として、例えば、1,1'-カルボニルジイミダゾール、クロロギ酸4-ニトロフェニル、トリホスゲンおよびホスゲンなどが知られている。
式[4]の化合物は、塩基の存在下もしくは不存在下、式[2]の化合物を式[3]の化合物と反応させることにより製造することができる。
この反応に使用される溶媒としては、反応に影響を及ぼさないものであれば特に限定されないが、例えば、ハロゲン化炭化水素類、エーテル類、エステル類、アミド類、ニトリル類、スルホキシド類および芳香族炭化水素類が挙げられ、これらの溶媒は混合して使用してもよい。
好ましい溶媒としては、エーテル類が挙げられ、テトラヒドロフランがより好ましい。
溶媒の使用量は、特に限定されないが、式[2]の化合物に対して、1~500倍量(v/w)であればよい。
この反応に用いられる塩基としては、無機塩基または有機塩基が挙げられる。塩基は有機塩基が好ましく、具体的には、トリエチルアミン、N,N-ジイソプロピルエチルアミン、4-メチルモルホリン、 ピリジン、1,8-ジアザビシクロ[5.4.0]-7-ウンデセン、またはN,N-ジメチルアミノピリジンなどが挙げられる。
塩基の使用量は、式[2]の化合物に対して、1~50倍モル、好ましくは、1~10倍モルであればよい。
式[3]の化合物の使用量は、特に限定されないが、式[2]の化合物に対して、0.3~10倍量(v/w)であればよい。
この反応は、-30~150℃、好ましくは0~100℃で5分間~48時間実施すればよい。
式[5]の化合物として、例えば、2,2'-((2-ジエチルアミノ)エチル)アザンジイル)ビス(エタン-1-オール)、2,2'-((2-ジメチルアミノ)エチル)アザンジイル)ビス(エタン-1-オール)および2,2'-((3-(ジエチルアミノ)プロピル)アザンジイル)ビス(エタン-1-オール)などが知られている。
式[1]の化合物は、塩基の存在下、式[4]の化合物を式[5]の化合物と反応させることにより製造することができる。
この反応に使用される溶媒としては、反応に影響を及ぼさないものであれば特に限定されないが、たとえば、ハロゲン化炭化水素類、エーテル類、エステル類、アミド類、ニトリル類、スルホキシド類および芳香族炭化水素類が挙げられ、これらの溶媒は混合して使用してもよい。
好ましい溶媒としては、ニトリル類が挙げられ、アセトニトリルがより好ましい。
溶媒の使用量は、特に限定されないが、式[4]の化合物に対して、1~500倍量(v/w)であればよい。
この反応に用いられる塩基としては、無機塩基または有機塩基が挙げられる。具体的には、炭酸カリウム、炭酸ナトリウム、炭酸リチウム、リン酸カリウム、リン酸ナトリウム、リン酸リチウム、トリエチルアミン、N,N-ジイソプロピルエチルアミン、4-メチルモルホリン、 ピリジン、1,8-ジアザビシクロ[5.4.0]-7-ウンデセン、またはN,N-ジメチルアミノピリジンなどが挙げられる。
塩基の使用量は、式[4]の化合物に対して、1~50倍モル、好ましくは、1~10倍モルであればよい。
式[5]の化合物の使用量は、特に限定されないが、式[4]の化合物に対して、0.1~10倍量(v/w)であればよい。
この反応は、-30~150℃、好ましくは0~100℃で5分間~48時間実施すればよい。
式[5]の化合物として、例えば、2-((2-(ジエチルアミノ)エチル)(エチル)アミノ)エタン-1-オールおよび2-((2-(ジエチルアミノ)エチル)(イソプロピル)アミノ)エタン-1-オールなどが知られている。
式[1]の化合物は、塩基の存在下、式[4]の化合物を式[6]の化合物と反応させることにより製造することができる。
この反応は、製造法(1-2)に準じて行えばよい。
脱離基として、例えば、クロロ基、フルオロ基、ブロモ基、トリクロロメトキシ基、4-ニトロ-フェノキシ基、2,4-ジニトロフェノキシ基、2,4,6-トリクロロフェノキシ基、ペンタフルオロフェノキシ基、2,3,5,6-テトラフルオロフェノキシ基、イミダゾリル基、トリアゾリル基、3,5-ジオキソ-4-メチル-1,2,4-オキサジアゾリジル基、N-ヒドロキシスクシンイミジル基などが挙げられる。
式[8]の化合物として、例えば、マロン酸エチルカリウムなどが知られている。
式[9]の化合物は、塩基の存在下もしくは不存在下、無水塩化マグネシウム存在下もしくは不存在下、式[7]の化合物を式[8]の化合物と反応させることにより製造することができる。
この反応に使用される溶媒としては、反応に影響を及ぼさないものであれば特に限定されないが、例えば、ハロゲン化炭化水素類、エーテル類、エステル類、アミド類、ニトリル類、スルホキシド類および芳香族炭化水素類が挙げられ、これらの溶媒は混合して使用してもよい。
好ましい溶媒としては、ニトリル類が挙げられ、アセトニトリルがより好ましい。
溶媒の使用量は、特に限定されないが、式[7]の化合物に対して、1~500倍量(v/w)であればよい。
この反応に用いられる塩基としては、無機塩基または有機塩基が挙げられる。有機塩基が好ましく、具体的には、トリエチルアミン、N,N-ジイソプロピルエチルアミン、4-メチルモルホリン、 ピリジン、1,8-ジアザビシクロ[5.4.0]-7-ウンデセン、またはN,N-ジメチルアミノピリジンなどが挙げられる。
塩基の使用量は、式[7]の化合物に対して、1~50倍モル、好ましくは、1~10倍モルであればよい。
式[8]の化合物の使用量は、特に限定されないが、式[7]の化合物に対して、0.1~10倍量(v/w)であればよい。
この反応は、-30~150℃、好ましくは0~100℃で5分間~48時間実施すればよい。
式[10]の化合物として、例えば、8-ブロモオクタン酸エチルなどが知られている。
式[11A]の化合物は、塩基の存在下もしくは不存在下、式[9]の化合物を式[10]の化合物と反応させることにより製造することができる。
この反応に使用される溶媒としては、反応に影響を及ぼさないものであれば特に限定されないが、例えば、ハロゲン化炭化水素類、エーテル類、エステル類、アミド類、ニトリル類、スルホキシド類および芳香族炭化水素類が挙げられ、これらの溶媒は混合して使用してもよい。
好ましい溶媒としては、アルコール類が挙げられ、エタノールおよびメタノールがより好ましい。
溶媒の使用量は、特に限定されないが、式[9]の化合物に対して、1~500倍量(v/w)であればよい。
この反応に用いられる塩基としては、無機塩基または有機塩基が挙げられる。具体的には、水酸化カリウム、水酸化ナトリム、水酸化リチウム、炭酸カリウム、炭酸ナトリウム、炭酸リチウム、リン酸カリウム、リン酸ナトリウム、リン酸リチウム、トリエチルアミン、N,N-ジイソプロピルエチルアミン、4-メチルモルホリン、 ピリジン、1,8-ジアザビシクロ[5.4.0]-7-ウンデセン、またはN,N-ジメチルアミノピリジンなどが挙げられる。
塩基の使用量は、式[9]の化合物に対して、0.1~50倍モル、好ましくは、1~10倍モルであればよい。
式[8]の化合物の使用量は、特に限定されないが、式[9]の化合物に対して、0.1~10倍量(v/w)であればよい。
この反応は、-30~150℃、好ましくは0~100℃で5分間~48時間実施すればよい。
式[11B]の化合物は、塩基または酸の存在下、式[11A]の化合物の加水分解反応により製造することができる。
この反応に使用される溶媒としては、反応に影響を及ぼさないものであれば特に限定されないが、たとえば、ハロゲン化炭化水素類、エーテル類、エステル類、アミド類、ニトリル類、スルホキシド類、芳香族炭化水素類および水が挙げられ、これらの溶媒は混合して使用してもよい。
溶媒の使用量は、特に限定されないが、式[11A]の化合物に対して、1~500倍量(v/w)であればよい。
この反応に用いられる塩基としては、無機塩基または有機塩基が挙げられる。無機塩基が好ましく、具体的には、水酸化カリウム、水酸化ナトリム、水酸化リチウム、炭酸カリウム、炭酸ナトリウム、炭酸リチウム、リン酸カリウム、リン酸ナトリウムおよびリン酸リチウムなどが挙げられる。
この反応に用いられる酸としては、無機酸または有機酸が挙げられる。無機酸が好ましく、具体的には、塩酸、臭化水素酸、ヨウ素酸、硫酸およびリン酸などが挙げられる。
塩基の使用量は、式[11A]の化合物に対して、0.1~50倍モル、好ましくは、1~10倍モルであればよい。
酸の使用量は、式[11A]の化合物に対して、0.01~50倍モル、好ましくは、1~10倍モルであればよい。
この反応は、-30~150℃、好ましくは0~100℃で5分間~48時間実施すればよい。
式[13]の化合物として、例えば、ヘキシルマグネシウムブロミドなどが知られている。
式[11B]の化合物は、式[12]の化合物を式[13]の化合物と反応させることにより製造することができる。
この反応に使用される溶媒としては、反応に影響を及ぼさないものであれば特に限定されないが、たとえば、ハロゲン化炭化水素類、エーテル類、アミド類および芳香族炭化水素類が挙げられ、これらの溶媒は混合して使用してもよい。
好ましい溶媒としては、エーテル類が挙げられ、テトラヒドロフランがより好ましい。
溶媒の使用量は、特に限定されないが、式[12]の化合物に対して、1~500倍量(v/w)であればよい。
式[13]の化合物の使用量は、特に限定されないが、式[12]の化合物に対して、0.8~10倍量(v/w)であればよい。
この反応は、-30~150℃、好ましくは0~100℃で5分間~48時間実施すればよい。
式[14]の化合物として、例えば、2-ブチル-1-オクタノール、2-ペンチル-1-ヘプタノールなどが知られている。
式[11C]の化合物は、酸の存在下もしくは不存在下、縮合剤または酸ハロゲン化物の存在下もしくは不存在下、塩基の存在下もしくは不存在下、式[11B]の化合物を式[14]の化合物と反応させることにより製造することができる。
この反応に使用される溶媒としては、反応に影響を及ぼさないものであれば特に限定されないが、例えば、ハロゲン化炭化水素類、エーテル類、エステル類、アミド類、ニトリル類、スルホキシド類および芳香族炭化水素類が挙げられ、これらの溶媒は混合して使用してもよい。
好ましい溶媒としては、芳香族炭化水素類およびエーテル類が挙げられ、トルエンおよびテトラヒドロフランがより好ましい。
溶媒の使用量は、特に限定されないが、式[11B]の化合物に対して、1~500倍量(v/w)であればよい。
この反応に用いられる酸としては、無機酸または有機酸が挙げられる。酸はスルホン酸類が好ましく、具体的には、硫酸、4-トルエンスルホン酸、メタンスルホン酸などが挙げられる。
この反応に使用される縮合剤としては、例えば、N,N’-ジシクロヘキシルカルボジイミドおよび1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミドなどのカルボジイミド類;カルボニルジイミダゾールなどのカルボニル類;ジフェニルホスホリルアジドなどの酸アジド類;ジエチルホスホリルシアニドなどの酸シアニド類;2-エトキシ-1-エトキシカルボニル-1,2-ジヒドロキノリン;O-ベンゾトリアゾール-1-イル-1,1,3,3-テトラメチルウロニウム=ヘキサフルオロホスフェートならびにO-(7-アザベンゾトリアゾール-1-イル)-1,1,3,3-テトラメチルウロニウム=ヘキサフルオロホスフェートなどのウロニウム類などが挙げられる。
この反応に使用される酸ハロゲン化物としては、例えば、塩化アセチルおよびトリフルオロアセチルクロリドなどのカルボン酸ハロゲン化物類;塩化メタンスルホニルおよび塩化トシルなどのスルホン酸ハロゲン化物類;クロロギ酸エチルおよびクロロギ酸イソブチルなどのクロロギ酸エステル類などが挙げられる。
この反応に用いられる塩基としては、無機塩基または有機塩基が挙げられる。塩基は有機塩基が好ましく、具体的には、トリエチルアミン、N,N-ジイソプロピルエチルアミン、4-メチルモルホリン、 ピリジン、1,8-ジアザビシクロ[5.4.0]-7-ウンデセン、またはN,N-ジメチルアミノピリジンなどが挙げられる。
塩基の使用量は、式[11B]の化合物に対して、1~50倍モル、好ましくは、1~10倍モルであればよい。
式[14]の化合物の使用量は、特に限定されないが、式[11B]の化合物に対して、0.8~10倍量(v/w)であればよい。
この反応は、-30~150℃、好ましくは0~100℃で5分間~48時間実施すればよい。
式[2A]の化合物は、還元剤の存在下、式[11C]の化合物の還元反応により製造することができる。
この反応に使用される溶媒としては、反応に影響を及ぼさないものであれば特に限定されないが、例えば、ハロゲン化炭化水素類、エーテル類、エステル類、アミド類、ニトリル類、アルコール類、スルホキシド類、芳香族炭化水素類および水が挙げられ、これらの溶媒は混合して使用してもよい。
溶媒の使用量は、特に限定されないが、式[11A]の化合物に対して、1~500倍量(v/w)であればよい。
この反応に用いられる還元剤としては、例えば、水素化ホウ素ナトリウムなどのホウ素化合物類などが挙げられる。
還元剤の使用量は、式[11A]の化合物に対して、0.1~50倍モル、好ましくは、1~10倍モルであればよい。
この反応は、-30~150℃、好ましくは0~100℃で5分間~48時間実施すればよい。
式[2A]の化合物として、例えば、1-ヘプタノール、2-(ヘキシルチオ)エタン-1-オールおよび8-(メチルチオ)オクタン-1-オールなどが知られている。
式[17]の化合物は、酸の存在下もしくは不存在下、縮合剤または酸ハロゲン化物の存在下もしくは不存在下、塩基の存在下もしくは不存在下、式[15]の化合物を式[16]の化合物と反応させることにより製造することができる。
この反応は、製造法(2-5)に準じて行えばよい。
式[2B]の化合物は、還元剤の存在下、式[17]の化合物の還元反応により製造することができる。
この反応は、製造法(2-6)に準じて行えばよい。
脱離基として、例えば、クロロ基、フルオロ基、ブロモ基、トリクロロメトキシ基、4-ニトロ-フェノキシ基、2,4-ジニトロフェノキシ基、2,4,6-トリクロロフェノキシ基、ペンタフルオロフェノキシ基、2,3,5,6-テトラフルオロフェノキシ基、イミダゾリル基、トリアゾリル基、3,5-ジオキソ-4-メチル-1,2,4-オキサジアゾリジル基、N-ヒドロキシスクシンイミジル基などが挙げられる。
式[19]の化合物として、例えば、2-クロロ-N,N-ジエチルエタン-1-アミン、3-クロロ-N,N-ジエチルプロパン-1-アミンおよび2-ブロモ-N,N-ジエチルエタン-1-アミンなどが知られている。
式[5]の化合物は、塩基の存在下もしくは不存在下、式[18]の化合物を式[19]の化合物と反応させることにより製造することができる。
この反応に使用される溶媒としては、反応に影響を及ぼさないものであれば特に限定されないが、例えば、アルコール類、ハロゲン化炭化水素類、エーテル類、エステル類、アミド類、ニトリル類、スルホキシド類、芳香族炭化水素類および水が挙げられ、これらの溶媒は混合して使用してもよい。
溶媒の使用量は、特に限定されないが、式[18]の化合物に対して、1~500倍量(v/w)であればよい。
この反応に用いられる塩基としては、無機塩基または有機塩基が挙げられる。塩基の使用量は、式[18]の化合物に対して、1~10000倍モル、好ましくは、1~5000倍モルであればよい。
式[19]の化合物の使用量は、特に限定されないが、式[18]の化合物に対して、1~10倍量(v/w)であればよい。
この反応は、-30~150℃、好ましくは0~100℃で5分間~48時間実施すればよい。
式[20]の化合物として、例えば、2-ブロモ-1-エタノール、3-ブロモ-1-プロパノールなどが知られている。
式[5]の化合物は、塩基の存在下もしくは不存在下、式[20]の化合物を式[21]の化合物と反応させることにより製造することができる。
この反応に使用される溶媒としては、反応に影響を及ぼさないものであれば特に限定されないが、例えば、アルコール類、ハロゲン化炭化水素類、エーテル類、エステル類、アミド類、ニトリル類、スルホキシド類、芳香族炭化水素類および水が挙げられ、これらの溶媒は混合して使用してもよい。
溶媒の使用量は、特に限定されないが、式[20]の化合物に対して、1~500倍量(v/w)であればよい。
この反応に用いられる塩基としては、無機塩基または有機塩基が挙げられる。塩基の使用量は、式[20]の化合物に対して、1~10000倍モル、好ましくは、1~5000倍モルであればよい。
式[21]の化合物の使用量は、特に限定されないが、式[20]の化合物に対して、1~10倍量(v/w)であればよい。
この反応は、-30~150℃、好ましくは0~100℃で5分間~48時間実施すればよい。
また、溶媒和物、水和物および種々の形状の結晶が存在する場合、これらの溶媒和物、水和物および種々の形状の結晶も使用することができる。
上記した製造法で得られる化合物は、例えば、縮合、付加、酸化、還元、転位、置換、ハロゲン化、脱水もしくは加水分解などの自体公知の反応に付すことにより、または、それらの反応を適宜組み合わせることにより、他の化合物に誘導することができる。
本発明においては、本発明の化合物またはその塩を含む脂質粒子を調製することができる。脂質粒子を調製する際には、本発明の化合物に加えて、ステロールおよび非イオン性親水性高分子鎖を有する脂質からなる群から選択される少なくとも一種の脂質を使用することができる。脂質粒子は、さらに中性脂質を含むことができる。脂質粒子は、さらに核酸を含むことができる。
本発明における脂質粒子は、ステロールを含むことが好ましい。本発明の脂質粒子において、ステロールを含むことで、膜流動性を低下させ、脂質粒子の安定化効果を得ることができる。
ステロールとしては、特に限定されないが、コレステロール、フィトステロール(シトステロール)、スチグマステロール、フコステロール、スピナステロール、ブラシカステロールなど)、エルゴステロール、コレスタノン、コレステノン、コプロスタノール、コレステリル-2’-ヒドロキシエチルエーテル、コレステリル-4’-ヒドロキシブチルエーテルなどを上げることができる。これらの中でも、コレステロールが好ましい。
本発明の脂質粒子において、ステロールの配合量は、全脂質量に対して10mol%~60mol%であることが好ましく、20mol%~55mol%であることがより好ましく、25mol%~50mol%であることがさらに好ましい。
本発明における脂質粒子は、中性脂質を含んでもよい。中性脂質としては、特に限定されないが、ホスファチジルコリン、ホスファチジルエタノールアミン、スフィンゴミエリン、セラミドなどが挙げられ、ホスファチジルコリンが好ましい。また、中性脂質としては、単独でも、複数の異なる中性脂質を組み合わせても良い。
セラミドとしては、特に限定されないが、卵黄由来セラミド、牛乳由来セラミドなどが挙げられる。
本発明における脂質粒子は、油相に非イオン性親水性高分子鎖を有する脂質を含んでもよい。本発明において、油相に非イオン性親水性高分子鎖を有する脂質を含むことで、脂質粒子の分散安定化効果を得ることができる。
非イオン性親水性高分子の例としては、特に限定されないが、非イオン性のビニル系高分子、非イオン性ポリアミノ酸、非イオン性ポリエステル、非イオン性ポリエーテル、非イオン性天然高分子、非イオン性改変天然高分子、これらの2種以上の高分子を構成単位とするブロック重合体またはグラフト共重合体が挙げられる。
これらの非イオン性親水性高分子のうち、好ましくは非イオン性ポリエーテル、非イオン性ポリエステル、非イオン性ポリアミノ酸もしくは非イオン性合成ポリペプチドであり、さらに好ましくは非イオン性ポリエーテルまたは非イオン性ポリエステル、よりさらに好ましくは非イオン性ポリエーテルまたは非イオン性モノアルコキシポリエーテルであり、特に好ましくはポリエチレングリコール(ポリエチレングリコールは、以下においてPEGとも称する)である。
上記非イオン性親水性高分子誘導体のPEG鎖の重量平均分子量は、500~5000が好ましく、750~3000がより好ましい。
非イオン性親水性高分子鎖は分岐していてもよく、ヒドロキシメチル基のような置換基を有していてもよい。
本発明の脂質粒子は核酸を含んでいても良い。核酸としてはプラスミド、1本鎖DNA、2本鎖DNA、siRNA(small interfering RNA) 、miRNA(micro RNA)、mRNA、アンチセンスオリゴヌクレオチド(ASOとも言う)、リボザイム、アプタマー、saRNA、sgRNA等が挙げられ、いずれを含んでもよい。また、修飾化された核酸を含んでもよい。核酸としては、RNAが特に好ましく、塩基数としては5~20000塩基であるRNAが好ましい。
本発明の脂質粒子において、核酸に対する脂質の質量比は2~1000であることが好ましく、3~500であることがより好ましく、5~200であることがさらに好ましく、5~100であることが特に好ましい。
本発明の脂質粒子の製造方法について説明する。
脂質粒子の製造方法は限定されないが、脂質粒子の構成成分全てまたは一部の油溶性成分を有機溶媒等に溶解させ油相とし、水溶性成分を水に溶解させ水相とし、油相と水相を混合して製造することができる。混合にはマイクロミキサーを使用してもよく、ホモジナイザー等の乳化機、超音波乳化機、高圧噴射乳化機等により乳化してもよい。
あるいは、脂質を含む溶液をエバポレータなどによる減圧乾固または噴霧乾燥機などによる噴霧乾燥などにより脂質を含む乾燥した混合物を調製し、この混合物を水系溶媒に添加し、さらに前述の乳化機などで乳化することで製造することもできる。
本発明の化合物を含む脂質粒子の構成成分を有機溶媒に溶解して油相を得る工程(a);
工程(a)で得た油相と、核酸を含む水相と、を混合する工程(b);
工程(b)で得た油相および水相を含む混合液を希釈して、核酸脂質粒子の分散液を得る工程(c);
工程(c)で得られた核酸脂質粒子の分散液から上記有機溶媒を除去する工程(d);
を含む方法が挙げられる。
また、本発明の脂質粒子を含む分散液を、一般的な方法により、凍結や凍結乾燥を施すことができる。
本発明において、脂質粒子とは、脂質から構成される粒子を意味し、脂質が凝集している脂質凝集体、ミセル、リポソームから選択されるいずれかの構造を有する組成物が含まれるが、脂質を含む組成物である限り脂質粒子の構造はこれらに限定されない。リポソームとしては、脂質二重層構造を有し、内部に水相を有し、二重膜が単層のリポソーム、多数層状に重なった多重層リポソームがある。本発明にはどちらのリポソームが含まれてもよい。
本発明における脂質粒子の利用の一例としては、核酸を含む脂質粒子を細胞に導入することによって、細胞に核酸(例えば、RNAなど)を導入することができる。また、本発明における脂質粒子に、医薬用途を有する核酸を含む場合、脂質粒子は核酸医薬として生体に投与することができる。
薬学的に許容される担体との混合物中における脂質粒子の濃度は、特に限定されず、一般的には0.05質量%から90質量%とすることができる。また、本発明の脂質粒子を含む核酸医薬は、薬学的に許容される他の添加物質、例えば、pH調整緩衝剤、浸透圧調整剤などを添加してもよい。
本発明の脂質粒子は、高い内包率で核酸を保持することが可能であるため、核酸送達キャリアとして非常に有用である。本発明を利用した核酸送達キャリアによれば、例えば、得られた脂質粒子を核酸などと混合して、in vitroまたはin vivoでトランスフェクションをすることにより、細胞に核酸などを導入することができる。また、本発明を利用した核酸送達キャリアは、核酸医薬における核酸送達キャリアとしても有用である。すなわち、本発明の脂質粒子は、in vitroまたはin vivo(好ましくはin vivo)での核酸送達のための組成物として有用である。
特に記載のない場合、シリカゲルカラムクロマトグラフィーにおける担体は、Chromatorex Q-Pack SI 50(富士シリシア化学株式会社)、ハイフラッシュカラムW001、W002、W003、W004またはW005(山善株式会社)を使用した。
NHシリカゲルは、Chromatorex Q-Pack NH 60(富士シリシア化学株式会社)を使用した。
NMRスペクトルは、内部基準としてテトラメチルシランを用い、Bruker AV300(Bruker社製)、Bruker AV400(Bruker社製)またはAVNEO400(Bruker社製)を用いて測定し、全δ値をppmで示した。
MSスペクトルは、ACQUITY SQD LC/MS System(Waters社製)を用いて測定した。
clogPは、ChemDraw Professional Version: 19.1.0.8(PerkinElmer社製)を用いて計算した。
(1)
1H-NMR(CDCl3)δ: 4.20 (2H, q, J=8.0Hz), 3.43 (2H, s), 2.53 (2H, t, J=8.0Hz), 1.65-1.52 (2H, m), 1.26-1.21 (9H, m), 0.88 (3H, t, 8.0Hz).
1H-NMR(CDCl3)δ: 2.45-2.28 (6H, m), 1.71-1.47 (6H, m), 1.40-1.20 (14H, m), 0.88 (3H, t, J=8.0Hz).
1H-NMR(CDCl3)δ:3.97 (2H, d, J=5.6Hz), 2.38 (4H, t, J=7.6Hz), 2.29 (2H, t, J=7.6Hz), 1.65-1.50 (7H, m), 1.35-1.20 (38H, m), 0.92-0.83 (9H, m).
1H-NMR(CDCl3)δ:3.97 (2H, d, J=6.0Hz), 3.61-3.54 (1H, m), 2.30 (2H, t, J=7.6Hz), 1.65-1.56 (3H, m), 1.48-1.22 (46H, m), 0.92-0.83 (9H, m).
1H-NMR(CDCl3)δ:8.28 (2H, dd, J=7.2Hz, 2.1Hz), 7.39 (2H, dd, J=7.2Hz, 2.1Hz), 4.86-4.76 (1H, m), 3.97 (2H, d, J=5.7Hz), 2.30 (2H, t, J=7.2Hz), 1.74-1.20 (49H, m), 0.92-0.85 (9H, m).
1H-NMR(CDCl3)δ:3.58 (4H, t, J=5.4Hz), 2.70 (4H, t, J=5.4Hz), 2.67-2.48 (8H, m), 1.04 (6H, t, J=7.5Hz).
MS m/z(M+H):205.
1H-NMR(CDCl3)δ: 4.71-4.59 (2H, m), 4.21-4.08 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.6Hz), 2.71-2.44 (8H, m), 2.29 (4H, t, J=7.8Hz), 1.65-1.50 (14H, m), 1.35-1.20 (84H, m), 1.10-0.96 (6H, m), 0.92-0.84 (18H, m).
MS m/z(M+H):1251.
clogP:30.3764
1H-NMR(CDCl3)δ: 4.72-4.58 (2H, m), 4.21-4.08 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.6Hz), 2.73-2.43 (8H, m), 2.29 (4H, t, J=7.8Hz), 1.65-1.50 (14H, m), 1.36-1.20 (68H, m), 1.10-0.96 (6H, m), 0.92-0.84 (18H, m).
MS m/z(M+H):1139.
clogP:26.1444
(1)
1H-NMR(CDCl3)δ: 3.62 (4H, t, J=5.2Hz), 2.26 (2H, t, J=6.0Hz), 2.61-2.49 (10H, m), 1.68-1.60 (2H, m), 1.04 (6H, t, J=7.2Hz).
MS m/z(M+H):219.
1H-NMR(CDCl3)δ: 4.72-4.60 (2H, m), 4.23-4.07 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.81 (4H, t, J=6.6Hz), 2.72-2.37 (8H, m), 2.29 (4H, t, J=7.8Hz), 1.65-1.50 (16H, m), 1.35-1.20 (68H, m), 1.00 (6H, t, J=7.2Hz), 0.90-0.85 (18H, m).
MS m/z(M+H): 1153.
clogP: 26.389
1H-NMR(CDCl3)δ: 4.72-4.58 (2H, m), 4.21-4.11 (4H, m), 3.97 (4H, t, J=7.2Hz), 2.84 (4H, t, J=6.6Hz), 2.71-2.64 (2H, m), 2.56-2.46 (6H, m), 2.29 (4H, t, J=7.8Hz), 1.65-1.50 (16H, m), 1.36-1.20 (70H, m), 1.01 (6H, t, J=7.2Hz), 0.92-0.84 (18H, m).
MS m/z(M+H):1167.
1H-NMR(CDCl3)δ: 4.72-4.58 (2H, m), 4.21-4.08 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.6Hz), 2.71-2.64 (2H, m), 2.56-2.46 (6H, m), 2.29 (4H, t, J=7.8Hz), 1.65-1.50 (14H, m), 1.36-1.20 (68H, m), 1.01 (6H, t, J=7.2Hz), 0.92-0.84 (18H, m).
MS m/z(M+H):1139.
clogP:26.1444
1H-NMR(CDCl3)δ: 4.72-4.58 (2H, m), 4.21-4.08 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.6Hz), 2.71-2.64 (2H, m), 2.56-2.46 (6H, m), 2.29 (4H, t, J=7.8Hz), 1.65-1.50 (14H, m), 1.36-1.20 (76H, m), 1.01 (6H, t, J=7.2Hz), 0.92-0.84 (18H, m).
MS m/z(M+H):1195.
clogP: 28.2604
(1)
1H-NMR(CDCl3)δ:3.67 (3H, s), 2.88 (2H, t, J=7.2Hz), 2.30 (2H, t, J=7.2Hz), 1.75-1.57 (4H, m), 1.38-1.25 (8H, m).
1H-NMR(CDCl3)δ:3.67 (3H, s), 2.38 (4H, t, J=7.2Hz), 2.30 (2H, t, 7.2Hz), 1.65-1.49 (6H, m), 1.35-1.20 (12H, m), 0.88 (3H, t, J=7.2Hz).
1H-NMR(CDCl3)δ:3.97 (2H, d, J=5.6Hz), 2.38 (4H, t, J=7.6Hz), 2.29 (2H, t, J=7.6Hz), 1.65-1.50 (7H, m), 1.35-1.20 (36H, m), 0.92-0.83 (9H, m).
1H-NMR(CDCl3)δ:3.97 (2H, d, J=6.0Hz), 3.61-3.54 (1H, m), 2.30 (2H, t, J=7.6Hz), 1.65-1.56 (3H, m), 1.48-1.22 (44H, m), 0.92-0.83 (9H, m).
1H-NMR(CDCl3)δ:8.28 (2H, dd, J=7.2Hz, 2.1Hz), 7.39 (2H, dd, J=7.2Hz, 2.1Hz), 4.86-4.76 (1H, m), 3.97 (2H, d, J=5.7Hz), 2.30 (2H, t, J=7.2Hz), 1.74-1.20 (47H, m), 0.92-0.85 (9H, m).
1H-NMR(CDCl3)δ: 4.72-4.58 (2H, m), 4.21-4.08 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.6Hz), 2.71-2.64 (2H, m), 2.56-2.46 (6H, m), 2.29 (4H, t, J=7.8Hz), 1.65-1.50 (14H, m), 1.36-1.20 (80H, m), 1.01 (6H, t, J=7.2Hz), 0.92-0.84 (18H, m).
MS m/z(M+H):1223.
clogP: 29.3184
(1)
1H-NMR(CDCl3)δ:2.50 (2H, t, J=7.2Hz), 2.40 (4H, t, J=7.2Hz), 2.02-1.80 (2H, m), 1.63-1.48 (2H, m), 1.37-1.20 (6H, m), 0.88 (3H, t, J=6.6Hz).
1H-NMR(CDCl3)δ:3.97 (2H, d, J=5.1Hz), 2.47 (2H, t, J=7.2Hz), 2.39 (2H, t, J=7.2Hz), 2.33 (2H, t, J=7.2Hz), 1.95-1.83 (2H, m), 1.66-1.49 (3H, m), 1.36-1.20 (22H, m), 0.92-0.82 (9H, m).
1H-NMR(CDCl3)δ:3.97 (2H, d, J=5.7Hz), 3.65-3.53 (1H, m), 2.35 (2H, t, J=7.2Hz), 1.87-1.20 (32H, m), 0.92-0.84 (9H, m).
1H-NMR(CDCl3)δ:8.28 (2H, d, J=9.3Hz), 7.39 (2H, d, J=9.3Hz), 4.88-4.77 (1H, m), 3.99 (2H, d, J=6.0Hz), 2.41-2.31 (2H, m), 1.80-1.48 (7H, m), 1.44-1.20 (24H, m), 0.92-0.83 (9H, m).
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.65 (2H, m), 2.55-2.48 (6H, m), 2.32 (4H, t, J=7.2Hz), 1.73-1.50 (14H, m), 1.33-1.20 (48H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):999.
clogP:20.8544
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.65 (2H, m), 2.55-2.48 (6H, m), 2.32 (4H, t, J=7.2Hz), 1.73-1.50 (14H, m), 1.33-1.20 (64H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):1111.
clogP:25.0864
(1)
1H-NMR(CDCl3)δ: 3.98 (2H, d, J=6.0Hz), 3.63-3.57 (1H, m), 2.41-2.28 (2H, m), 1.84-1.22 (32H, m), 0.88 (9H, t, J=7.2Hz).
1H-NMR(CDCl3)δ: 8.14-8.12 (1H, m), 7.43-7.41 (1H, m), 7.08-7.06 (1H, m), 5.11-5.04 (1H, m), 3.97 (2H, d, J=5.6Hz), 2.38-2.32 (2H, m), 1.80-1.54 (7H, m), 1.40-1.22 (24H, m), 0.91-0.85 (9H, m).
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.65 (2H, m), 2.55-2.48 (6H, m), 2.32 (4H, t, J=7.2Hz), 1.73-1.50 (14H, m), 1.33-1.20 (48H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):999.
clogP:20.8544
(1)
1H-NMR(CDCl3)δ: 3.57 (4H, t, J=5.2Hz), 2.71 (4H, t, J=5.2Hz), 2.64 (2H, t, J=5.2Hz), 2.41 (2H, t, J=5.2Hz), 2.61 (6H, s).
MS m/z(M+H): 177.
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.85 (4H, t, J=6.4Hz), 2.77-2.65 (2H, m), 2.46-2.19 (12H, m), 1.73-1.50 (14H, m), 1.33-1.20 (48H, m), 0.91-0.84 (18H, m).
MS m/z(M+H):970.
clogP:19.7964
(1)
1H-NMR(CDCl3)δ: 3.58 (4H, t, J=5.4Hz), 2.70 (4H, t, J=5.4Hz), 2.67-2.62 (2H, m), 2.54-2.48 (2H, m), 2.45-2.38 (4H, m), 1.57-1.43 (4H, m), 0.88 (6H, t, J=7.2Hz).
MS m/z(M+H):233.
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.83 (4H, t, J=6.4Hz), 2.69-2.62 (2H, m), 2.52-2.47 (2H, m), 2.39-2.29 (8H, m), 1.74-1.49 (14H, m), 1.49-1.37 (4H, m), 1.36-1.20 (48H, m), 0.91-0.84 (24H, m).
MS m/z(M+H):1027.
clogP:21.9124
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.80 (4H, t, J=6.4Hz), 2.61-2.45 (6H, m), 2.44-2.37 (2H, m), 2.32 (4H, t, J=7.2Hz), 1.74-1.49 (16H, m), 1.35-1.21 (48H, m), 1.00 (6H, t, J=7.2Hz), 0.91-0.85 (18H, m).
MS m/z(M+H):1013.
clogP:21.099
(1)
1H-NMR(CDCl3)δ: 3.62 (4H, t, J=5.2Hz), 2.65 (4H, t, J=5.2Hz), 2.57-2.49 (6H, m), 2.44-2.39 (2H, m), 1.53-1.43 (4H, m), 1.02 (6H, t, J=7.2Hz).
MS m/z(M+H):233.
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.80 (4H, t, J=6.4Hz), 2.58-2.47 (6H, m), 2.44-2.37 (2H, m), 2.32 (4H, t, J=7.2Hz), 1.74-1.49 (14H, m), 1.45-1.39 (4H, m), 1.35-1.21 (48H, m), 1.00 (6H, t, J=7.2Hz), 0.91-0.85 (18H, m).
MS m/z(M+H):1027.
clogP:20.68
(1)
1H-NMR(CDCl3)δ: 3.74 (4H, t, J=5.2Hz), 2.61-2.51 (12H, m), 1.74-1.66 (4H, m), 1.04 (6H, t, J=7.2Hz).
MS m/z(M+H):233.
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.56-2.46 (12H, m), 2.32 (4H, t, J=7.2Hz), 1.83-1.75 (4H, m), 1.73-1.50 (14H, m), 1.35-1.21 (48H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):1027.
clogP:21.4444
(1)
1H-NMR(CDCl3)δ:3.62-3.58 (4H, m), 2.59-2.46 (12H, m), 1.66-1.59 (8H, m), 1.03 (6H, t, J=7.2Hz).
MS m/z(M+H):261.
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.60-2.41 (12H, m), 2.32 (4H, t, J=7.2Hz), 1.75-1.45 (22H, m), 1.35-1.21 (48H, m), 1.03 (6H, t, J=6.8Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):1055.
clogP:20.9424
(1)
1H-NMR(CDCl3)δ: 4.13 (2H, q, J=6.8Hz), 2.72 (2H, t, J=7.2Hz), 2.57 (2H, t, J=7.2Hz), 2.45 (2H, t, J=7.2Hz), 1.62-1.51 (2H, m), 1.33-1.23 (9H, m), 0.88 (3H, t, J=6.8Hz).
1H-NMR(CDCl3)δ: 2.75-2.68 (2H, m), 2.66-2.61 (2H, m), 2.45 (2H, t, J=7.2Hz), 1.63-1.54 (2H, m), 1.34-1.23 (6H, m), 0.88 (3H, t, J=6.8Hz).
1H-NMR(CDCl3)δ: 3.97 (2H, d, J=6.0Hz), 3.65-3.58 (1H, m), 2.49-2.43 (2H, m), 1.89-1.56 (7H, m), 1.49-1.23 (22H, m), 0.89 (9H, t, J=6.8Hz).
1H-NMR(CDCl3)δ: 4.75-4.68 (2H, m), 4.23-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.4Hz), 2.71-2.64 (2H, m), 2.55-2.48 (6H, m), 2.45-2.29 (4H, m), 2.01-1.81 (4H, m), 1.67-1.48 (6H, m), 1.36-1.20 (48H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):970.
clogP:20.9884
1H-NMR(CDCl3)δ: 4.71-4.63 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.65 (2H, m), 2.55-2.48 (6H, m), 2.30 (4H, t, J=7.2Hz), 1.73-1.51 (14H, m), 1.46-1.22 (52H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):1027.
clogP:21.9124
(1)
1H-NMR(CDCl3)δ: 3.98 (2H, d, J=6.0Hz), 3.85-3.76 (1H, m), 2.41-2.86 (2H, m), 1.81-1.54 (3H, m), 1.51-1.43 (3H, m), 1.31-1.21 (16H, m), 1.20 (3H, d, J=6.0Hz), 0.89 (6H, t, J=6.8Hz)
1H-NMR(CDCl3)δ: 4.78-4.71 (2H, m), 4.21-4.10 (4H, m), 3.97 (4H, d, J=5.6Hz), 2.84 (4H, t, J=6.4Hz), 2.69-2.65 (2H, m), 2.55-2.49 (6H, m), 2.34-2.30 (4H, m), 1.75-1.56 (10H, m), 1.39-1.20 (38H, m), 1.01 (6H, t, J=7.2Hz), 0.90-0.86 (12H, m).
MS m/z(M+H):858.
clogP:15.5644
1H-NMR(CDCl3)δ: 4.67-4.61 (2H, m), 4.22-4.10 (4H, m), 3.97 (4H, d, J=5.6Hz), 2.84 (4H, t, J=6.4Hz), 2.69-2.65 (2H, m), 2.55-2.49 (6H, m), 2.34-2.31 (4H, m), 1.74-1.55 (14H, m), 1.34-1.20 (32H, m), 1.01 (6H, t, J=7.2Hz), 0.94-0.87 (18H, m).
MS m/z(M+H):886.
clogP:16.6224
1H-NMR(CDCl3)δ: 4.74-4.67 (2H, m), 4.22-4.10 (4H, m), 3.97 (4H, d, J=5.6Hz), 2.83 (4H, t, J=6.4Hz), 2.69-2.65 (2H, m), 2.55-2.49 (6H, m), 2.34-2.30 (4H, m), 1.74-1.48 (14H, m), 1.43-1.20 (36H, m), 1.01 (6H, t, J=7.2Hz), 0.93-0.87 (18H, m).
MS m/z(M+H):914.
clogP:17.6804
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.65 (2H, m), 2.55-2.48 (6H, m), 2.32 (4H, t, J=7.2Hz), 1.73-1.50 (14H, m), 1.33-1.20 (40H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):942.
clogP:18.7384
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.65 (2H, m), 2.56-2.48 (6H, m), 2.32 (4H, t, J=7.2Hz), 1.73-1.50 (14H, m), 1.33-1.20 (44H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):970.
clogP:19.7964
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.65 (2H, m), 2.56-2.48 (6H, m), 2.32 (4H, t, J=7.2Hz), 1.73-1.50 (14H, m), 1.33-1.20 (52H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):1027.
clogP:21.9124
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.65 (2H, m), 2.56-2.48 (6H, m), 2.32 (4H, t, J=7.2Hz), 1.73-1.50 (14H, m), 1.33-1.20 (56H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):1055.
clogP:22.9704
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (4H, m), 3.97 (4H, d, J=6.0Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.65 (2H, m), 2.55-2.48 (6H, m), 2.32 (4H, t, J=7.2Hz), 1.73-1.50 (14H, m), 1.33-1.20 (48H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.84 (18H, m).
MS m/z(M+H):999.
clogP:20.8544
1H-NMR(CDCl3)δ: 4.72-4.65 (2H, m), 4.22-4.09 (8H, m), 2.84 (4H, t, J=6.4Hz), 2.70-2.65 (2H, m), 2.55-2.48 (6H, m), 2.30 (4H, t, J=7.2Hz), 1.97-1.92 (6H, m), 1.74-1.48 (36H, m), 1.44-1.22 (20H, m), 1.01 (6H, t, J=7.2Hz), 0.88 (6H, t, J=6.4Hz).
MS m/z(M+H):986.
clogP:19.1704
1H-NMR(CDCl3)δ: 4.73-4.67 (2H, m), 4.22-4.10 (4H, m), 3.97 (4H, d, J=5.6Hz), 2.80 (4H, t, J=6.4Hz), 2.58-2.47 (6H, m), 2.43-2.39 (2H, m), 2.34-2.30 (4H, m), 1.74-1.48 (16H, m), 1.43-1.20 (36H, m), 1.01 (6H, t, J=7.2Hz), 0.94-0.87 (18H, m).
MS m/z(M+H):928.
clogP:17.925
(1)
1H-NMR(CDCl3)δ: 9.57 (1H, s), 4.18 (2H, q, J=7.2Hz), 2.58-2.44 (6H, m), 2.32 (2H, t, J=6.8Hz), 1.95-1.87 (2H, m), 1.27 (3H, t, J=6.8Hz).
MS m/z(M+H):213.
1H-NMR(CDCl3)δ: 2.43 (4H, t, J=7.2Hz), 2.19 (4H, t, J=7.2Hz), 1.66 (4H, quin, J=7.2Hz).
MS m/z(M-H):201.
1H-NMR(CDCl3)δ: 4.06 (4H, d, J=6.8Hz), 2.47 (4H, t, J=7.2Hz), 2.32 (4H, t, J=7.2Hz), 1.93-1.85 (4H, m), 1.66-1.56 (4H, m), 1.36-1.24 (16H, m), 0.89 (6H, t, J=6.8Hz).
1H-NMR(CDCl3)δ: 4.06 (4H, d, J=6.8Hz), 3.65-3.56 (1H, m), 2.39-2.27 (4H, m), 1.83-1.39 (12H, m), 1.36-1.23 (16H, m), 0.88 (6H, t, J=6.8Hz).
1H-NMR(CDCl3)δ: 8.14-8.12 (1H, m), 7.43-7.41 (1H, m), 7.08-7.06 (1H, m), 5.12-5.05 (1H, m), 4.06 (4H, d, J=6.4Hz), 2.35 (4H, t, J=6.4Hz), 1.80-1.54 (12H, m), 1.35-1.23 (16H, m), 0.88 (6H, t, J=7.2Hz).
1H-NMR(CDCl3)δ: 4.74-4.66 (2H, m), 4.15 (4H, t, J=6.0Hz), 4.05 (8H, t, J=6.8Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.64 (2H, m), 2.55-2.48 (6H, m), 2.34-2.28 (8H, m), 1.72-1.54 (24H, m), 1.36-1.24 (32H, m), 1.01 (6H, t, J=7.2Hz), 0.88 (12H, t, J=6.8Hz).
MS m/z(M+H):1059.
clogP:16.9164
1H-NMR(CDCl3)δ: 4.75-4.66 (2H, m), 4.15 (4H, t, J=6.0Hz), 3.96 (8H, d, J=5.6Hz), 2.83 (4H, t, J=6.4Hz), 2.70-2.64 (2H, m), 2.55-2.48 (6H, m), 2.34-2.28 (8H, m), 1.73-1.56 (20H, m), 1.36-1.24 (80H, m), 1.01 (6H, t, J=7.2Hz), 0.88 (24H, t, J=6.8Hz).
MS m/z(M+H):1451.
clogP: 31.2084
1H-NMR(CDCl3)δ: 4.74-4.66 (2H, m), 4.15 (4H, t, J=6.0Hz), 4.05 (8H, t, J=6.8Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.64 (2H, m), 2.55-2.48 (6H, m), 2.34-2.28 (8H, m), 1.72-1.54 (24H, m), 1.36-1.24 (16H, m), 1.01 (6H, t, J=7.2Hz), 0.88 (12H, t, J=6.8Hz).
MS m/z(M+H):946.
clogP:12.6844
1H-NMR(CDCl3)δ: 4.74-4.66 (2H, m), 4.15 (4H, t, J=6.0Hz), 4.05 (8H, t, J=6.8Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.64 (2H, m), 2.55-2.48 (6H, m), 2.34-2.28 (8H, m), 1.72-1.54 (24H, m), 1.36-1.24 (24H, m), 1.01 (6H, t, J=7.2Hz), 0.88 (12H, t, J=6.8Hz).
MS m/z(M+H):1002.
clogP:14.8004
1H-NMR(CDCl3)δ: 4.74-4.66 (2H, m), 4.15 (4H, t, J=6.0Hz), 4.05 (8H, t, J=6.8Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.64 (2H, m), 2.55-2.48 (6H, m), 2.34-2.28 (8H, m), 1.72-1.54 (24H, m), 1.36-1.24 (40H, m), 1.01 (6H, t, J=7.2Hz), 0.88 (12H, t, J=6.8Hz).
MS m/z(M+H):1115.
clogP:19.0324
1H-NMR(CDCl3)δ: 4.74-4.66 (2H, m), 4.15 (4H, t, J=6.0Hz), 4.05 (8H, t, J=6.8Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.64 (2H, m), 2.55-2.48 (6H, m), 2.34-2.28 (8H, m), 1.72-1.54 (24H, m), 1.36-1.24 (48H, m), 1.01 (6H, t, J=7.2Hz), 0.88 (12H, t, J=6.8Hz).
MS m/z(M+H):1171.
clogP:21.1484
1H-NMR(CDCl3)δ: 4.74-4.66 (2H, m), 4.15 (4H, t, J=6.0Hz), 4.05 (8H, t, J=6.8Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.64 (2H, m), 2.55-2.48 (6H, m), 2.34-2.28 (8H, m), 1.72-1.54 (24H, m), 1.36-1.24 (56H, m), 1.01 (6H, t, J=7.2Hz), 0.88 (12H, t, J=6.8Hz).
MS m/z(M+H):1227.
clogP:23.2644
(1)
1H-NMR(CDCl3)δ: 4.73-4.66 (1H, m), 4.20 (2H, t, J=6.0Hz), 4.06 (4H, t, J=6.8Hz), 3.54 (2H, t, J=5.2Hz), 2.88 (2H, t, J=6.2Hz), 2.71-2.66 (4H, m), 2.58-2.47 (6H, m), 2.33-2.29 (4H, m), 1.74-1.55 (13H, m), 1.36-1.27 (12H, m), 1.03 (6H, t, J=7.0Hz), 0.91-0.87 (6H, m).
MS m/z(M+H):604.
1H-NMR(CDCl3)δ: 4.73-4.66 (2H, m), 4.15 (4H, t, J=6.8Hz), 4.05 (8H, t, J=6.6Hz), 2.83 (4H, t, J=6.4Hz), 2.69-2.65 (2H, m), 2.54-2.49 (6H, m), 2.33-2.29 (8H, m), 1.74-1.55 (24H, m), 1.38-1.25 (20H, m), 1.01 (6H, t, J=7.2Hz), 0.93-0.87 (12H, m).
MS m/z(M+H):974.
clogP:13.7424
1H-NMR(CDCl3)δ: 4.73-4.66 (2H, m), 4.16 (4H, t, J=6.8Hz), 4.05 (8H, t, J=6.6Hz), 2.83 (4H, t, J=6.0Hz), 2.70-2.66 (2H, m), 2.55-2.49 (6H, m), 2.33-2.29 (8H, m), 1.73-1.56 (24H, m), 1.38-1.23 (28H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.86 (12H, m).
MS m/z(M+H):1030.
clogP:15.8584
1H-NMR(CDCl3)δ: 4.73-4.66 (2H, m), 4.15 (4H, t, J=6.8Hz), 4.05 (8H, t, J=6.6Hz), 2.80 (4H, t, J=6.4Hz), 2.58-2.47 (6H, m), 2.42-2.39 (2H, m), 2.33-2.29 (8H, m), 1.74-1.57 (26H, m), 1.35-1.21 (32H, m), 1.00 (6H, t, J=7.2Hz), 0.90-0.86 (12H, m).
MS m/z(M+H):1073.
clogP:17.161
(1)
1H-NMR(CDCl3)δ: 2.82-2.74 (4H, m), 2.68-2.58 (4H, m).
MS m/z(M-H):173.
1H-NMR(CDCl3)δ: 4.80-4.73 (2H, m), 4.16 (4H, t, J=6.0Hz), 4.06 (8H, t, J=6.8Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.64 (2H, m), 2.55-2.48 (6H, m), 2.44-2.31 (8H, m), 2.00-1.85 (8H, m), 1.66-1.56 (8H, m), 1.36-1.24 (32H, m), 1.01 (6H, t, J=7.2Hz), 0.88 (12H, t, J=6.8Hz).
MS m/z(M+H):1002.
clogP:17.1844
(1)
1H-NMR(CDCl3)δ: 3.72 (2H, q, J=6.0Hz), 2.73 (2H, t, J=6.0Hz), 2.52 (2H, t, J=7.2Hz), 2.23 (1H, t, J=6.0Hz), 1.63-1.54 (2H, m), 1.43-1.21 (10H, m), 0.88 (3H, t, J=6.8Hz).
1H-NMR(CDCl3)δ: 4.74-4.66 (2H, m), 4.21 (8H, t, J=6.8Hz), 4.16 (4H, t, J=6.4Hz), 2.84 (4H, t, J=6.4Hz), 2.75-2.65 (10H, m), 2.57-2.48 (14H, m), 2.36-2.31 (8H, m), 1.72-1.54 (16H, m), 1.42-1.23 (48H, m), 1.01 (6H, t, J=7.2Hz), 0.88 (12H, t, J=6.8Hz).
MS m/z(M+H):1354.
clogP:21.954
1H-NMR(CDCl3)δ: 4.73-4.66 (2H, m), 4.16 (4H, t, J=6.4Hz), 3.87 (8H, d, J=6.8Hz), 2.84 (4H, t, J=6.4Hz), 2.70-2.64 (2H, m), 2.57-2.46 (6H, m), 2.34-2.30 (8H, m), 1.76-1.55 (40H, m), 1.30-0.90 (26H, m).
MS m/z(M+H):1050.
clogP:14.8204
1H-NMR(CDCl3)δ: 4.73-4.66 (2H, m), 4.16 (4H, t, J=6.4Hz), 4.07-4.03 (8H, m), 2.84 (4H, t, J=6.4Hz), 2.70-2.66 (2H, m), 2.56-2.50 (6H, m), 2.33-2.29 (8H, m), 1.73-1.54 (24H, m), 1.37-1.21 (32H, m), 1.02 (6H, t, J=7.2Hz), 0.91-0.86 (12H, m).
MS m/z(M+H):1059.
clogP:16.9164
(1)
1H-NMR(CDCl3)δ: 3.72 (2H, dt, J=6.0, 6.0Hz), 2.73 (2H, t, J=6.0Hz), 2.52 (2H, t, J=7.6Hz), 2.22-2.15 (1H, m), 1.63-1.53 (2H, m), 1.42-1.22 (6H, m), 0.89 (3H, t, J=6.8Hz).
1H-NMR(CDCl3)δ: 4.72-4.66 (2H, m), 4.21 (8H, t, J=7.0Hz), 4.16 (4H, t, J=6.2Hz), 2.84 (4H, t, J=6.4Hz), 2.73 (8H, t, J=6.8Hz), 2.69-2.65 (2H, m), 2.57-2.49 (14H, m), 2.36-2.32 (8H, m), 1.75-1.54 (24H, m), 1.42-1.23 (24H, m), 1.01 (6H, t, J=7.2Hz), 0.91-0.87 (12H, m).
MS m/z(M+H):1242.
clogP:17.722
(1)
1H-NMR(CDCl3)δ: 3.68-3.61 (2H, m), 2.53 (2H, dt, J=7.6, 7.6Hz), 1.71-1.53 (5H, m), 1.42-1.20 (9H, m).
1H-NMR(CDCl3)δ: 3.67-3.62 (2H, m), 2.49 (2H, t, J=7.4Hz), 2.10 (3H, s), 1.63-1.53 (4H, m), 1.42-1.20 (9H, m).
1H-NMR(CDCl3)δ: 4.72-4.66 (2H, m), 4.16 (4H, t, J=6.4Hz), 4.05 (8H, t, J=6.6Hz), 2.84 (4H, t, J=6.4Hz), 2.69-2.65 (2H, m), 2.55-2.46 (14H, m), 2.33-2.29 (8H, m), 2.10 (12H, s), 1.72-1.56 (32H, m), 1.42-1.31 (32H, m), 1.01 (6H, t, J=7.0Hz).
MS m/z(M+H):1298.
clogP:17.5084
<EPO mRNA内包脂質粒子の調製>
表1に記載の化合物、中性脂質、コレステロール(製品名:Cholesterol HP;日本精化株式会社)、1,2-ジミリストイル-rac-グリセロ-3-(メチルポリオキシエチレン2000)(以下、DMG-PEG2000)(製品名:SUNBRIGHT(R)GM-020;NOF corporation)を、表1のモル比で、総脂質濃度が20mmol/Lとなるようにエタノールに溶解させ、油相を得た。
mRNA内包脂質粒子の粒子径は、脂質粒子分散液について、ゼータ電位・粒径測定システムELS-Z2(大塚電子)を用いて、リン酸緩衝生理食塩水(PBS)で10倍希釈し、測定した。結果を表1に示す。
(総mRNA濃度定量)
mRNAを保持する脂質粒子30~60μLに、3mol/L酢酸ナトリウム水溶液15~30μLとグリコーゲン4.5~9μLを添加し、つづいてエタノール0.75~1.5mLを添加することで脂質を溶解し、mRNAのみを沈殿させた。その後、遠心分離を行い、上清を除去した。15分以上風乾させた後、水を加えて再溶解させ、ナノドロップNF1000(Thermo Fisher Scientific)を用いて濃度測定することで、総mRNA濃度を定量した。
Quant-iT RiboGreen RNA Assay Kit(Thermo Fisher Scientific)を用い、プロトコルに従って定量した。まず、上述のキットに含まれる20×TEバッファーを水で希釈し、1×TEバッファーとした。なお、TEは、Tris/EDTA(エチレンジアミン四酢酸)を示す。外水相のmRNAのみを定量するため、mRNAを保持する脂質粒子分散液を1×TEバッファーで10000倍に希釈した。10000倍に希釈した脂質粒子分散液100μLを、96ウェルプレートに入れ、つづいて1×TEバッファーで2000倍に希釈したRiboGreen試薬(上記したQuanti-iT Ribogreen RNA Assay Kitに含まれている試薬)100μLをサンプルに加え、プレートリーダーInfinit eF200(TECAN)を用いて蛍光(励起波長:485nm、蛍光波長:535nm)を測定することで、外水相におけるmRNA濃度を定量した。
上述の工程で得られた総mRNA濃度および外水相でのmRNA濃度の定量結果を用いて、下記式に従って、mRNA脂質粒子のmRNA内包率を算出した。結果を表1に示す。
mRNA内包率(%)=(総mRNA濃度-外水相におけるmRNA濃度)÷総mRNA濃度×100
C57BL/6Jマウスに上記<EPO mRNA内包脂質粒子の調製>において調製したmRNA脂質粒子の分散液をmRNA投与量として0.1mg/kgになるように静脈投与した。投与20~24時間後に後大静脈より採血を行い、血漿を得た。得られた血漿を用いてab119522 Erythropoietin (EPO) Human Elisa Kit(Abcam)を使用してヒトEPO酵素活性を定量した。定量値は比較例1を1としたときの相対的EPOタンパク量で記載した。
結果を表1に示す。
<FLuc mRNA内包脂質粒子の調製>
表2に記載の化合物、中性脂質、コレステロール(製品名:Cholesterol HP;日本精化株式会社)、1,2-ジミリストイル-rac-グリセロ-3-(メチルポリオキシエチレン2000)(以下、DMG-PEG2000)(表2のモル比で、総脂質濃度が20mmol/Lとなるようにエタノールに溶解させ、油相を得た。
mRNA内包脂質粒子の粒子径は、脂質粒子分散液について、ゼータ電位・粒径測定システムELS-Z2(大塚電子)を用いて、リン酸緩衝生理食塩水(PBS)で10倍希釈し、測定した。結果を表2に示す。
(総mRNA濃度定量)
mRNAを保持する脂質粒子30~60μLに、3mol/L酢酸ナトリウム水溶液15~30μLとグリコーゲン4.5~9μLを添加し、つづいてエタノール0.75~1.5mLを添加することで脂質を溶解し、mRNAのみを沈殿させた。その後、遠心分離を行い、上清を除去した。15分以上風乾させた後、水を加えて再溶解させ、ナノドロップNF1000(Thermo Fisher Scientific)を用いて濃度測定することで、総mRNA濃度を定量した。
Quant-iT RiboGreen RNA Assay Kit(Thermo Fisher Scientific)を用い、プロトコルに従って定量した。まず、上述のキットに含まれる20×TEバッファーを水で希釈し、1×TEバッファーとした。なお、TEは、Tris/EDTA(エチレンジアミン四酢酸)を示す。外水相のmRNAのみを定量するため、mRNAを保持する脂質粒子分散液を1×TEバッファーで10000倍に希釈した。10000倍に希釈した脂質粒子分散液100μLを、96ウェルプレートに入れ、つづいて1×TEバッファーで2000倍に希釈したRiboGreen試薬(上記したQuanti-iT Ribogreen RNA Assay Kitに含まれている試薬)100μLをサンプルに加え、プレートリーダーInfinit EF200(TECAN)を用いて蛍光(励起波長:485nm、蛍光波長:535nm)を測定することで、外水相におけるmRNA濃度を定量した。
上述の工程で得られた総mRNA濃度および外水相でのmRNA濃度の定量結果を用いて、下記式に従って、mRNA脂質粒子のmRNA内包率を算出した。結果を表2に示す。
mRNA内包率(%)=(総mRNA濃度-外水相におけるmRNA濃度)÷総mRNA濃度×100
ICRマウスに、上記<FLuc mRNA内包脂質粒子の調製>において調製したmRNA脂質粒子の分散液をmRNA投与量として1μgになるように背側より大腿直筋内に単回投与した。投与5時間50後に150mg/kgのD-ルシフェリンカリウム(富士フイルム和光純薬)を腹腔内投与し、イソフルランガス麻酔下,投与6時間後に伏臥位でのIVIS Imaging System(PerkinElmer)を用いて発光を測定した。投与した側の下肢がすべて入るようにROIを設定し,Living Image Software(PerkinElmer)にて発光量(Photone/Sec)を定量した。表2におけるLuciferase[P/S]は、Photons/sec(光の強さ)を示す。
PTEN(Phosphatase and Tensin Homolog Deleted from Chromosome 10)は、イノシトールリン脂質であるホスファチジルイノシトール3,4,5-三リン酸の脱リン酸化反応を触媒する酵素である。
PTENタンパク質に対するアンチセンスオリゴヌクレオチド核酸(PTEN ASO)を北海道システムサイエンス株式会社より購入した。20塩基からなるオリゴヌクレオチドのホスホジエステル結合であり,配列を以下に記載する。
5(m)^t(m)^g(m)^5(m)^t(m)^a^g^5c^5c^t^5c^t^g^g^a^t(m)^t(m)^t(m)^g(m)^a(m)
ただし、小文字(a、g、t)はそれぞれアデニン、グアニン、チミジンを表し、(m)は2’MOE修飾を表す。
5(m)=2’-MOE 5-Meシトシンt(m)=2’-MOE チミジンg(m)=2’-MOE グアニンa(m)=2’-MOE アデニン,5c=5-メチル-dシトシンを表し、^は、ホスホロチオエートを表す。
2’-MOEは、2’-O-methoxyethylを示す。
表3に示す第一の脂質、リン脂質、コレステロール、及びポリエチレングリコール脂質(PEG脂質)を表3に記載のモル比で,総脂質濃度が20mmol/Lとなるようにエタノールに溶解させ,油相を得た。
脂質粒子の粒子径及び多分散指数は、脂質粒子分散液について、ゼータ電位・粒径測定システムELS-Z2(大塚電子)を用いて、リン酸緩衝生理食塩水(PBS)で10倍希釈し、測定した。測定結果を表3に示す。
(総核酸濃度定量)
核酸を保持する脂質粒子60μLに,3mol/L酢酸ナトリウム水溶液30μLとグリコーゲン9μLを添加し、つづいてエタノール1.5mLを添加することで脂質を溶解し,核酸のみを沈殿させた。その後、遠心分離を行い、上清を除去した。15分以上風乾させた後、水を加えて再溶解させ,ナノドロップND1000(Thermo Fisher Scientific)を用いて濃度測定することで、総核酸濃度を定量した。
Quant-iT RiboGreen RNA Assay Kit(Thermo Fisher Scientific)を用い、プロトコルに従って定量した。まず、上述のキットに含まれる20×TEバッファーを水で希釈し、1×TEバッファーとした。なお、TEは、Tris/EDTA(エチレンジアミン四酢酸)を示す。外水相の核酸のみを定量するため、核酸を保持する脂質粒子分散液を1×TEバッファーで10000倍に希釈した。
上述の工程で得られた総核酸濃度および外水相での核酸濃度の定量結果を用いて、下記式に従って、核酸脂質粒子の核酸内包率を算出した。
核酸内包率(%)=(総核酸濃度-外水相における核酸濃度)÷総核酸濃度×100
算出の結果を表3に示す。
(評価に用いた細胞)
A431細胞(American Type Culture Collection)を用いたin vitro試験では、E-MEM(gibco)、FBS(fetal bovine serum)(gibco)、Penicillin-streptomycin(gibco)、NEAA(Non-Essential Amino Acid)(富士フイルム和光純薬)をそれぞれ88:10:1:1の割合で混合したものを培養培地として用いた。
PTENタンパク質 mRNA測定はTaqMan(登録商標)Fast Advanced Cells-to-CTTMKit(Thermo fisher scientific)のプロトコルに従った。A431細胞もしくはSH-SY5Y細胞に対し、最終濃度がASO濃度として500nmol/Lとなるように調製した核酸脂質粒子の分散液、Naked ASOもしくはPBSを添加した。37℃、5%CO2管理下で24時間暴露後、培養上清を除去し、4℃のPBSで1回洗浄した。PBSを除去後、Lysis solutionを50μL/wellで添加し、室温で5分静置することで細胞ライセートを得た。細胞ライセートについてTaqMan(登録商標)Fast Advanced Cells-to-CTTMKit(Thermo fisher scientific)、PCR反応試薬として、Hs02621230_s1,FAM/MGB(Thermo fisher scientific)、およびHuman GAPDH Endogenous Control、VIC(登録商標)/MGB(Thermo fisher scientific)を使用して逆転写及びPCR反応を実施した。
Claims (19)
- 下記式(1)で示される化合物またはその塩。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、及び-O-R56から選択される1以上の置換基で置換されていてもよく、
R4は、炭素数1~8の炭化水素基を示し、
R5およびR6がそれぞれ独立に、炭素数1~8の炭化水素基、又は-R8-L1-R9を示し、但し、R5およびR6がともに炭素数1~8の炭化水素基である場合は除かれ、
R7は、-R10-L2-R11-L3-R12を示し、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53,R54,R55,およびR56はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
R53,R54,R55,およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、
前記の炭素数6~20のアリール基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57で置換されていてもよく、
R58は、炭素数1~12の炭化水素基を示し、
R57は、-OH、COOH、-NR61R62、-OC(O)O-R63、-C(O)O-R64、-OC(O)-R65、-O-R66を示す。
R61およびR62はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R63,R64,R65,およびR66はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
R63,R64,R65,およびR66が示す炭化水素基は、炭素数6~20のアリール基または-S-R68で置換されていてもよく、
前記の炭素数6~20のアリール基は、-OH、COOH、-NR61R62、-OC(O)O-R63、-C(O)O-R64、-OC(O)-R65、-O-R66、または-(炭素数1~12の炭化水素基)-R67で置換されていてもよく、
R68は、炭素数1~12の炭化水素基を示し、
L1、L2、及びL3はそれぞれ独立に、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示す。
R8は、炭素数1~12の炭化水素基を示し、
R9は、炭素数1~24の炭化水素基を示し、
R10は、炭素数1~8の炭化水素基を示し、
R11は、炭素数1~24の炭化水素基を示し、
R12は、炭素数1~24の炭化水素基を示し、
R9、およびR12が示す炭化水素基は、アリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-S-R58で置換されていてもよく、R53、R54、R55、およびR58の定義は上記の通りであり、
R11が示す炭化水素基は、-OC(O)O-R53、-C(O)O-R54、または-OC(O)-R55で置換されていてもよく、R53、R54、およびR55の定義は上記の通りである。 - R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、R3は、炭素数2~4の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OHで置換されていてもよく、
R4は、炭素数1~8の炭化水素基を示し、
R5およびR6がそれぞれ独立に、炭素数1~8の炭化水素基、又は-R8-L1-R9を示し、但し、R5およびR6がともに炭素数1~8の炭化水素基である場合は除かれ、
R7が、-R10-L2-R11-L3-R12を示し、
L1、およびL3はそれぞれ独立に、-C(O)O-、または-OC(O)-を示す。
L2は、-OC(O)O-、-C(O)O-、または-OC(O)-を示す。
R8は、炭素数1~8の炭化水素基を示し、
R9は、炭素数1~16の炭化水素基を示し、
R10は、炭素数1~8の炭化水素基を示し、
R11は、炭素数1~9の炭化水素基を示し、
R12は、炭素数1~16の炭化水素基を示し、
R9、およびR12が示す炭化水素基は、アリール基、又は-S-R58で置換されていてもよく、
R58は、炭素数1~8の炭化水素基を示し、
R11が示す炭化水素基は、-C(O)O-R55、又は-OC(O)-R56で置換されていてもよく、
R55,およびR56はそれぞれ独立に、炭素数1~16の炭化水素基を示し、
R55,およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、R58の定義は上記の通りである、
請求項1に記載の化合物またはその塩。 - 下記式(1-1)で示される化合物またはその塩である、請求項1に記載の化合物またはその塩。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-O-R56で置換されていてもよく、
R4は、炭素数1~8の炭化水素基を示し、
R5およびR6がそれぞれ独立に、炭素数1~8の炭化水素基、又は-R8-L1-R9を示し、但し、R5およびR6がともに炭素数1~8の炭化水素基である場合は除かれ、
L1は、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、
R8は、炭素数1~12の炭化水素基を示し、
R9は、炭素数1~24の炭化水素基を示し、R9が示す炭化水素基は、アリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-S-R58で置換されていてもよく、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53,R54,R55,およびR56はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
R53,R54,R55,およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、
前記の炭素数6~20のアリール基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57で置換されていてもよく、
R58は、炭素数1~12の炭化水素基を示し、
R57は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56を示す。
R13は、炭素数1~8の炭化水素基を示し、
R14は、-R15-L5-R16を示し、R15は炭素数1~24の炭化水素基を示し、L5は-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、R16は、炭素数1~24の炭化水素基を示し、
R15が示す炭素数1~24の炭化水素基は、-OC(O)O-R53、-C(O)O-R54、又は-OC(O)-R55で置換されていてもよく、R53、R54、およびR55の定義は上記の通りであり、
R16が示す炭素数1~24の炭化水素基は、炭素数6~20のアリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-S-R58で置換されていてもよく、R53、R54、R55、およびR58の定義は上記の通りである。 - 式(1-1)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、R3は、炭素数2~4の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OHで置換されていてもよく、
R4は、炭素数1~8の炭化水素基を示し、
R5およびR6がそれぞれ独立に、炭素数1~8の炭化水素基、又は-R8-L1-R9を示し、但し、R5およびR6がともに炭素数1~8の炭化水素基である場合は除かれ、
L1は、-C(O)O-、または-OC(O)-を示し、
R8は、炭素数1~8の炭化水素基を示し、
R9は、炭素数1~18の炭化水素基を示し、R9が示す炭化水素基は、炭素数6~20のアリール基、又は-S-R58で置換されていてもよく、
R58は、炭素数1~8の炭化水素基を示し、
R13は、炭素数1~8の炭化水素基を示し、
R14は、-R15-L5-R16を示し、R15は炭素数1~18の炭化水素基を示し、L5は-OC(O)O-を示し、R16は、炭素数1~18の炭化水素基を示し、
R15が示す炭素数1~18の炭化水素基は、-C(O)O-R55、又は-OC(O)-R56で置換されていてもよく、
R55,およびR56はそれぞれ独立に、炭素数1~16の炭化水素基を示し、R55、およびR56が示す炭化水素基は、炭素数6~20のアリール基または-S-R58で置換されていてもよく、R58の定義は上記の通りであり、
R16が示す炭素数1~18の炭化水素基は、アリール基、又は-S-R58で置換されていてもよく、R58の定義は上記の通りである、
請求項3に記載の化合物またはその塩。 - 下記式(1-2)で示される化合物またはその塩である、請求項1に記載の化合物またはその塩。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-O-R56で置換されていてもよく、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素を示し、
R21およびR22はそれぞれ独立に、炭素数1~18の炭化水素基を示し、
R23およびR24はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
R25およびR26はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
L21およびL22はそれぞれ独立に、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、
R25およびR26が示す炭化水素基は、炭素数6~20のアリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、または-S-R58で置換されていてもよく、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53、R54、R55およびR56はそれぞれ独立に、炭素数1~18の炭化水素基を示し、
前記の炭素数6~20のアリール基は、OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57により置換されていてもよく、
R57は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56を示す。
R58は、炭素数1~12の炭化水素基を示す。 - 式(1-2)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、R1およびR2が示す炭化水素基は、-OHで置換されていてもよく、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素を示し、
R21およびR22はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R23およびR24はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R25およびR26はそれぞれ独立に、炭素数1~16の炭化水素基を示し、
L21およびL22はそれぞれ独立に、-C(O)O-、または-OC(O)-を示す、
請求項5に記載の化合物またはその塩。 - 式(1-2)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素を示し、
R21およびR22はそれぞれ独立に、炭素数1~6の炭化水素基を示し、
R23およびR24はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R25およびR26はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
L21およびL22はそれぞれ独立に、-C(O)O-、または-OC(O)-を示す、
請求項5に記載の化合物またはその塩。 - 下記式(1-3)で示される化合物またはその塩である、請求項1に記載の化合物またはその塩。
R1およびR2はそれぞれ独立に、炭素数1~18の炭化水素基を示し、R3は、炭素数2~8の炭化水素基を示し、R1、R2およびR3が示す炭化水素基は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、又は-O-R56で置換されていてもよく、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、炭素数1~24の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-OC(O)O-、-C(O)O-、-OC(O)-、または-O-を示し、
R35、R36、R37、およびR38が示す炭化水素基は、炭素数6~20のアリール基、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、またはS-R58で置換されていてもよく、
R51およびR52はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R53、R54、R55、およびR56はそれぞれ独立に、炭素数1~18の炭化水素基を示し、
前記の炭素数6~20のアリール基は、OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56、または-(炭素数1~12の炭化水素基)-R57により置換されていてもよく、
R57は、-OH、COOH、-NR51R52、-OC(O)O-R53、-C(O)O-R54、-OC(O)-R55、-O-R56を示す。
R58は、炭素数1~12の炭化水素基を示す。 - 式(1-3)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、R1およびR2が示す炭化水素基は、-OHで置換されていてもよく、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、炭素数1~16の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-C(O)O-、または-OC(O)-を示し、
R35、R36、R37、およびR38が示す炭化水素基は、炭素数6~20のアリール基、またはS-R58で置換されていてもよく、
R58は、炭素数1~8の炭化水素基を示す、
請求項8に記載の化合物またはその塩。 - 式(1-3)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-C(O)O-、または-OC(O)-を示し、
R35、R36、R37、およびR38が示す炭化水素基は、-S-R58で置換されていてもよく、
R58は、炭素数1~8の炭化水素基を示す、
請求項8に記載の化合物またはその塩。 - 式(1-3)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、-S-R58で置換された炭素数1~12の炭化水素基を示し、R58は、炭素数1~8の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-C(O)O-、または-OC(O)-を示す、
請求項8に記載の化合物またはその塩。 - 式(1-3)において、
R1およびR2はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R3は、炭素数2~4の炭化水素基を示し、
R4およびR8はそれぞれ独立に、炭素数1~8の炭化水素基を示し、
R31、R32、R33、およびR34はそれぞれ独立に、炭素数1~3の炭化水素基を示し、
R35、R36、R37、およびR38はそれぞれ独立に、炭素数1~12の炭化水素基を示し、
L31、L32、L33、およびL34はそれぞれ独立に、-C(O)O-、または-OC(O)-を示す、
請求項8に記載の化合物またはその塩。 - 以下に記載の化合物またはその塩;
ビス(2-ブチルオクチル)16-(3-(ジエチルアミノ)プロピル)-10,22-ジヘキシル-12,20-ジオキソ-11,13,19,21-テトラオキサ-16-アザヘントリアコンタンジオエート;
- 請求項1から13の何れか一項に記載の化合物またはその塩と、脂質とを含む、脂質粒子。
- 脂質が、ステロールおよび非イオン性親水性高分子鎖を有する脂質からなる群から選択される少なくとも一種の脂質である、請求項14に記載の脂質粒子。
- さらに中性脂質を含む、請求項14または15に記載の脂質粒子。
- さらに核酸を含む、請求項14から16の何れか一項に記載の脂質粒子。
- 核酸が、塩基数が50以上の核酸を含む、請求項17に記載の脂質粒子。
- 請求項14から18の何れか一項に記載の脂質粒子を有効成分として含有する、医薬組成物。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3216416A CA3216416A1 (en) | 2021-04-28 | 2022-04-28 | Compound or salt thereof, lipid particles, and pharmaceutical composition |
EP22795877.4A EP4332086A1 (en) | 2021-04-28 | 2022-04-28 | Compound or salt thereof, lipid particles, and pharmaceutical composition |
AU2022263899A AU2022263899B2 (en) | 2021-04-28 | 2022-04-28 | Compound or salt thereof, lipid particles, and pharmaceutical composition |
CN202280031089.0A CN117279888A (zh) | 2021-04-28 | 2022-04-28 | 化合物或其盐、脂质颗粒及药物组合物 |
KR1020237036793A KR20230162043A (ko) | 2021-04-28 | 2022-04-28 | 화합물 또는 그 염, 지질 입자 및 의약 조성물 |
JP2023517612A JPWO2022230964A1 (ja) | 2021-04-28 | 2022-04-28 | |
US18/495,200 US20240124389A1 (en) | 2021-04-28 | 2023-10-26 | Compound or salt thereof, lipid particles, and pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-075525 | 2021-04-28 | ||
JP2021075525 | 2021-04-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/495,200 Continuation US20240124389A1 (en) | 2021-04-28 | 2023-10-26 | Compound or salt thereof, lipid particles, and pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022230964A1 true WO2022230964A1 (ja) | 2022-11-03 |
Family
ID=83848515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/019220 WO2022230964A1 (ja) | 2021-04-28 | 2022-04-28 | 化合物またはその塩、脂質粒子および医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240124389A1 (ja) |
EP (1) | EP4332086A1 (ja) |
JP (1) | JPWO2022230964A1 (ja) |
KR (1) | KR20230162043A (ja) |
CN (1) | CN117279888A (ja) |
AU (1) | AU2022263899B2 (ja) |
CA (1) | CA3216416A1 (ja) |
WO (1) | WO2022230964A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010054401A1 (en) | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Novel lipids and compositions for the delivery of therapeutics |
JP5288254B2 (ja) | 2008-10-17 | 2013-09-11 | 株式会社ニコン | レンズ系 |
WO2018232120A1 (en) * | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
WO2019235635A1 (ja) | 2018-06-08 | 2019-12-12 | 富士フイルム株式会社 | 化合物またはその塩および脂質粒子 |
WO2020246581A1 (ja) * | 2019-06-07 | 2020-12-10 | 富士フイルム株式会社 | 脂質組成物 |
WO2021095876A1 (ja) * | 2019-11-15 | 2021-05-20 | 富士フイルム株式会社 | 脂質組成物 |
WO2021117770A1 (ja) * | 2019-12-10 | 2021-06-17 | 富士フイルム株式会社 | 医薬組成物及び処置剤 |
-
2022
- 2022-04-28 JP JP2023517612A patent/JPWO2022230964A1/ja active Pending
- 2022-04-28 CA CA3216416A patent/CA3216416A1/en active Pending
- 2022-04-28 EP EP22795877.4A patent/EP4332086A1/en active Pending
- 2022-04-28 WO PCT/JP2022/019220 patent/WO2022230964A1/ja active Application Filing
- 2022-04-28 AU AU2022263899A patent/AU2022263899B2/en active Active
- 2022-04-28 CN CN202280031089.0A patent/CN117279888A/zh active Pending
- 2022-04-28 KR KR1020237036793A patent/KR20230162043A/ko unknown
-
2023
- 2023-10-26 US US18/495,200 patent/US20240124389A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5288254B2 (ja) | 2008-10-17 | 2013-09-11 | 株式会社ニコン | レンズ系 |
WO2010054401A1 (en) | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Novel lipids and compositions for the delivery of therapeutics |
WO2018232120A1 (en) * | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
WO2019235635A1 (ja) | 2018-06-08 | 2019-12-12 | 富士フイルム株式会社 | 化合物またはその塩および脂質粒子 |
WO2020246581A1 (ja) * | 2019-06-07 | 2020-12-10 | 富士フイルム株式会社 | 脂質組成物 |
WO2021095876A1 (ja) * | 2019-11-15 | 2021-05-20 | 富士フイルム株式会社 | 脂質組成物 |
WO2021117770A1 (ja) * | 2019-12-10 | 2021-06-17 | 富士フイルム株式会社 | 医薬組成物及び処置剤 |
Also Published As
Publication number | Publication date |
---|---|
CA3216416A1 (en) | 2022-11-03 |
CN117279888A (zh) | 2023-12-22 |
US20240124389A1 (en) | 2024-04-18 |
KR20230162043A (ko) | 2023-11-28 |
AU2022263899B2 (en) | 2024-08-29 |
AU2022263899A1 (en) | 2023-11-09 |
JPWO2022230964A1 (ja) | 2022-11-03 |
EP4332086A1 (en) | 2024-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7547335B2 (ja) | 修飾されたアミン脂質 | |
US10385030B2 (en) | Cationic lipid | |
JP2024102224A (ja) | イオン化可能なアミン脂質 | |
JP7241869B2 (ja) | 脂質組成物 | |
JP7389134B2 (ja) | 脂質組成物 | |
CN114262275B (zh) | 一种高效低毒性dna及rna脂质递送载体 | |
WO2019235635A1 (ja) | 化合物またはその塩および脂質粒子 | |
JP6605477B2 (ja) | 核酸送達のためのカチオン性脂質 | |
JP2001515082A (ja) | リン脂質類似化合物 | |
WO2023176822A1 (ja) | 化合物および脂質組成物 | |
EP2802556B1 (en) | Lipopolyamines of spermine type for construction of liposomal transfection systems | |
WO2022230964A1 (ja) | 化合物またはその塩、脂質粒子および医薬組成物 | |
JP6826014B2 (ja) | 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット | |
JP6388700B2 (ja) | 脂質粒子の製造法および脂質粒子を有する核酸送達キャリア | |
WO2024190817A1 (ja) | 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア | |
US20170121714A1 (en) | Method for producing lipid particles and nucleic acid delivery carrier having lipid particles | |
WO2023176821A1 (ja) | 脂質組成物 | |
WO2010026621A1 (ja) | ポリカチオン化リン脂質誘導体 | |
CN115745788A (zh) | 一种可电离脂质化合物及其制备方法和应用 | |
CN117534585A (zh) | 一种新型可电离阳离子脂质化合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22795877 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023517612 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022263899 Country of ref document: AU Ref document number: 2022263899 Country of ref document: AU Ref document number: 3216416 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20237036793 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237036793 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280031089.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202347073191 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2022263899 Country of ref document: AU Date of ref document: 20220428 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022795877 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022795877 Country of ref document: EP Effective date: 20231128 |